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2. Abbreviations 
 
AMD Age-related macular degeneration 
Ang-1/-2  Angiopoietin-1/-2 
ATP  Adenosine triphosphate 
AUC Analytical ultracentrifugation 
BSA  Bovine serum albumin 
CD  Carboxy-terminal domain 
c-Kit  Stem cell factor receptor 
CSF1  Colony stimulating factor-1 
CSF1R  Colony stimulating factor-1 receptor 
Da, kDa  Dalton, kilo-Dalton 
DAG 1, 2-diacylglycerol 
DMEM  Dulbecco's modified eagle's medium 
DNA  Deoxyribonucleic acid 
DTT  Dithiothreitol 
E.coli Escherichia coli 
ECD  Extracellular domain 
ECM  Extracellular matrix 
EDG Endothelial differentiation sphingolipid G-protein 
 coupled receptor 
EDTA  Ethylenediamine tetraacetic acid 
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
EM  Electron microscopy 
eNOS  Endothelial nitric oxide synthase 
Eph  Ephrin receptor 
ER  Endoplasmic reticulum 
ERK  Extracellular signal-regulated kinase 
FAK  Focal adhesion kinase 
FBS  Fetal bovine serum 
FGF  Fibroblast growth factor 
FGFR  Fibroblast growth factor receptor 
Flt1 Fms-related tyrosine kinase 1 
Flk-1  Fetal liver kinase-1 = VEGFR-2 
Flt-4  Fetal liver kinase-4 = VEGFR-3 
HEK 293  Human embryonic kidney cells 293 
HIF-1  Hypoxia inducible factor-1 
HSPG  Heparan sulfate proteoglycan 
ICD  Intracellular domain 
Ig  Immunoglobulin 
IMAC  Immobilized metal affinity chromatography 
ITC  Isothermal titration calorimetry 
KID  Kinase insert domain 
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MALS  Multi Angle Light Scattering 
MAPK  Mitogen-activated protein kinase 
MEK  MAPK kinase 
MW  Molecular weight 
N-terminus  Amino-terminus or NH2-terminus 
Ni-NTA  Nickel-nitrilotriacetic acid 
NO  Nitric oxide 
Nrp-1/-2  Neuropilin-1/-2 
PAE  Porcine aortic endothelial cells 
PAO  Phenyl arsine oxide 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PDGF  Platelet derived growth factor 
PDGFR  Platelet derived growth factor receptor 
PI3-K  Phosphoinositol-3 kinase 
PIP2 Phosphatidylinositol 4, 5-bisphosphate 
PKB  Protein kinase B 
PKC  Protein kinase C 
PLC-γ Phospholipase C gamma 
PlGF  Placenta growth factor 
PMSF  Phenylmethylsulfonyl fluoride 
PTB  Phosphotyrosine binding domain 
PVDF  Polyvinylidene fluoride 
rpm  Rounds per minute 
RTK  Receptor tyrosine kinase 
SAXS  Small angle X-ray scattering 
SCF  Stem cell factor 
SDS-PAGE  Sodium dodecylsulfate polyacryl gel electrophoresis 
SEC  Size exclusion chromatography 
Sf21  Spodoptera frugiperda cells 
Sf9  Spodoptera frugiperda cells 
SH2  Src homology-2 domain 
Shb  Src homology-2 protein in beta-cells 
sVEGFR  Soluble VEGFR 
TEV  Tobacco etch virus 
Tie-1/-2  Angiopoietin receptor-1/-2 
TGF  Transforming growth factor 
TK  Tyrosine kinase 
TMD  Transmembrane domain 
TSAd  T-cell-specific adaptor 
VE-cadherin  Vascular endothelial cadherin 
VEGF  Vascular endothelial growth factor 
VEGFR  Vascular endothelial growth factor receptor 
WT Wild type 
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3. Summary 
 
Vascular Endothelial Growth Factors (VEGFs) are key players in blood and lymphatic 
vessel development and homeostasis. The family consists of five members, VEGF-A, 
-B, -C, -D and placenta growth factor (PLGF). They bind to three type V receptor 
tyrosine kinases (RTKs): VEGF-receptor-1 (VEGFR)-1 (Flt1), VEGFR-2 (KDR/Flk1), 
and VEGFR-3 (Flt4). VEGFR-2 is the major receptor responsible for angiogenic and 
vasculogenic signaling by VEGFs involving cell survival, migration and mitogenesis. 
VEGFRs consist of an extracellular domain (ECD) with seven immunoglobulin-
homology domains (Ig-homology domains). The ECD is responsible for ligand 
binding and contributes to the dimerization process of the receptors by forming 
homotypic receptor contacts. A single transmembrane helix connects the ECD to the 
intracellular kinase domain. Ligand binding to VEGFR ectodomains induces 
dimerization of receptor monomers followed by autophosphorylation of specific 
tyrosine residues in the intracellular kinase domains. The phosphotyrosine containing 
activated kinase subsequently recruits signaling proteins thereby activating distinct 
cellular pathways. Here we show that the introduction of glutamic acid residues into 
the transmembrane domain (TMD) of VEGFR-2 leads to dimerization and induces 
conformational changes in the TMD. A subsequent rearrangement of the intracellular 
kinase domains gives rise to either active or inactive receptor dimers. We also show 
that the ECD of VEGFR-2 plays an essential autoinhibitory role in the absence of 
ligand. Furthermore, high-resolution structural analysis of isolated wild type (wt) and 
mutant TMD by NMR spectroscopy reveal TMD conformations presumably essential 
for receptor activation.  
In a second project, we analysed the function of the kinase insert domain (KID) and 
the C-terminal domain (CD) in VEGFR-2 activation. We show that these domains 
regulate VEGFR-2 activity. The KID, and particularly a canonical tyrosine residue 
located at position 951 are highly relevant for kinase activation. Deletion of the CD 
renders VEGFR-2 constitutively active and we thus think that the CD of VEGFR-2 
maintains the receptor in the inactive state in the absence of ligand. Low resolution 
structural data derived from small angle X-ray scattering (SAXS) and MALS (Multi 
Angle Light Scattering) give evidence that the kinase domain of VEGFR-2 undergoes 
significant conformational changes when switching from the inactive to the active 
state. The activated kinase domain adopts an elongated, open conformation whereas 
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the inactivated kinase domain remains in a globular compact conformation with the 
CD presumably blocking the catalytic site of the kinase similar to the autoinhibited 
conformation previously demonstrated for the Tie-2 kinase domain. Additional 
sedimentation equilibrium analytical ultracentrifugation (AUC) experiments of kinase 
domain mutants demonstrated that the KID and the CD are necessary to sustain an 
intrinsic dimerization propensity that potentially supports the dimerization process 
induced by ligand binding to the ECD. Deletion mutants showed lower affinity forming 
dimers only at higher concentration. In experiments aiming to investigate 
phosphorylation kinetics of the VEGFR-2 kinase domain we finally showed that 
VEGFR-2 follows a well-ordered sequence of residue-by-residue phosphorylation. 
In a third project we were interested in characterizing the in vitro interaction between 
TSAd and activated VEGFR-2. Y951 mediated complex formation of TSAd with 
VEGFR-2 was found to be critical for VEGF-induced actin reorganization and 
migration but did not affect mitogenicity in endothelial and tumour cells. We were 
interested to gain insights on the binding mode by means of high and low-resolution 
structural biology methods. Initial size exclusion chromatography (SEC) and MALS 
analysis verified TSAd-VEGFR-2 interaction in vitro. SAXS analysis of the isolated 
binding partners and the complex revealed that pY951 mediated binding of TSAd 
resulted in an elongated multiprotein complex in which the binding partners orient in 
a presumably parallel orientation. 
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4. Zusammenfassung 
 
Die Familie der vaskulären endothelialen Wachstumsfaktoren (VEGFs) spielt eine 
entscheidende Rolle bei der Entwicklung und Aufrechterhaltung des Blut- und 
Lymphgefässsystems. Die Familie besteht aus VEGF-A, -B, -C, -D und PLGF. Die 
Wachstumshormone binden an drei Typ V Rezeptor-Tyrosin-Kinasen: VEGFR-1 
(Flt1), VEGFR-2 (Flk1) und VEGFR-3 (Flt4). VEGFR-2 ist mehrheitlich für die VEGF 
induzierte Aktivierung von angiogenen und vaskulogenen Signalwegen und den 
daraus resultierenden biologischen Effekten verantwortlich.  Die VEGF-Rezeptoren 
besitzen eine extrazelluläre Domäne bestehend aus sieben immunoglobulin-
ähnlichen Proteindomänen, die nebst der Rekrutierung von Liganden auch der 
Dimerisierung des Rezeptors durch Ausbildung von homotypischen Kontakten dient. 
Eine einzelne Transmembranhelix verbindet die extrazelluläre Domäne mit der 
intrazellulär geteilten Kinasedomäne. Die Ligandenbindung an den Rezeptor führt zu 
Dimerisierung und der darauf folgenden Aktivierung durch Autophosphorylierung an 
spezifischen Tyrosinen in der Kinasedomäne. Die Phosphotyrosine rekrutieren 
daraufhin Signalmoleküle, die in der Lage sind spezifische Signalwege zu aktivieren. 
Wir konnten zeigen, dass Glutaminsäure-Mutationen in der Transmembrandomäne 
von VEGFR-2 zu Konformationsänderungen in der Helix führen. Die daraus folgende 
Neuausrichtung der Kinasedomänen resultierte in aktiven und inaktiven 
Rezeptorkonformationen. Es gelang uns auch aufzuzeigen, dass die extrazelluläre 
Domäne von VEGFR-2 eine wichtige Rolle bei der Blockierung des Rezeptors im 
inaktiven Zustand in Abwesenheit des Liganden spielt. Hochaufgelöste 
Strukturanalysen von isolierten Wildtyp und mutierten Transmembrandomänen 
ergaben Strukturen, die höchstwahrscheinlich bei der Aktivierung des Rezeptors eine 
essentielle Rolle spielen. 
Ein zweites Projekt hatte zum Ziel, die Rolle der Kinase-Insertions-Domäne (KID) 
und der C-terminalen Domäne (CD) bei der VEGFR-2 Aktivierung zu entschlüsseln. 
Wir konnten zeigen, dass die KID und die CD die VEGFR-2 Aktivierung regulieren. 
Die KID und ein spezifisches Tyrosin in Position 951 innerhalb der KID waren 
essentiell für die Kinaseaktivierung. Deletion der CD führte zu konstitutiver 
Aktivierung von VEGFR-2. Wir denken, dass die CD den Rezeptor in Abwesenheit 
des Liganden im inaktiven Zustand behält. Mittels Small Angle X-ray Scattering 
(SAXS) und Multi Angle Light Scattering (MALS) erhaltene Strukturdaten beweisen, 
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dass die Aktivierung der Kinasedomäne von VEGFR-2 mit einer signifikanten 
Änderungen in der Konformation einhergeht. Die aktive Kinasedomäne nimmt eine 
längliche, offene Konformation ein, wohingegen die Inaktive in einer globulären, 
geschlossenen Konformation verbleibt. Sehr wahrscheinlich blockiert die CD dabei 
das katalytische Zentrum des Enzyms, vergleichbar mit dem Mechanismus der von 
der Tie-2 Kinasedomäne verwendet wird. Sedimentation Equillibrium Analytical 
Ultracentrifugation (AUC) Experimente haben gezeigt, dass die KID und die CD 
wichtig sind, um die intrinsische Dimerisierungskapazität der Kinasedomäne zu 
erhalten. Diese intrinsische Tendenz unterstützt vermutlich die ligandeninduzierte 
Dimerisierung bei der Rezeptoraktivierung. Deletionsmutanten zeigen eine niedrigere 
Tendenz zur Dimerisierung mit steigender Proteinkonzentration. Experimente, die 
zum Ziel hatten die Phosphorylierungskinetik der Kinasedomäne zu untersuchen, 
ergaben eine zeitlich geordnete sequentielle Aktivierungssequenz. 
In einem dritten Projekt untersuchten wir die in vitro Interaktion von T-Zell 
spezifischem Adapterprotein (TSAd) mit der aktiven Kinasedomäne von VEGFR-2. 
Es wurde gezeigt, dass die Y951 vermittelte Komplexbildung von TSAd mit VEGFR-2 
zu VEGF induzierter Aktinreorganisation in den Zellen führt. Die Endothel- und 
Tumorzellen wurden dadurch zur Migration gebracht, wobei die Mitogenität 
unverändert blieb. Unser Ziel war es, mittels hoch- und niedrigauflösenden 
strukturbiologischen Methoden spezifische Informationen zur Interaktion von TSAd 
und VEGFR-2 abzuleiten. Erste chromatographische Analysen und Experimente 
mittels Multi Angle Light Scattering (MALS) bewiesen die Interaktion der beiden 
Proteine in vitro. SAXS Analysen der isolierten Bindungspartner und des Komplexes 
ergaben einen länglichen Signalkomplex, in dem sich die Bindungspartner parallel 
ausrichten.  
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5. Introduction 
 
5.1. Vasculogenesis and angiogenesis 
 
The mammalian circulatory systems consist of the cardiovascular and the Lymphatic 
system. The cardiovascular system is responsible for the delivery of oxygen and 
nutrients to every cell and organ and at the same time the removal of catabolic 
products such as carbon dioxide. The lymphatic system, on the other hand, is 
responsible for draining interstitial fluids from tissues and returning them back into 
the blood circulation. Furthermore, the lymphatic system filters the blood and the 
lymph. The lymph is a colourless liquid containing a remarkable number of 
lymphocytes that are able to fight infections. Vasculogenesis and angiogenesis are 
the essential processes required for the formation and maintenance of the vascular 
system. Vasculogenesis describes the de novo process of vessel formation from 
endothelial precursor cells, known as angioblasts, in early development of the 
embryo. Angioblasts that are differentiated endothelial cells originating from the 
mesoderm build up an early network of vascular tubes known as the primary vascular 
plexus (Risau, 1997; Yancopoulos et al., 2000). Pericytes and smooth muscle cells 
that are recruited towards the vasculature stabilize and support this early network. 
This primary vascular plexus is then further developed by angiogenic processes. 
Angiogenesis is defined as the formation of new vessels from the pre-existing 
vasculature. Angiogenic processes are crucial for the maturation of the new 
vasculature during embryonic development. Wound healing or e.g. the female 
reproductive cycle are dependent on angiogenesis in the adult individual (Hyder and 
Stancel, 1999; Li et al., 2003a). Angiogenesis can be subdivided into two types 
denoted as sprouting and non-sprouting angiogenesis (intussusception). During 
sprouting angiogenesis vascular endothelial cells migrate (sprout) into the initially 
proteolytically degraded extracellular matrix (ECM) guided by the angiogenic signal. 
During intussusception the vessel proliferates and extends into the lumen and splits 
into new vessels.  
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5.2. Molecular basis of vessel formation 
 
Vessel formation and organization relies on complex processes that are not yet fully 
understood. These mechanisms are orchestrated by a plethora of growth hormones 
and their receptors. Fibrobalst growth factor (FGF) and later Vascular endothelial 
growth factor (VEGF) signaling plays a key role during embryonic development of the 
vascular network. The primary vascular plexus that already contains important vessel 
structures such as the dorsal aorta or the cardinal vein is formed by VEGFR positive 
angioblasts. Maturation and sprouting of the vessels is then further directed by 
VEGF-A. VEGF is the driving force in the formation of the immature vasculature by 
vasculogenesis and angiogenesis. The importance of VEGF signaling in embryonic 
development was demonstrated in mice that carried mutations in the VEGF-A alleles. 
Mice deficient for VEGF-A expression die at embryonic day 9.5-10.5 whereas mice 
carrying a mutation in one single allele die at embryonic day 11-12 (Carmeliet et al., 
1996; Ferrara et al., 1996). VEGF levels must therefore be tightly regulated. The 
secretion of platelet-derived growth factor-B (PDGF-B) by vascular endothelial cells 
in response to VEGF-A recruits mural cells such as vascular smooth muscle cells 
and pericytes to stabilize the immature vasculature. PDGF-B is an important 
mediator of mural cell proliferation and migration. PDGF-B knockout mice die during 
embryonic development due to lack of pericyte-associated vessels, microvascular 
aneurysms and abnormal vascular morphogenesis (Hellstrom et al., 2001). A very 
similar phenotype can be found in endothelial differentiation sphingolipid G-protein 
coupled receptor-1 (EDG-1) knockout mice. The EDG1 pathway is therefore also 
important for mural cell recruitment. Mural cell differentiation from mesenchymal 
progenitors is induced by transforming growth factor-β1 (TGF-β1) that is mainly 
produced by endothelial and preexisting mural cells. Studies in mice with targeted 
disruption of Smad genes, the intracellular mediators of TGF-β signaling, revealed a 
crucial role of TGF-β1 in embryonic development and initiating angiogenesis 
(Pepper, 1997). During blood vessel formation Notch signaling is known to inhibit 
mural cells adjacent to tip cells (Siekmann et al., 2008). Vessel remodelling and 
stabilization are also guided by the Tie receptors consisting of Tie1 and Tie2 and two 
ligands, angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). The angiopoietins act 
together with VEGF. Ang1 is able to stabilize nascent vessels while Angiopietin-2 
(Ang2) prepares the extracellular matrix (ECM) for the invading angiogenic sprouts 
(Maisonpierre et al., 1997). In the presence of VEGF, Ang2 is able to support 
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angiogenic sprouting of vessels whereas in its absence Ang2 acts as an antagonist 
of ang1 and therefore destabilizes nascent vessels. Mice lacking Ang1 show a 
normal primary vasculature but this vasculature fails to undergo further remodelling 
due to lack of association with surrounding cells such as pericytes (Sato et al., 1995; 
Suri et al., 1996). These mice show mainly heart failures caused by problems in 
association of the endocardium and myocardium. A phenotype similar to Ang1/Tie2-
deficient mice is known for mice lacking ephrin-B2 and EphB4 (Wang et al., 1998). 
Eph receptor tyrosine kinases represent the largest family of receptor tyrosine 
kinases (RTKs). EphrinB2 was found to regulate angiogenic sprouting by regulating 
VEGFR-2 and VEGFR-3 internalization through its PDZ domain (Sawamiphak et al., 
2010; Wang et al., 2010). Ephrins play therefore a significant role in early angiogenic 
remodelling. Moreover, ephrin signaling establishes the arterial-venous vessel fate in 
late stage vascular development. EphrinB2 is expressed in primordial arterial vessels 
whereas EphB4, its receptor, is expressed in the endothelium of primordial venous 
vessels (Wang et al., 1998). This expression pattern is suggested to accomplish 
arterial and venous identity. Along with ephrin signaling, notch signaling besides 
being involved in vessel sprouting was found to favour arterial vs. venous cell 
differentiation in zebrafish (Lawson and Weinstein, 2002). 
A 
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Figure 1: Illustration of vasculogenic and angiogenic processes 
A) Schematic representation of vascular formation with involved growth factors and receptors 
(Yancopoulos et al., 2000). B) Ligands and receptors involved in vasculogenesis and 
angiogenesis (Jain et al., 2003).  
 
In addition to the mentioned signaling pathways such as ephrin or notch signaling the 
extracellular matrix (ECM) influences branching, remodelling, and pruning of vessels 
and therefore guides patterning of the mature vasculature. The ECM is able to store 
several growth factors such as VEGF or FGF. During vascular formation matrix 
metallo proteases (MMPs) can release these factors by degrading the basement 
membranes to create spaces for invading vessel sprouts. Hence, further studies are 
necessary to understand the complex interplay between signaling pathways and the 
patterning role of extracellular space in vessel formation and maturation.  
 
5.3. Pathological angiogenesis in cancer 
 
Various human diseases are characterized by abnormal or excessive vessel growth. 
The most famous one is cancer. Solid tumors show poorly organized vasculature 
impaired to physiological vascular networks. Abnormal angiogenesis can also be 
found in other diseases such as psoriasis, arthritis or retinopathies induced by age 
(age-related macular degeneration, AMD) or diabetes. Degenerative diseases like 
osteoporosis are characterized by a regression of blood vessels (Ferrara and Kerbel, 
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2005). The growth of quiescent tumors that are modulated by pro- and anti-
angiogenic factors (angiogenic switch) can be initiated by various effectors such as 
engagement of an immune response due to an inflammation or the mutation of 
oncogenes (Carmeliet and Jain, 2000). Many tumors initially start to grow as 
avascular cellular masses and subsequently induce angiogenic vessel sprouting 
towards the tumor site to allow further growth (figure 2a) (Folkman, 1971; Hanahan 
and Folkman, 1996). If tumors grow to a certain size of approximately 2 mm they 
become hypoxic. Hypoxia induces the upregulation of the transcription factor 
hypoxia-inducible factor 1 (HIF-1) that is responsible for the transcription of pro-
angiogenic factors such as VEGF or FGF (Carmeliet et al., 1998). The tumor 
vasculature is organized in a chaotic fashion and vessel walls show abnormal 
features. Vascular endothelial cells associate in an inhomogeneous way containing 
wide junctions or forming stacks. Cells undergo spontaneous apoptosis rendering 
vessel integrity weak and opening space for tumor cells. So called mosaic vessels 
are thought to have implications in metastasis. Furthermore, endothelial cells show 
fenestration and some lack expression of endothelial markers such as CD31. 
Adhesion molecules are not expressed homogeneously. Vessel diameters can vary 
due to compression of the vessels by the proliferating tumor (Helmlinger et al., 2000). 
The tumor vasculature also lacks proper assocation with perivascular cells. 
Moreover, tumor associated pericytes show an abnormal morphology. These 
features often render vessels leaky. Characteristic for cancerous tissue is an 
imbalance of pro- and anti-angiogenic factors (Jain and Munn, 2000). VEGF family 
members are known to induce vessel-leakage (Fukumura et al., 1998) whereas 
growth factors such as Ang1 do the opposite. Vessel co-option, the use of pre-
existing vessels to support tumor growth, represents another way for tumor cells to 
progress as an initially well-vascularized tumor (Holash et al., 1999a; Holash et al., 
1999b). Co-option results in a response of the host vessels since upon tumor growth 
vessels start to regress due to expression of Ang2 (figure 2b, left). Ang2 therefore 
represents a biomarker for co-opted vessels. The vessel regression causes the 
tumor environment to become hypoxic. The hypoxic environment leads to significant 
tumor cell death but surviving cancerous tissue induces novel angiogenesis by 
expression of VEGF (figure 2b, middle) (Holash et al., 1999a; Holash et al., 1999b). 
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Figure 2: Mechanisms of pathological tumor angiogenesis 
A) Induction of angiogenesis by an avascular tumor. B) Tumor growth involving host vessel 
co-option (Yancopoulos et al., 2000).  
 
5.4. The VEGF/VEGFR signaling system 
 
Vascular Endothelial Growth Factors (VEGFs) and their receptors are the key players 
in blood and lymphatic vessel development and homeostasis. Three type V receptor 
tyrosine kinases (RTKs): VEGF-receptor-1 (VEGFR)-1 (Flt1), VEGFR-2 (KDR/Flk1), 
and VEGFR-3 (Flt4) recruit five ligands: VEGF-A,-B,-C,-D and placenta growth factor 
(PLGF) in an overlapping receptor binding pattern (figure 3A). VEGF-E, found in orf 
family parapox viruses, and VEGF-F, found in snake venoms, are structurally highly 
related to mammalian VEGFs (Shibuya, 2003; Yamazaki et al., 2009). VEGF-A, -B, -
C, and PLGF are required for both blood and lymphatic vessel formation and 
development while VEGF-C and -D were sufficient for lymphatic vessel formation. 
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Figure 3: Signaling pathways of VEGFRs 
(A) Binding of VEGFs to VEGFRs and neuropilins and signaling pathways of VEGFR-2. (B) 
Splice variants of the VEGF family. Red: VEGF-A, blue: PLGF, green: VEGF-B, turquoise: 
VEGF-C and –D, magenta: VEGF-E. Numbers depicted on the right indicate the amino acid 
sequence identity with VEGF-A165. Arrows show sites of proteolytic processing for the 
generation of VEGF-C and -D with VEGFR-2 specificity (Takahashi and Shibuya, 2005). 
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VEGF binding to the VEGFR extracellular domains induces dimerization of receptor 
monomers followed by autophosphorylation of specific tyrosine residues in the 
receptor kinase domain within the cell. The phosphotyrosine containing activated 
kinase domains subsequently recruits signaling proteins that are able to activate 
specific cellular pathways (figure 3A). Alternative splicing or proteolytic processing of 
VEGFs results in various isoforms (figure 3B), which modulate biological signal 
transduction. (Takahashi and Shibuya, 2005). Furthermore, known co-receptors such 
as neuropilin-1 (Nrp-1), neuropilin-2 (Nrp-2) or heparan sulfate proteoglycans 
(HSPG) influence endothelial cell signaling (Grünewald et al., 2010). 
 
5.4.1. Structure and function of VEGFs and VEGFRs 
 
The VEGF family growth factors represent secreted, dimeric cysteine-linked 
glycoproteins with a Mr of ~40 kDa. VEGFRs consist of an extracellular domain 
(ECD) with seven immunoglobulin-homology domains (Ig-homology domains). The 
fifth Ig-like domain of VEGFR-3 is split in disulfide-linked subunits The ECD is 
responsible for ligand binding and contributes to receptor dimerization by forming 
homotypic receptor contacts (Ruch et al., 2007). A single transmembrane helix 
connects the ECD to the intracellular kinase domain with a regulatory JMD.  
 
VEGF-A 
VEGF-A plays pivotal role in vascular development in the embryo but also in adults. 
The deletion of one single allele in mice causes early lethality at embryonic day 11-
12 (Carmeliet et al., 1996;Ferrara et al., 1996). VEGF-A exists in up to nine isoforms 
due to alternative splicing: VEGF-A121, VEGF-A145, VEGF-A148, VEGF-A162, VEGF-
A165, VEGF-A165B, VEGF-A183, VEGF-A189, and VEGF-A206 (Figure 3B). All VEGF-A 
isoforms bind to VEGFR-1 and VEGFR-2 with high affinity. The VEGFR sites of 
interaction lie on opposite sides of the dimeric VEGF molecule. VEGF-A is expressed 
in vascular endothelial and immune cells (Ferrara and Davis-Smyth, 1997). The 
VEGF-A gene consists of eight exons and seven introns (Tischer et al., 1991). All 
isoforms contain exon 1-5 and in addition exons 8a or 8b. Further combinations of 
exon 6-7/8 enable binding of heparan sulphate (HS) by basic amino acids. Exon 6a is 
part of VEGF-A145, VEGF-A162, VEGF-A189, VEGF-A183 and VEGF-A206 whereas exon 
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6b is part of VEGF-A162 and VEGF-A206. Furthermore, a basic sequence encoded by 
exon 7 can be found in VEGF-A189 and VEGF-A206 (Keyt et al., 1996;Poltorak et al., 
2000;Poltorak et al., 1997). The importance of HS binding becomes clear when 
studying VEGF-A164, VEGF-A188 knockout mice. Knockout of VEGF-A164 or VEGF-
A188 causes lethality immediately after birth. The reason are organ bleedings or 
cardiac dysfunction (Carmeliet et al., 1999). Mice expressing only VEGF-A120 suffer 
from impaired angiogenesis in the myocardium, the retina and developmental 
problems of the skeleton (Maes et al., 2002; Zelzer et al., 2002). VEGF-A165b, a splice 
variant that lacks the last amino acids compared to VEGF-A165 and its family 
members VEGF-A121b, VEGF-A145b and VEGF-A169b are not expressed in tumors, but 
are part of the normal VEGF-A pool in normal tissue (Bates et al., 2002; Perrin et al., 
2005; Nowak et al., 2008; Woolard et al., 2004; Pritchard-Jones et al., 2007). The 
aforementioned exon 8b exerts this inhibitory effect by acting as partial agonists of 
VEGFR-2 (Woolard et al., 2004) due to a lack of binding to Nrp-1 (Cébe-Suarez et 
al., 2006).  
 
VEGF-B  
VEGF-B exists in two alternative isoforms: VEGF-B167 and VEGF-B186. Both isoforms 
have different C-termini compared to VEGF-A. VEGF-B167 and VEGF-B186 are 
expressed in muscle tissue, heart, brain or skin and both bind to VEGFR-1 and Nrp-1 
(Makinen et al., 1999). VEGF-B167 and VEGF-B186 differ in their ability to bind to 
HSPGs. VEGF-B167 binds to HSPGs and is located on the cell surface and the ECM 
whereas VEGF-B186 is not able to bind to HSPSGs and is therefore freely diffusable 
upon secretion (Olofsson et al., 1996a; Olofsson et al., 1996b). Mice lacking VEGF-B 
showed no severe defects. VEGF-A could possibly take over the role of VEGF-B and 
prevent major biological failure (Mould et al., 2003; Sun et al., 2006). Nevertheless, 
mice demonstrate reduced recovery form brain and heart ischemia. Furthermore they 
show an impaired heart vasculature and abnormal heart morphology (Aase et al., 
2001). VEGF-B has been found in several cancer types but its role in cancer 
progression has not been attributed at the moment (Salven et al., 1998). It is possible 
that synergistic effects of VEGF-B with other growth factors can play a role.  
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VEGF-C 
After translation VEGF-C undergoes proteolytic maturation where its carboxy- and 
amino-terminal ends are cleaved giving rise to the final product being able to bind to 
VEGFR-3 and with lower affinity to VEGFR-2 (Joukov et al., 1996). VEGF-C plays an 
important role in lymphangiogenesis and is mainly expressed in the lung or heart but 
the expression is also enhanced in various solid tumors (Kukk et al., 1996; Pepper, 
2001). VEGF-C knockout mice die as embryos due to impaired lymphatic vasculature 
and severe oedemas (Karkkainen et al., 2003).  
 
VEGF-D 
VEGF-D does also undergo proteolytic maturation, similar to VEGF-C by cleavage of 
its carboxy- and amino-terminal ends to bind to VEGFR-3 and with lower affinity to 
VEGFR-2. VEGF-D is involved in growth and development of the lymphatic and the 
blood vasculature. Remarkably VEGF-D knockout mice are viable with negligible 
defects (Baldwin et al., 2005). The lack of VEGF-D could possibly be compensated 
by VEGF-C. The exact role of VEGF-D remains to be determined. However, VEGF-D 
was found to influence metastasis of cancer cells (Stacker et al., 2001). 
 
PlGF 
Alternative splicing of PlGF, that was initially isolated from human placenta, 
(Maglione et al., 1991), gives rise to four different isoforms: PlGF-1 (PlGF131), PlGF-2 
(PlGF152), PlGF-3 (PlGF203), and PlGF-4 (PlGF224). PlGFs bind to VEGFR-1 but not to 
VEGFR-2 and -3 (Park et al., 1994). Furthermore, PlGF-2 recognizes Nrp-1 and 2. 
PlGFs show distinct heparin binding properties. PlGF-2 and -4 bind heparin whereas 
PLGF-1 and -3 do not (Maglione et al., 1993; Yang et al., 2003). PlGF is expressed 
in the placenta during human gestation and in the lung, heart or thyroid gland 
(Persico et al., 1999). PlGF knockout mice did not develop an abnormal vasculature 
in the embryo but deletion of PlGF had an impact on cancer angiogenesis and 
pathology such as ischemia (Carmeliet et al., 2001). Cancer progression could be 
stopped by blocking PlGF and ischemic tissue recovered upon revascularisation. 
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VEGFR-1 
In 1990 VEGFR-1 was isolated from a placental cDNA-library (Shibuya et al., 1990). 
VEGF-A, VEGF-B, PlGF and some VEGFs in snake venoms bind to VEGFR-1 with 
high affinity. VEGF-A binding affinity to VEGFR-1 was found to be more than 10 fold 
higher binding to VEGFR-2 and Ig-homology domain 2 was identified as the ligand- 
binding site of VEGF-A to VEGFR-1 (Wiesmann et al., 1997). VEGFR-1 expression 
can be found in vascular endothelial cells, dendritic cells, perycytes, macrophages, 
monocytes or hematopoietic stem cells (Barleon et al., 1996; Hattori et al., 2002; 
Sawano et al., 2001). VEGFR-1 knockout mice die at embryonic day 8.5-9. It was 
shown that death occurs due to increased proliferation of endothelial progenitor cells 
resulting in a disorganized vasculature (Fong et al., 1995; Fong et al., 1999). Mice 
expressing a kinase domain-deleted version of VEGFR-1 in contrary developed a 
normal vasculature and were viable (Hiratsuka et al., 1998). It was suggested that 
VEGFR-1 acts as decoy receptor modulating embryonic development by 
sequestering VEGF-A and preventing overstimulation via VEGFR-2. Furthermore, 
the localization of VEGFR-1 in the membrane seems to be important. 50% of the 
mice expressing a soluble form of VEGFR-1 ECD die prenatally due to defective 
vasculogenesis (Hiratsuka et al., 2005). Moreover, Shibuya et al. found a soluble 
VEGFR-1 isoform (sVEGFR-1) consisting of the first six Ig-homology domains that 
supports the hypothesis that VEGFR-1 acts as a scavenger (Shibuya et al., 1990). 
The kinase domain of VEGFR-1 exhibits only weak tyrosine autophosphorylation and 
signal transduction although VEGF-A shows higher affinity for VEGFR-1 than for 
VEGFR-2 (Seetharam et al., 1995; Waltenberger et al., 1994). Gille et al. found a 
repressor sequence in the juxtamembrane domain (JMD) that constitutively inhibits 
receptor kinase and phosphatidylinositol 3`-kinase (PI3K) activation and endothelial 
cell migration (Gille et al., 2000). Moreover, mutation of N1050D in the activation loop 
of VEGFR-1 leads to an increase in activity (Meyer et al., 2006). Depending on 
ligand-binding VEGFR-1 is able to change its tyrosine phosphorylation pattern and 
the resulting signaling output (Cunningham et al., 1995; Sawano et al., 1997). VEGF-
A binding to VEGFR-1 leads to Y1213 phosphorylation whereas PlGF binding 
resulted in phosphorylation of Y1309 (Autiero et al., 2003). Both ligands may induce 
distinct conformational changes in the receptor ECD giving rise to different signal 
transduction. To date the downstream signaling network of VEGFR-1 is still not well 
characterized. Various regulatory molecules such as p85/PI3K, PLC-γ1, growth-
Doctoral Thesis   Sandro Manni 
 
23 
factor-receptor-bound-2 protein (Grb2), Src-homology phosphatase-2 (SHP2) or Nck 
are known to interact with phosphotyrosine residues in the intracellular kinase 
domain of VEGFR-1 (Matsumoto and Claesson-Welsh, 2001). VEGFR-1 could 
regulate VEGFR-2 not only by its ability to sequester VEGF-A. It was shown that 
VEGFR-1 is able to suppress VEGFR-2-induced proliferation of endothelial cells 
(Zeng et al., 2001). Embryonic stem cells lacking VEGFR-1 show increased VEGFR-
2 phosphorylation (Autiero et al., 2003; Olsson et al., 2006) on the other hand earlier 
studies show that VEGFR-1 is able to amplify VEGFR-2 activity (Autiero et al., 2003; 
Hiratsuka et al., 2001). The exact mechanism by which VEGFR-1 and VEGFR-2 
regulate each other remains to be discovered.  
 
VEGFR-2  
VEGFR-2, also known as KDR (kinase insert domain-containing receptor) or Flk-1 
(fetal liver kinase-1), is the major receptor responsible for angiogenic and 
vasculogenic processes by VEGFs involving cell survival, migration, mitogenesis and 
permeability. The gene was initially isolated in 1991. VEGF-A, VEGF-C, VEGF-E, 
and proteolitically processed VEGF-D bind to VEGFR-2. Ligand binding of VEGFR-2 
involves Ig-homology domains 2 and 3 (Fuh et al., 1998; Leppänen et al., 2010) 
(Brozzo et al., 2012a). VEGFR-2 is expressed in vascular endothelial cells, 
hematopoietic cells but was also found in neurons or retinal cells (Kabrun et al., 
1997; Shiote et al., 2005; Yang and Cepko, 1996). VEGFR-2 knockout mice die at 
embryonic day 8 to 9 due to lack of a functional vasculature similar to the deletion of 
VEGF-A reflecting the importance of the receptor in vasculogenesis (Shalaby et al., 
1995). Interestingly VEGF-A has a lower affinity for VEGFR-2 than for VEGFR-1. 
Nevertheless, VEGFR-2 exhibits strong kinase activity upon ligand binding. VEGFR-
2 dimerization and activation leads to autophosphorylation of intracellular tyrosine 
residues. Of the 19 tyrosine residues in the intracellular domain Y801 in the JMD, 
Y1054 and Y1059 in the activation loop, Y951 in in the KID and Y1175 and Y1214 in 
the C-terminus have been mapped as important autophosphorylation sites serving as 
docking sites for regulatory proteins. These proteins interact with these 
phosphotyrosines via their Src-homology (SH) or phospho-tyrosine binding (PTB) 
domains. Phosphorylation of Y1054 and Y1059 is critical for kinase activation and 
catalytic potentiation (Kendall et al., 1999; Takahashi et al., 2001a). TSAd (T-cell 
specific adapter protein), an adapter protein lacking intrinsic catalytic activity, was 
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found to interact with phosphorylated Y951 in the KID of VEGFR-2 via its SH2 
domain. Binding of TSAd to Y951 and the subsequent SH3-domain mediated binding 
of Src to TSAd leads to actin stress fibre formation and cell migration but does not 
induce mitogenesis (Matsumoto et al., 2005; Wu et al., 2000). Tyrosine 1175 
represents the most important autophosphorylation site that initiates multiple 
signaling pathways. PLC-γ interacts with phosphorylated Y1175 in the CD of the 
kinase of VEGFR-2 via its SH2-domain. The PLC-γ mediated signaling pathway is a 
key regulator of vasculogenesis and angiogenesis. In mice the Y1173F mutation 
(corresponding to Y11775 in humans) induces embryonic death (Sakurai et al., 
2005). Binding of PLC-γ to pY1175 results in 1, 2-diacylglycerol (DAG) release 
following phosphatidylinositol 4, 5-bisphosphate (PIP2) hydrolysis. DAG is able to 
activate protein kinase C (PKC) and to trigger the release of intracellular calcium. 
PKC activates the Ras-independent MAPK pathway (Raf-MEK-ERK) that leads to 
gene transcription and finally endothelial cell proliferation (Cébe-Suarez et al., 2006; 
Cunningham et al., 1997; Koch and Claesson-Welsh, 2012; Takahashi et al., 1999; 
Takahashi et al., 2001b). Another adaptor protein, Shb (Src homology 2 protein in 
beta cells) binds to phosphorylated Y1175 and directly interacts with PI3-K 
(phosphoinositol-3-kinase) that provokes PKB/Akt (protein kinase B) activation. This 
pathway leads to an increase of nitric oxide (NO) that results in vascular permeability 
and in the survival of endothelial cells (Fujio and Walsh, 1999;Holmqvist et al., 2004). 
Furthermore, Shb is able to bind to FAK (focal adhesion kinase), which modulates 
focal adhesion complexes and leads to migration of cells (Abedi and Zachary, 1997) 
(figure 4). Phosphorylated Y1214 recruits Nck that activates a pathway through p38 
and induces migration of endothelial cells (Lamalice et al., 2006). 
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Figure 4: VEGF-A165 mediated signal transduction of VEGFR-2  
(Koch and Claesson-Welsh, 2012) 
 
VEGFR-2 does also exist in a soluble form similar to VEGFR-1. Soluble VEGFR-2 
could be found in mouse and human plasma and consists of only the first six Ig-
homology domains. Its function is still not clear. Some studies show that it acts as a 
scavenger for VEGF-C and negatively regulates lymphangiogenesis (Albuquerque et 
al., 2009; Ebos et al., 2004). 
 
VEGFR-3 
VEGFR-3 (Flt-4) binds to VEGF-C and VEGF-D. It is the main receptor for the 
development, regulation and survival of lymphatic vessels and plays also a role in the 
remodelling of the immature blood vasculature. VEGFR-3 is present in endothelial 
cells during embryogenesis (Kaipainen et al., 1995). VEGFR-3 is synthesized as a 
precursor molecule and proteolytically processed in the fifth Ig-homology domain of 
the ECD. The split ECD is held together by a disulfide bridge. As mentioned, during 
embryonic development VEGFR-3 is expressed in all endothelial cells. In adults 
expression is restricted to lymphatic vessels (Oliver and Detmar, 2002). VEGFR-3 
knockout mice die at embryonic day 9.5 due to defective vascular development 
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(Dumont et al., 1998). Interestingly, this phenotype differs from VEGF-C knockout 
mice that die from impaired lymphatic vessels but show normal blood vessels. This 
indicates the important role of VEGFR-3 in early angiogenesis. Another explanation 
for such a phenotype is the modulation of VEGFR-2 during embryogenesis. It was 
shown that VEGFR-3 is able to form heterodimers with VEGFR-2 (Dixelius et al., 
2003; Nilsson et al., 2010). 
 
5.4.2. The role of the transmembrane domain of VEGFR-2 
 
RTKs contain a single helical transmembrane segment that for a long time has been 
considered to play a passive role in dimerization and activation of the receptor. 
Disease related mutations within the transmembrane domain (TMD) of some 
receptors demonstrated that the TMD of RTKs is able to contribute to receptor 
dimerization and activation. Bargmann et al. identified a single V664E mutation in the 
TMD of the oncogene that gives rise to constitutive dimerization and activation of the 
receptor leading to tumor formation (Bargmann et al., 1986; Bargmann and 
Weinberg, 1988). The substitution of the single G380R in the TMD of FGFR-3 leads 
to achondroplasia, that is a form of dwarfism (Li et al., 1997) and the substitution of 
A392E has been associated with a human disease called Crouzon syndrome. Two 
single substitutions of M701N and G708N in the TMD helix of integrin αIIbβ3 are able 
to activate the integrin such that it constitutively binds fibrinogen (Li et al., 2003b). 
These examples of induced receptor activations were thought to be driven by 
interhelical hydrogen bonding of the glutamic acid residues or residues that are 
capable to act simultaneously as hydrogen bond donor and acceptor (Smith et al., 
1996; Sternberg and Gullick, 1989; Zhou et al., 2000). Biochemical studies of 
receptor mutants carrying polar amino acids such as Asn, Glu, Gln or Asp in micelles 
and cell membranes proved this assumption (Choma et al., 2000; Gratkowski et al., 
2001; Zhou et al., 2000). Moreover, specific dimerization motifs could be identified 
that presumably drive the dimerization process of the two TMD helices. Sequence 
motifs such as the heptat repeat (XxxxxxxX, X=G, A or S) the GG4-like repeat 
(XxxxX X=G, A, S or T, P0 requires a small amino acid, P1 and P2 are hydrophobic 
residues, P3 an aliphatic side chain and P4 again a small amino acid) or Leucine 
zippers (Kubatzky et al., 2001; Ruan et al., 2004) are present in several RTKs. The 
GxxxG motif as an example is present in c-Kit, PDGFR-A, -B or ErbB (Gerber et al., 
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2004; Mendrola et al., 2002; Sternberg and Gullick, 1990) or Glycophorin A (Lemmon 
et al., 1992; MacKenzie et al., 1997). Remarkably, the TMD helices of all human 
RTKs are enriched in small amino acids and thus indicate the importance of these 
residues in mediating and stabilizing helix-helix contacts in the lipid bilayer. Structural 
evidence comes from NMR-studies of dimerized TMD-helices. The TMD-helices of 
ErbB2 associate through a tandem variant of the GG4-motif Thr652-X3-Ser656-X3-
Gly660 that is located in the N-terminal part of the helix (Bocharov et al., 2008). A 
global analysis of the TMD of the existing 58 RTKs showed that the TMD helices 
encode an intrinsic propensity to form dimeric structures within the cell membrane 
and that specific interactions are generally involved in signaling by RTKs (Finger et 
al., 2009a). Nevertheless, the various RTKs show remarkable differences in the 
interaction propensity relative to the interaction of the human GpA wt-TMD that 
reflects the strongest interaction. In this study the TMD-helices of VEGFR-2 showed 
a moderate intrinsic propensity to form dimers and indeed none of the known 
dimerization motifs are present. However, the role of the TMD of VEGFR-2 remains 
unclear so far. It has previously been shown that RTKs can be artificially activated by 
mutating the TMD. Bell et al. (Bell et al., 2000) designed a dimerization interface in 
an valine TMD of the neu receptor carrying two sequentially positioned glutamic acid 
residues seven amino acids apart that gave rise to activating and inactivating 
receptor constructs. However, other results showed that the TMDs of RTK are more 
likely to interact in an X-shaped conformation (Bocharov et al., 2008; Gullick et al., 
1992; Mineev et al., 2010; Smith et al., 1996). Introduction of the dimerization 
interface used by Bell et al. into the TMD of VEGFR-2 resulted in an activation 
pattern of VEGFR-2 similar to neu. Sequentially arranged glutamic acid residues in 
an otherwise all valine TMD helix in VEGFR-2 gave rise to either active or inactive 
dimers. Dimerization is therefore required but not sufficient for activation of VEGFR-2 
(Dell'Era Dosch and Ballmer-Hofer, 2009a). 
 
5.4.3. The intracellular kinase domain of VEGFR-2 
 
Tyrosine phosphorylation plays an essential role in signal transduction of cells. This 
posttranslational modification of proteins must be tightly controlled in order to avoid 
deregulation of cells. Protein tyrosine kinases are the enzymes that catalyse the 
phosphoryl transfer from ATP (γ-phosphate) onto the hydroxyl group of specific 
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protein substrate side chains. VEGFRs belong to the platelet-derived growth factor 
receptor (PDGFR) family. Other members of this family are PDGFRα and -β, colony 
stimulating factor-1 receptor (CSF-1R) or stem cell growth factor receptor (c-Kit). 
Compared to other kinases, these family members contain a kinase insertion domain 
(KID). The only structural information available for the intracellular domain of 
VEGFR-2 derives from a partial structure lacking parts of the JMD, 50 of the 68 
residues of the KID and the entire ~200 residues carboxy-terminal domain (CD) 
(McTigue et al., 1999a). Several crystal structures of the same protein in complex 
with various inhibitors are available at present. A crystal structure of the kinase 
domain of VEGFR-1 in complex with an inhibitor has been solved in 2009 and is 
available in the PDB database (3HNG). The intracellular kinase domain of VEGFR-1 
and VEGFR-2 adopts a typical bilobal structure that is split by the KID. The N-lobe of 
the kinase domain consists predominantly of antiparallel β-sheets and one single α-
helix denoted as the αC-helix. The αC-helix is an important element that is used to 
switch the kinase on or off. The C-lobe of the kinase domain is of mainly α-helical 
nature. The active site of the enzyme is located in the cleft between the N- and the C-
lobe. VEGFR-2 is activated according to the general mechanism accounting for 
RTKs activation. RTKs are activated through ligand-induced dimerization, which 
rearranges the cytoplasmic tyrosine kinase domains. Dimerization facilitates 
autophosphorylation of specific tyrosine residues in the kinase domain that serve as 
recruitment sites for regulatory proteins. Activation of tyrosine kinases usually 
requires the phosphorylation of tyrosine residues on the JMD and in the activation 
loop. Substantial reorientation of the αC-helix is necessary to activate the kinase 
domain. In the open conformation ATP and substrate bind to specific sites between 
the N- and the C-lobe of the enzyme. Detachment of the γ-phosphate of ATP and its 
transfer to the substrate occurs in the closed conformation. Finally release of ADP 
and phosphorylated substrate take place in the transition from the closed to the open 
conformation (Kornev et al., 2006). Coordinated movements between the open and 
the closed conformation of both lobes are thought to be stabilized by hydrophobic 
contacts referred to as flexible hydrophobic “spine” (figure 5). 
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Figure 5: The intracellular kinase domain 
(A) Overall structure of VEGFR-2 kinase domain (McTigue et. al, 1999, 1VR2). Orange: 
Glycine-rich loop. Green: Activation loop. Yellow: Catalytic loop. Magenta: Boundaries of the 
KID. (B) Diagram with interaction between the human VEGFR-2 protein tyrosine kinase 
catalytic core residues, ATP and the substrate.  Important residues in contact with ATP or the 
substrate are depicted in the light khaki background. Secondary structures and residues 
important for regulation of the catalytic activity can be found in the grey background. 
Hydrophobic interactions between the HRD motif, the DFG motif and the αC-helix are 
indicated by black arrows. Polar contacts are indicated by dashed lines. Pho: 
phosphotyrosine (Roskoski et al., 2008). (C) General model of protein kinase activation in 
PKA: Inactive kinase conformation. The activation loop and the “spine” are distorted. The 
molecule is destabilized and the lobes can move independently. (D) General model of protein 
kinase activation in PKA: Active kinase conformation. T197 orients the DFG aspartate to 
interact with ATP and the DFG phenylalanine for building up a hydrophobic “spine” that is 
completed by the movement of the αC-helix. The hydrophobic spine stabilizes the kinase 
domain for catalysis. This conformation is stabilized by the K72-E91 interaction. Spine residues 
are indicated as blue disks and the shaded grey portion of the N-lobe (Kornev et al., 2006). 
 
It was shown that activation of certain RTKs such as the FGFR or the EGFR family 
are additionally controlled by an allosteric interaction between the two kinase 
domains in an asymmetric dimer (Stamos et al., 2002; Zhang et al., 2006). The 
mechanism resembles that of a cyclin and its cyclin dependent protein kinase. One 
kinase domain (the activator) acts as the “cyclin” by activating the second kinase 
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domain that plays the role of a cyclin dependent protein kinase (the receiver). In later 
studies it was shown that the JMD of EGFR is actively involved in the formation of 
the asymmetric dimer (Endres et al., 2013). Disruption of the asymmetric dimer 
interface in EGFR leads to drastic reduction of autophosphorylation and enzymatic 
activity (Jura et al., 2009). The same mechanism was found in FGFR1 and FGFR2. 
The structures of FGFR1 and FGFR2 show an asymmetric dimer in the process of 
autophosphorylation at their canonical tyrosine sites (Bae et al., 2010; Bae and 
Schlessinger, 2010; Chen et al., 2008) (figure 6). 
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Figure 6: Asymmetric dimer formation in RTKs 
Top panel: Schematic representation of (A) monomeric forms of EGFR. (B) Asymmetric 
dimer formation upon ligand binding. The JMD stabilizes the asymmetric dimer. (C) 
Asymmetric EGFR dimers in the event of trans autophosphorylation. The green kinase is the 
enzyme-acting kinase while the blue kinase is the substrate-acting one. Middle panel: (A) 
Asymmetric dimer formation in the event of initial activation of EGFR. Activator kinase: Cyan. 
Receiver kinase: Green. The activation loop in the receiver (red) adopts an open 
conformation. The interface of the asymmetric region (blue) is mainly formed by the α-C 
helix, and the JMD of the receiver kinase. (B) Complex structure of CDK2 and Cyclin A 
(1FIN). Bottom panel: (C) Asymmetric dimer formation of FGFR1 in the event of trans 
phosphorylation (3GQI). Y583 in the KID of the kinase domain is bound to the catalytic site of 
the other kinase. (D) Asymmetric dimer formation of FGFR2in the event of trans 
autophosphorylation (3CLY). C-terminal Y769 is bound to the catalytic site of the other 
kinase. The Glycine-rich loop participates in asymmetric homodimer formation in both 
FGFR1 and FGFR2 (Bae and Schlessinger, 2010) 
 
5.4.4. The active site of VEGFR-2 
 
Protein tyrosine kinases catalyse the phosphotransfer reaction of the γ-phosphate 
from ATP onto a protein substrate. This important posttranslational modification is 
evolutionarily conserved from prokaryotes to humans. As a result, also the catalytic 
subunits of protein kinases are highly conserved. The active site between the N- and 
the C-lobe of the kinase domain consists of a nucleotide binding site, the catalytic 
loop that is essential for the transfer reaction and the large and flexible activation 
loop that regulates the activity of the kinase domain. In VEGFR-2 the residues 
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forming the ATP binding site are E917-N923 that connect the N- and the C-lobe and 
residues L840-I849. Among these residues is the glycine-rich (G-loop) or often also 
referred to as the nucleotide binding loop (G841-G846). In the crystal structure of the 
truncated VEGFR-2 kinase domain The G-loop adopts a well-ordered conformation 
resembling the unliganded FGFR1 structure (Mohammadi et al., 1997). The G-loop is 
able to alter its position depending on the activation and ligand-bound state of a 
kinase. The position of the G-loop in FGFR1 and VEGFR-2 is comparable although 
the VEGFR-2 structure contains no bound ATP (McTigue et al., 1999b). The adenine 
ring of ATP is known to form two conserved hydrogen bonds with the protein 
backbone. In the crystal structure of FGFR1 that contains the ATP analog adenylyl 
methylenediphosphate (AMP-PCP) these two hydrogen bonds are formed between 
the adenine amino group and the backbone carbonyl of E562 that corresponds to 
E917 in the G-loop of VEGFR-2. Efficient catalysis depends on a protein stretch 
denoted as the catalytic loop. In kinases the catalytic loop connects helix αE with β-
sheet β7. The sequence of the catalytic loop contains a highly conserved stretch of 
residues: HRD-LAARN that in VEGFR-2 corresponds to H1026-N1033. Moreover, a 
conserved aspartate (D1028) within this stretch that acts as a “catalytic base” is 
highly important for the phosphotransfer reaction (Johnson et al., 1996). The position 
of the loop backbone and its residues in VEGFR-2 show similarities with the catalytic 
loop in the unliganded FGFR1 and in the activated insulin receptor tyrosine kinase 
(IRK) in complex with a peptide substrate and an ATP analogue (Hubbard, 1997). 
The side chain carboxylate of the catalytic aspartate D1028 is hydrogen-bonded to 
the conserved side chains arginine R1032 and asparagine N1033. The activation 
loop, a large flexible loop in the active site of kinases, is known to regulate kinase 
activity by changing its conformation and is characterized by conserved residues 
DFG at the beginning and APE at the end of the loop (Johnson et al., 1996). 
Conformational change is often induced by phosphorylation of specific tyrosine 
residues in this loop. The structure of the insulin receptor kinase domain was first to 
demonstrate autoinhibition of RTKs by its own activation loop (Hubbard, 2004). 
Tyrosine Y1162 in the activation loop blocks the active site from being accessed by 
ATP and the substrate. Upon trans-phosphorylation of the residue the cis-
autoinhibitory conformation of the activation loop is disrupted and the kinase is 
activated. The αC-helix subsequently stabilizes ATP binding by reorienting itself. In 
FGFR1 the tyrosines in the activation loop stabilize the inactive state of the kinase 
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and do not directly block the substrate binding site. The ATP binding site remains still 
accessible (Bae and Schlessinger, 2010; Chen et al., 2007). In VEGFR-2 the 
activation loop involves residues D1046-E1075. Two tyrosines being part of the 
activation loop are known to be phosphorylated upon activation of the kinase: Y1054 
and Y1059 (Dougher Vermazen et al., 1994). The VEGFR-2 protein used to 
determine the 3D structure was in vitro phosphorylated prior to crystallization and 
phosphorylation at Y1059 was detected (McTigue et al., 1999a). Surprisingly, the 
activation loop adopted an inhibited conformation. Electron densities for the central 
segment of the activation loop (G1048-G1063) could not be assigned due to the high 
flexible nature of the loop also observed in other kinases (Huse and Kuriyan, 2002). 
Residues 1064-E1075 adopted a conformation comparable to the unliganded FGFR1 
structure. The crystal-packing environment possibly induces this conformation 
inhibitory to substrate binding. 
 
5.4.5. The JMD of VEGFR-2 
 
It has previously been shown that subdomains outside the active site of RTKs are 
important for recruitment of regulatory proteins, stabilization of the active 
conformation and the triggering of autoinhibition of the kinase domain. As 
demonstrated in several crystal structures, the JMD is such a regulatory element. 
The JMD is involved in formation of the activated asymmetric dimer in EGFR. Models 
and recently NMR structures proved that parts of the JMD form an antiparallel helical 
dimer (Endres et al., 2013). Phosphorylation of the JMD in c-Kit is required for 
activation (Ma et al., 1999). In the insulin receptor, phosphorylation of tyrosine 
residues in the JMD creates binding sites for signaling molecules. Here the JMD 
does not regulate kinase activity. In muscle-specific kinase (MuSK), Eph family 
(figure 7a, 7b) or TGF-β family RTks the JMD binds to an autoinhibitory cleft in the N-
lobe. The JMD forms an alpha-helical structure and reorients the the catalytically 
important alpha C-helix (Hubbard, 2004; Wybenga-Groot et al., 2001). The JMD of 
type III receptor kinases Flt3, c-Kit or CSF-1 (figure 7c) binds in an interface between 
the N- and the C-lobe of the kinase domain and sterically prevents the activation loop 
and the C-α helix from adopting an active conformation (Griffith et al., 2004; Mol et 
al., 2004; Mol et al., 2003; Schubert et al., 2006).  
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Figure 7: Autoinhibitory mechanisms of the JMD in RTKs  
Crystal structures of (A) unphosphorylated EPHB2 (B) unphosphorylated MuSK (C) 
unphosphorylated FLT3 (D) unphosphorylated insulin receptor and (E) phosphorylated 
insulin receptor. Figures are shown as backbone representations. The side chains and ATP 
in part are shown in stick representation. Juxtamembrane regions: Orange. N-terminal kinase 
lobes: Light blue with α-helix C in dark blue. C-terminal kinase lobes: Grey with catalytic loop 
in pink and the activation segments in green. Disordered regions are represented in spheres 
(Hubbard, 2004). 
 
The JMD of VEGFR-2 may follow a similar mechanism previously found in type III 
RTKs. It was shown that the kinase domain of VEGFR-2 carrying the JMD exhibits 
higher thermostability than the JMD-deleted kinase domain (Solowiej et al., 2009). 
Furthermore, it was shown that in vitro activation of the isolated kinase domain of 
VEGFR-2 by ATP leads to phosphorylation at Y801 as a first event followed by 
phosphorylation of Y1054 and Y1059 in the activation loop that finally leads to 
activation of the kinase (Dougher Vermazen et al., 1994;Kendall et al., 1999; 
Solowiej et al., 2009). The initial phosphorylation of Y801 occurs via an 
intramolecular mechanism and the kinase domain may therefore initiate the release 
of the autoinhibitory JMD from the catalytic cleft as a first step in the activation 
process. Further structural studies will be required to explain the exact autoinhibitory 
mechanism of the JMD in VEGFR-2. 
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5.4.6. The KID of VEGFR-2 
 
The KID or the region between helices αD and αE does not show any conservation 
among kinase domains. Length, amino acid composition and structure of the 
insertion domains seem not to follow strict rules. In earlier studies it was shown that 
deletion or mutation of the KID did not alter the kinetic properties of the enzyme but 
rather that the KID was important for recruitment of signaling molecules through 
phosphorylated tyrosine residues residing on the KID (Heidaran et al., 1991; 
Kazlauskas and Cooper, 1989; Lev et al., 1992). The deletion of 58 of the 64 
residues of the CSF-1R KID decreased substrate phosphorylation by 10% and the 
complete deletion of 98 residues of the KID in PDGFR-β decreased the kinase 
activity by 80%. The crystal structure of the kinase domain of Tie-2 revealed an 
important role for the KID as a regulatory element for kinase activation. In the inactive 
state the phenyl ring of Y1112 of the CD of Tie-2 is packed between hydrophobic 
side chains of L696, L579, F1114 and R577 inside the KID. As a result the CD folds 
back onto the kinase domain and blocks the active site. The KID of VEGFR-2 
comprises 68 residues (N933 to L1000). These residues connecting helices αD and 
αE are highly charged and hydrophilic. The KID contains six lysine, five arginine, 
eight glutamic acid and five aspartic acid residues. Furthermore it contains a 
canonical tyrosine residue denoted Y951 is a target for autophosphorylation 
(Matsumoto et al., 2005). 
 
5.4.7. The C-terminal domain of VEGFR-2 
 
Not much is known about the role of the C-terminal domain in VEGFR-2 activation. 
Chimeric receptor constructs that contained the ECD of colony stimulating factor 
receptor (CSF) receptor fused to the C-terminus-deleted kinase domain of VEGFR-2 
showed no activation of the kinase domain upon CSF stimulation (Meyer et al., 
2003). Based on that Meyer et al. proposed that the kinase domains of VEGFR-2 
adopt an inactive dimeric conformation in the absence of the CD. The same effects 
could be found in CD-deleted EGFR. The deletion of the 164 amino acid CD of 
EGFR inactivates the receptor (Wedegaertner et al, 1992). Peptides derived from the 
C-terminus of Met were able to inhibit kinase domain activation in vitro. Furthermore, 
cell delivery of such peptides abolished HGF-dependent Met phosphorylation and 
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downstream signaling (Bardelli et al., 1999). The only structural evidence for an 
active contribution of the CD in receptor activation comes from the Tie-2 receptor 
(figure 9). The C-terminus inhibits the monomeric kinase domain of Tie-2 in the 
inactive state (Shewchuk et al., 2000a). Tyrosine Y1112, a major C-terminal 
phosphorylation site, is packed in a hydrophobic pocket inside the KID of the kinase 
domain. This enables the C-terminal strand to block substrate access to the active 
site of the kinase. 
 
A B 
 
 
 
 
 
 
 
Figure 9: Crystal structure of Tie-2  
(A) Ribbon representation of the inactive Tie-2 kinase domain structure. α-helices: Blue. β-
sheets: Red. Nucleotide-binding loop: White. Catalytic loop: Green. Activation loop: Yellow. 
KID: pink. The inhibitory C-terminal tail is depicted in orange (Shewchuck et al., 2000). (B) 
PyMOL model of Y1112-KID interaction. The C-terminal tail is shown in magenta. Tyrosine 
Y1112 is depicted in red. The KID is colored in white. 
 
Interestingly, the activation loop of Tie-2 adopts an active conformation in the crystal 
structure. Cell biological follow-up studies verified these structural data (Niu et al., 
2002; Sturk et al., 2009). A similar mechanism may also exist in PDGFR but to date 
structural studies have not been described. The crystal structures of the kinase 
domain of VEGFR-2 does not reveal valuable insights on the role of specific kinase 
subdomains in VEGFR-2 activation (McTigue et al., 1999a). This is due to the fact 
that dramatic protein truncations were necessary to crystallize the protein. 
 
 
 
Doctoral Thesis   Sandro Manni 
 
37 
5.5. Aim of the thesis 
 
The VEGF/VEGFR signaling system is a critical regulator of angiogenesis and 
vasculogenesis during normal development but also in several pathological 
conditions such as cancer. The five VEGF ligands bind to three receptors with 
overlapping specificity. Additional VEGF co-receptors such as neuropilins or HSPGs 
further modulate the final biological output. VEGF binding to its receptor induces 
dimerization of receptor monomers, followed by rearrangement of the intracellular 
kinase domains. The proper alignment of the kinase domains leads to 
autophosphorylation on distinct tyrosine residues and recruitment of intracellular 
signaling molecules. The subsequent activation of specific cellular pathways leads to 
the biological output. Although there is an increasing amount of data describing 
angiogenic processes, the exact mechanism of activation, modulation and inhibition 
of the intracellular kinase domain of VEGFRs still needs more profound insights.  
One of the aims of this thesis was to study the role of the TMD during VEGFR-2 
activation. At the beginning we knew that many RTKs are artificially dimerized and 
activated by manipulating the TMD. Furthermore, we had the knowledge from studies 
of our own lab showing that the use of an artificial all valine TMD carrying two 
sequentially arranged glutamic acid residues promotes the formation of either active 
or inactive VEGFR-2 dimers. From these experiments using such artificial TMDs we 
knew that dimerization of VEGFR-2 is necessary, but not sufficient for receptor 
activation. We wanted to confirm the previous findings in the context of the wt-TMD 
and therefore gain additional insights using a more physiological system. In order to 
shed light on conformational changes within the TMD helices during the activation 
process of VEGFR-2 we also used high-resolution structural biology methods. 
Another aim was to analyse the function of individual kinase subdomains such as the 
KID and the CD in VEGFR-2 activation using cell biological and structural biology 
methods. We knew from other VEGFR-2 related RTKs that these subdomains have 
the ability to regulate the activity of the intracellular receptor kinase domains. In this 
project we also performed experiments aiming to investigate the phosphorylation and 
dimerization kinetics of the VEGFR-2 kinase domain to obtain deeper insights into 
the mechanism of kinase activation. 
As a third aim, we characterized the in vitro interaction between TSAd and activated 
VEGFR-2. From cell biological studies it was known that pY951 mediated complex 
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formation of TSAd with VEGFR-2 is required for VEGF-induced actin reorganization 
and migration of endothelial and tumor cells. Our goal was to understand the mode of 
binding of the non-canonical SH2-domain of TSAd interacting with pY951 of VEGFR-
2. Furthermore, we aimed to analyse the overall structure of the complex using low- 
and high-resolution structural biology methods. 
 
6. Materials and Methods 
 
6.1. Functional analysis of transmembrane and kinase domain  
 mutants of VEGFR-2 
 
In order to investigate the role of the TMD and define contributions of the ECD in the 
activation process of VEGFR-2 we designed several TMD mutants. Further we 
designed VEGFR-2 mutants containing deletions in distinct domains within the 
catalytic kinase. TMD mutants were cloned by introducing a single or double glutamic 
acid mutation into the wt-TMD helix. The two glutamic acid residues in the double 
mutants were spaced seven amino acids apart. Glutamic acid residues were then 
sequentially moved across the TMD helix for both types of mutants. For the TMD and 
the catalytic domain mutants we designed both ligand-independent, ECD truncated 
constructs (deletion of amino acids 25–755, accession number P35968) and full-
length constructs including the complete ECD of VEGFR-2. Constructs were cloned 
into mammalian expression vectors. The ECD truncated constructs were cloned into 
the mammalian expression vector pCDNA3 (Invitrogen) whereas the full-length 
VEGFR-2 mutant constructs were cloned into the eGFP expression vector pBE. All 
constructs contained a HA tag. 
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6.1.1. Cloning of transmembrane and kinase domain mutants of  
VEGFR-2 
 
ΔECD-VEGFR-2 TMD mutant constructs 
The HA-tagged wt-TMD ΔECD-VEGFR-2 construct was cloned by Debora Dell’Era-
Dosch. In order to generate mutations within the TMD we applied site-directed 
mutagenesis on the wt-construct. To introduce a second point mutation we used the 
mutated constructs as a template for site-directed mutagenesis. We used the 
following primers (mutated bases in red): 
 
 
5‘-3‘ primer sequence TMD Mutation 
 
For 5‘-GAACTTGGAAATCATTGAACTAGTAGGCA-3‘ 
Rev 5‘-GAAGTAGCCAGAAGAACATGGCAATC-3‘ 
 
I767E 
 
For 5‘-TGGAAATCATTATTGAAGTAGGCACG-3‘ 
Rev 5‘-GAAGTAGCCAGAAGAACATGGCAATC-3‘ 
 
L768E 
 
For 5‘-CATTATTCTAGAAGGCACGGCGGTG-3‘ 
Rev 5‘-GTAGCCAGAAGAACATGGCAATCACC-3‘ 
 
V769E 
 
For 5‘-CATTATTCTAGTAGAAACGGCGGTGATTG-3‘ 
Rev 5‘-GAAGTAGCCAGAAGAACATGGCAATC-3‘ 
 
G770E 
 
For 5‘-CTAGTAGGCGAAGCGGTGATTGC-3‘ 
Rev 5‘-CAAGAAGTAGCCAGAAGAACATGGC-3‘ 
 
T771E 
 
For 5‘-CTAGTAGGCACGGAAGTGATTGCC-3‘ 
Rev 5‘-CAAGAAGTAGCCAGAAGAACATGGC-3‘ 
 
A772E 
 
For 5‘-GCACGGCGGAAGTGATTGCC-3‘ 
Rev 5‘-CAAGAAGTAGCCAGAAGAACATGGC-3‘ 
 
V773E 
 
For 5‘-CGGCGGTGGAAGCCATGTTCT-3‘ 
Rev 5‘-CAAGAAGTAGCCAGAAGAACATGGC -3‘ 
 
I774E 
 
For 5‘-GGCGGTGATTGAAATGTTCTTCT-3‘ 
Rev 5‘-CAAGAAGTAGCCAGAAGAACATGGC-3‘ 
 
A775E 
 
For 5‘-GGTGATTGCCGAATTCTTCTGGCTAC3‘ 
Rev 5‘-GTAGCCAGAAGAATTCGGCAATCACC-3‘ 
 
M776E 
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For 5‘-GTGATTGCCATGGAATTCTGGCTACTTCT-3‘ 
Rev 5‘-GAAGTAGCCAGAAGAACATGGCAATC -3‘ 
 
F777E 
 
For 5‘-CATTATTCTAGAAGGCACGGCGGTG-3‘ 
Rev 5‘-GTAGCCAGAAGAATTCGGCAATCACC-3‘ 
 
V769E 
M776E 
 
For 5‘-CATTATTCTAGTAGAAACGGCGGTGATTG-3‘ 
Rev 5‘-GAAGTAGCCATTCGAACATGGCAATC-3‘ 
 
G770E 
F777E 
 
For 5‘-CTAGTAGGCGAAGCGGTGATTGC-3‘ 
Rev 5‘-CAAGAAGTAGCCATTCGAACATGGC-3‘ 
 
T771E 
F778E 
 
Table 1: Primers used for TMD mutagenesis of VEGFR-2 in pCDNA3 
Glutamic acid mutations are colored in red. 
 
The constructs were amplified by PCR using Phusion High-Fidelity DNA polymerase 
(Finnzymes). Template DNA was digested by adding 1 µL of DpnI (Fermentas) to the 
PCR mixture and incubating 6h at 37°C. To select for the mutated constructs 0.5 µL 
of the PCR reaction mixture was transformed into electrocompetent E.Coli DH10β 
and plated on LB-Amp agar plates. After 16 h incubation at 37°C colonies were 
picked from the plate to set up 5 mL overnight cultures. Plasmid-DNAs were 
extracted with a Miniprep Kit (Qiagen). The introduced mutations were verified by 
sequencing the plasmid-DNAs (Microsynth AG).  
 
Full-length VEGR-2 TMD mutant constructs 
The HA-tagged full-length wt-TMD-VEGFR-2 construct was cloned by Debora 
Dell'Era-Dosch. In order to generate single glutamic acid mutations within the TMD 
we applied site-directed mutagenesis on the wt construct. To introduce a second 
point mutation we used the initially mutated constructs as a template for site-directed 
mutagenesis. We used the following primers (mutated bases in red):  
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5‘-3‘ primer sequence TMD Mutation 
 
For 5‘-GAACTTGGAAATCATTGAACTAGTAGGCA-3‘ 
Rev 5‘-GAAGTAGCCAGAAGAACATGGCAATC-3‘ 
 
I767E 
 
For 5‘-TGGAAATCATTATTGAAGTAGGCACG-3‘ 
Rev 5‘-GAAGTAGCCAGAAGAACATGGCAATC-3‘ 
 
L768E 
 
For 5‘-CATTATTCTAGAAGGCACGGCGGTG-3‘ 
Rev 5‘-GTAGCCAGAAGAACATGGCAATCACC-3‘ 
 
V769E 
 
For 5‘-CATTATTCTAGAAGGCACGGCGGTG-3‘ 
Rev 5‘-GTAGCCAGAAGAATTCGGCAATCACC-3‘ 
 
V769E 
M776E 
 
For 5‘-CATTATTCTAGTAGAAACGGCGGTGATTG-3‘ 
Rev 5‘-GAAGTAGCCATTCGAACATGGCAATC-3‘ 
 
G770E 
F777E 
 
For 5‘-CTAGTAGGCGAAGCGGTGATTGC-3‘ 
Rev 5‘-CAAGAAGTAGCCATTCGAACATGGC-3‘ 
 
T771E 
F778E 
 
For 5‘-CTAGTAGGCACGGAAGTGATTGCC-3‘ 
Rev 5‘-GACAAGAAGTAGTTCGAAGAACATGGC-3‘ 
 
A272E 
W779E 
 
For 5‘-GCACGGCGGGAAATTGCC-3‘ 
Rev 5‘-ATGACAAGAAGTTCCCAGAAGAACATG-3‘ 
 
V773E 
L780E 
 
For 5‘-CGGCGGTGGAAGCCATGTTCT-3‘ 
Rev 5‘-GGATGATGACAAGTTCTAGCCAGAAGAACA-3‘ 
 
I774E 
L781E 
 
Table 2: Primers used for TMD mutagenesis of VEGFR-2 in pCDNA3 and pBE 
Glutamic acid mutation is colored in red. 
 
ΔECD-VEGFR-2 KD and full-length VEGFR-2 KD deletion constructs 
The HA-tagged ΔECD-VEGFR-2 and the HA-tagged full-length VEGFR-2 kinase 
domain deletion mutants were cloned with two separate PCR reactions. In order to 
generate the final constructs we designed hybrid primers with sections coding for the 
donor and the acceptor vector. The first section of the primer was used for a first 
PCR reaction with the purpose to amplify the sequence of interest. The second part 
of the primers with overhangs complementary to the destination vectors served as 
primer for a second PCR reaction with the aim to insert the initially amplified 
sequence into the acceptor vector. Fragments resulting from the first PCR reaction 
were gel purified by using a gel-purification Kit (Qiagen) and used for the second 
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PCR reaction. For the PCR reactions we used Phusion High-Fidelity DNA 
polymerase (Finnzymes). Template DNA in the second PCR reaction was digested 
by adding 1 µL of DpnI (Fermentas) to the PCR mixture and incubating 6h at 37°C. 
To select for the correct constructs 0.5 µL of the PCR reaction mixture was 
transformed into electrocompetent E.Coli DH10β and plated on LB-Amp agar plates. 
After 16 h incubation at 37°C colonies were picked from the plate to set up 5 mL 
overnight cultures. Plasmid-DNAs were extracted with a Miniprep Kit (Qiagen). The 
constructs were verified by sequencing the plasmid-DNAs (Microsynth AG). We used 
the following primer: 
 
5‘-3‘ primer sequence Construct 
 
For 5‘-CAGGAAAAGACGAACTTGGAAATCATTATTCTAGTAGGCACG-3‘ 
Rev 5‘-TTCCATGCTCAAAGTCTCTGATATCGGAAGAACAATGTAGTCTT-3‘ 
 
Wt-TMD ΔKID 
 
For 5‘-CAGGAAAAGACGAACTTGGAAATCATTATTCTAGTAGGCACG -3‘ 
Rev 5‘-ATAGAATAGGGCCCTCTAGTTTATCACGGAAGAACAATGTAGTCTT-3‘ 
 
Wt-TMD ΔC 
 
For 5‘-CAGGAAAAGACGAACTTGGAAATCATTATTCTAGTAGGCACG-3‘ 
Rev 5‘-GAATAGGGCCCTCTAGTTTATCACGGAAGAACAATGTAGTCTT 
TGCCATCCTGCTGAGCATTAGC-3‘ 
 
Wt-TMD 
ΔKIDΔC 
 
Table 3: Primers used for cloning of VEGFR-2 kinase domain deletion mutants 
 
6.2. Cell culture and activity screening of transmembrane and 
kinase domain mutants of VEGFR-2 
 
HEK293 cells were cultured at 37°C, 5% CO2 in DMEM (BioConcept, #1-26F03-I) 
containing 10% fetal bovine serum (FBS), 100 units/mL penicillin and 100 µg/mL 
streptomycin. In order to monitor receptor activity of the various TMD constructs, 
HEK293 cells were transiently transfected with the appropriate plasmid and their 
lysates were analysed via immunoblotting 24 h post transfection. For transfection 
HEK293 cells were seeded in 6-well plates to reach a confluency of 60%. After 24 h 
the cells were transiently transfected using Fugene® (Roche Diagnostics) according 
to the suppliers manual. To prevent overexpression and therefore spontaneous 
activation of the receptor on the membrane the 2 µg of DNA were diluted 1:5 with the 
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empty vector. Cells transfected with constructs that were ECD-deleted were 
incubated 24 h before lysis. Cells transfected with the full-length VEGFR-2 mutants 
were cultured for 24 h and then starved (DMEM + 0.1% BSA) for 4 h. Full-length 
VEGFR-2 constructs were stimulated for 10 min with 50 ng/mL VEGF-A165 (produced 
by Thomas Schleier) prior to lysis. Immediately after incubation or stimulation cells 
were washed twice with ice cold PBS. After washing cells were incubated 15 min with 
150 µL of Lysis buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.1% Triton X-100, 
Roche protease inhibitor cocktail and 1 mM Na3VO4) on ice. After lysis the cell 
suspensions were flash frozen in liquid nitrogen and stored at –20°C. Prior to 
analysis of cell lysates, debris were removed by centrifugation (10’000 x g, 25 min, 
4°C) and total amount of protein in the supernatant was measured with the DC assay 
(modified Lowry assay) of Biorad. The cell lysates were then subjected to western 
blot analysis. Secondary antibodies were alkaline phosphatase (AP) coupled.  Lumi-
Phos™ WB (Thermo Scientific) was used as an AP substrate. We used the following 
primary and secondary antibodies: 
Antibody Primary Secondary Dilution 
pY1054/59, mouse, Calbiochem X  1:1000 
pY951 (15D2), rabbit, Cell Signaling X  1:1000 
pY1175 (19A10), rabbit, Cell Signaling X  1:1000 
PLC-γ1 (D9H10), rabbit, Cell Signaling X  1:1000 
pPLC-γ (Y783), rabbit, Cell Signaling X  1:1000 
β-actin (clone AC-74), mouse, Sigma X  1:1000 
HA (clone 3F10), rat, Roche Diagnostics X  1:1000 
Goat anti-mouse AP, Southern Biotech  X 1:10’000 
Goat anti-rabbit AP, Southern Biotech  X 1:10’000 
Goat anti-rat AP, Southern Biotech  X 1:10`000 
 
Table 4: Primary and secondary antibodies used for activity screening of TMD and KD 
mutants of VEGFR-2 
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6.3. Structural analysis of the transmembrane domain of VEGFR2 
by NMR 
 
In collaboration with Alexander S. Arseniev we determined the spatial structure of wt 
and mutant TMD homodimers of VEGFR-2 (residues 759-795) in membrane 
mimicking DPC micelles by conventional 13C, 15N-heteronuclear NMR techniques. 
The sequence for the modified TMD-helices were PCR amplified out of an artificially 
synthesized sequence (Genewiz) coding for the TMD of VEGFR-2 and digested with 
NdeI, HindIII prior to ligation into an E.Coli expression vector. The helical proteins 
were subsequently expressed in a cell free expression system. We used the 
following coding sequences: 
 
PCR fragment: wt-TMD 
TAC CAG CAT ATG GAA AAA ACC AAC CTG GAG ATC ATT ATT CTA GTA GGC 
ACG GCG GTG ATT GCC ATG TTC TTC TGG CTA CTT CTT GTC ATC ATC CTA 
CGG ACC GTT AAG CGT GCT AAC GGT GGC TAA TAG AAG CTT GCT TAC CAG 
Amino acid sequence: wt-TMD  
IIILVGTAVIAMFFWLLLVIILRTV 
EKTNLEIIILVGTAVIAMFFWLLLVIILRTVKRANGG 
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PCR fragment: V769E-TMD 
TAC CAG CAT ATG GAA AAA ACC AAC CTG GAG ATC ATT ATT CTA GAA GGC 
ACG GCG GTG ATT GCC ATG TTC TTC TGG CTA CTT CTT GTC ATC ATC CTA 
CGG ACC GTT AAG CGT GCT AAC GGT GGC TAA TAG AAG CTT GCT TAC CAG 
Amino acid sequence: V769E-TMD (activated) 
IIILEGTAVIAMFFWLLLVIILRTV 
EKTNLEIIILEGTAVIAMFFWLLLVIILRTVKRANGG 
 
Figure 10: PCR fragments and corresponding amino acid sequences of VEGFR-2- 
TMDs used for preparation of expression vectors for cell free expression. 
The sequences depicted in green are flanking TMD residues to minimize terminal effects on 
water-membrane interfaces. In order to improve expression with the cell free expression 
system we exchanged the rare codons (cyan) coding for Leu and Arg (CTA->CTG/CGG-
>CGT). DNA and amino acid sequence coding for the activating glutamic acid is colored in 
red. Restriction sites for NdeI and HindIII endonucleases are underlined. 
 
Expression, labelling, purification and lipid/detergent reconstitution of the proteins as 
well as data acquisition and data processing was performed according to (Bocharov 
et al., 2008; Mineev et al., 2010). 
 
6.4. Cloning of VEGFR-2 kinase domain mutants for protein 
expression 
 
In order to biophysically investigate the role of distinct regulatory domains in the 
kinase domain of VEGFR-2 we designed mutant constructs for insect cell expression.  
All constructs were TMD-deleted. The constructs were cloned into the previously 
described MultiBac vector pfl (Fitzgerald et al., 2006). All constructs contained a  
C-terminal 10xHis tag with a preceding tobacco etch virus (TEV) cleavage site. The 
soluble ΔTMD-VEGFR-2 KD constructs were cloned with two separate PCR 
reactions described in 6.1.1. We used the following primers: 
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5‘-3‘ primer sequence Construct 
 
For 5‘-CGGAATTCAAAGGCCTACGTCGACCACCATGCTACGGACCGTTA 
AGCGGGC -3‘ 
Rev 5‘-CTTTTATCAGTGATGGTGATGGTGATGGTGATGGTGATGCTGGA 
AGTAGAGGTTCTCAACAGGAGGAGAGAGCTCAGTGTGGTC-3‘ 
 
VEGFR-2 KD 
 
For 5‘-CGGAATTCAAAGGCCTACGTCGACCACCATGCTACGGACCGTTAA 
GCGGGC-3‘ 
Rev 5‘-CTTTTATCAGTGATGGTGATGGTGATGGTGATGGTGATGCTGGAAGT 
AGAGGTTCTCAACAGGAGGAGAGAGCTCAGTGTGGTC-3‘ 
 
K868M VEGFR-2 KD 
 
For 5‘-GGAGGGGAACTGAAGACAGGCTACTTGTCCATCGTCATGGATCCAGA 
TGAACTCCCATTG-3‘ 
Rev 5‘-CAAAGTCTCTGATATCGGAAGAACAATGTAGTCTTTGCCATCCTGCTG 
AGCATTAGCTTGCA-3‘ 
 
ΔKID VEGFR-2 KD 
 
For 5‘-TGGAGAACTCTCTGTGGATCTGAAACGGCACTTAG-3‘ 
Rev 5‘-ACAGAGAGTTCTCCAACGTAGTCTTTCCCTTGACGGAATCG-3‘ 
 
mKID VEGFR-2 KD 
(mutated out of VEGFR-2 
KD) 
 
For 5‘-CGGAATTCAAAGGCCTACGTCGACCACCATGCTACGGACCGTTAAGC 
GGGC-3‘ 
Rev 5‘-CTTTTATCAGTGATGGTGATGGTGATGGTGATGGTGATGCTGGAAGT 
AGAGGTTCTCATCCTGCTGAGCATTAGCTTGCA-3‘ 
 
ΔC VEGFR-2 KD 
 
For 5‘-CGGAATTCAAAGGCCTACGTCGACCACCATGATGGATCCAGATGAACT 
CCCATTG-3‘ 
Rev 5‘-CTTTTATCAGTGATGGTGATGGTGATGGTGATGGTGATGCTGGAAGTA 
GAGGTTCTCATCCTGCTGAGCATTAGCTTGCA -3‘ 
 
ΔJMDΔKIDΔC VEGFR-2 
(Y1175) KD 
 
Table 5: Primers used for cloning of VEGFR-2 kinase domain mutants in pfl used for 
protein expression in insect cells 
 
6.5. Expression, purification and determination of 
phosphorylation state of VEGFR-2 kinase domain proteins 
 
Expression of kinase domain constructs was performed in Sf21 insect cells. 
Baculovirus production, infection and expression procedures were applied according 
to (Fitzgerald et al, 2006). Insect cells were cultured at 27°C in serum-free Insect-
XPRESS™ medium with L-glutamine (Lonza, #BE12-730Q). In order to maintain a 
suitable oxygen level within the culture vessel, cells were grown in such a way that 
they did not exceed a density of 1.5 x 106 cells/mL during protein expression. All 
constructs were monitored for their protein expression levels over a period of 5 days 
after initial infection. Protein expression-levels in the cells were analysed by taking 
aliquots of 0.2 x 106 cells every day (5 Aliquots). Cell pellets were lysed with lysis 
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buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.1% Triton X-100, Roche protease 
inhibitor cocktail) and subjected to western blot analysis. Blots were decorated with a 
primary anti 5xHis (Sigma) and with a secondary goat anti-mouse AP (Bioconcept) 
antibody using dilutions of 1:1000 and 1:10’000, respectively. Cells were harvested at 
their highest protein expression-levels 3 days post infection. After a centrifugation 
step of 30 min at 900 x g and 4°C the cell pellets were flash frozen in liquid nitrogen 
and stored at -80°C. Harvested cell pellets were thawed on ice and resuspended in 
hypotonic buffer (50mM Hepes pH 8, 10 mM NaCl, 10 mM imidazole, 5% glycerol, 
Roche inhibitor cocktail). After incubation of 1h at 4°C the solution was vortexed and 
a centrifugation step of 30 min at 900 x g and 4°C was applied to remove the nuclei. 
The supernatant containing the protein of interest was filtered (45 µm) and then 
purified with a previously equilibrated nickel charged 1 mL HiTrap™ Chelating HP 
column (GE Healthcare). The proteins were loaded on the column and washed with 
wash buffer (50mM Hepes pH 7.5, 500 mM NaCl, 10% glycerol, 1mM DTT). The 
elution of the proteins was performed by applying an imidazole gradient up to 350 
mM. For the second purification step the eluate of the NiNTA column was 
concentrated up to 2 mL and loaded on a Superdex 200 16/60 column. Proteins were 
eluted with elution buffer: 50 mM Hepes pH 7.5, 150 mM NaCl, 5% glycerol, 1 mM 
DTT. The eluates of the NiNTA and the SEC column were analyzed by Coomassie 
stained SDS-PAGE and Immunoblotting using an antibody of Sigma recognizing the 
His-tag (anti penta-His, mouse, 1:1000). The phosphorylation state of the purified 
proteins was determined via Immunoblotting using phospho-specific antibodies 
described in section 6.2. 
 
6.5.1. In vitro phosphorylation / dephosphorylation 
 
In order to achieve phosphorylation of all the tyrosine residues in the purified kinase 
domain proteins we incubated the proteins with 4 mM ATP and 28 mM MgCl2 
immediately after elution from the NiNTA column. ATP and MgCl2 were automatically 
removed in the SEC purification step. Dephosphorylation of kinase domain proteins 
was performed with AP (Fermentas). 1 mL purified proteins of 2 mg/mL were 
incubated with 1000 units of AP for 48 h at 4°C. AP was removed by loading the 
protein-AP mixture on a 1 mL NiNTA column and applying a wash step with following 
final elution at 350 mM imidazole with buffers described in section 6.5. The eluted 
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fractions contained the dephosphorylated kinase domain proteins. Dephosphorylation 
of proteins was verified by immunoblotting using phospho-specific antibodies 
described in section 6.2. 
 
6.6. Cloning of murine TSAd for protein expression 
 
The coding sequence of murine TSAd was cloned into the Multibac vector pfl 
according to section 6.4. TSAd was designed with a C-terminal 10xHis tag with a 
preceding TEV site. We used the following primers: 
 
5‘-3‘ primer sequence Construct 
 
For 5‘-CGGAATTCAAAGGCCTACGTCGACCACCATGGAGTTCTGCTTGGCCCAAC-3‘ 
Rev 5‘ –CTTTTATCAGTGATGGTGATGGTGATGGTGATGGTGATGCTGGAAGTAGAG 
GTTCTCGGAGGGGCTCCCTCTTTC-3‘ 
 
Murine TSAd 
 
Table 6: Primers used for cloning of murine TSAd into pfl vector for protein 
expression in insect cells 
 
6.7. Expression and purification of murine TSAd and TSAd-
VEGFR-2 complex 
 
Expression and purification of murine TSAd and TSAd-VEGFR-2 complex was 
conducted according to section 6.5 except of the usage of different buffers: 
Harvested cells were thawed on ice and resuspended in the following hypotonic 
buffer: 50 mM Tris ph 8.5, 10 mM NaCl, 10 mM imidazole, 5% glycerol, Roche 
protease inhibitor cocktail. IMAC purification was performed with the following wash 
and elution buffer: 50 mM Tris pH 8.3, 500 mM NaCl, 10 % glycerol, 1 mM DTT and 
50 mM Tris pH 8.3, 350 mM NaCl, 350 mM imidazole, 10 % glycerol, 1 mM DTT, 
respectively. For the SEC purification step we used the following SEC buffer: 50mM 
Tris pH 8.3, 150 mM NaCl, 5% glycerol, 1 mM DTT. 
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6.8. Biophysical characterization of recombinant proteins 
 
6.8.1. Multi Angle Light Scattering analysis 
 
Multi Angle Light Scattering (MALS) analysis was conducted on an Agilent 1100 
HPLC-system (Agilent Technologies) coupled to a Superdex 200HR 10/30 column 
(GE Healthcare) of analytical-grade quality. The column was further connected to the 
Wyatt miniDAWN Tristar (Wyatt Technologies) unit. The instruments and the 
attached column were equilibrated with buffer prior to run. 100 µL of concentrated 
protein was injected into the system for analysis. The elution profiles of the 
experiments were collected as UV-absorbance (280nm) spectra and intensity of 
Rayleigh scattering at three different angles. The ASTRA™ software (Wyatt 
Technologies) was applied to assign the molecular mass averages. 
 
6.8.2. Small-Angle X-ray Scattering  
 
Small-angle X-ray scattering (SAXS) data was collected at the cSAXS beamline 
X12SA at the Swiss Light Source (SLS) in Villigen, Switzerland. The scattered 
intensities were recorded on a Pilatus 2M detector. The intensities were collected in 
the scattering vector interval between 0.008 [1/Å] – 0.400 [1/Å]. The length of the 
scattering vector is defined as q = 4πsinθ/λ, where 2θ is the scattering angle and the 
wavelength λ=1 Å. A Silver Behenate sample was used to calibrate the length of the 
scattering vector q (Huang et al., 1993). Protein samples and the corresponding 
buffer solutions were measured in quartz capillaries of 1mm in diameter (Hilgenberg 
GmbH, Germany). The data of each protein sample was measured at three different 
concentrations. The background scattering was recorded by measuring the empty 
capillaries and the corresponding protein buffers prior to protein sample 
measurements. For data collection 10 different spots along the capillary were 
scanned with an exposure time of 0.5 s. The collected frames were analyzed for 
radiation damage. Frames showing no signs of damage were averaged using 
MATLAB with macros programmed by John Missimer and Kaisa Kisko. Background 
scattering of the buffer was subtracted by using MATLAB. In order to check for 
complete folding and domain flexibility of all measured proteins we calculated Kratky-
plots. The distance distribution function p(r) was calculated using GNOM and 
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AUTOPOROD out of the ATSAS package (Petoukhov et al., 2007a). The radius of 
gyration Rg was calculated with the p(r) function and out of the data in the linear 
Guinier-region. The program DAMMIF (Petoukhov et al., 2007b) was used for ab 
initio shape reconstructions from the p(r) functions. At least 10 and up to 20 
independent DAMMIF runs were averaged, aligned and, refined back to the original 
envelope volume using DAMAVER and DAMFILT (Petoukhov et al., 2007b). 
SUPCOMB13 was used to overlay calculated DAMMIF structures. Superimpositions 
of existing crystal structures with the SAXS envelopes was done with the program 
SITUS (Wriggers and Chacon, 2001). CRYSOL was used to calculate p(r) functions 
of existing crystal structures. The model-p(r) functions were subsequently compared 
with experimental data to monitor data consistency. Models were visualised using 
PyMol (www.schrodinger.org). 
 
6.8.3. Analytical ultracentrifugation 
 
For the analytical ultracentrifugation (AUC) experiments we used a Beckman 
ProeomLab XL-I centrifuge. The sedimentation equilibrium experiments were 
performed as duplicates at 4°C for three different concentrations of 10, 30 and 80 
µM. The three concentrations were chosen based on previous MALS experiments at 
high protein concentrations (>20 mg/mL) where dimers could be assigned. Protein 
sample concentration was adjusted in SEC buffer described in section 6.5. For the 
AUC experiments we used an An-50 Ti rotor (Beckmann) and charcoal-filled epon six 
sector cells. The runs were performed at two speeds of 14’000 and 20’000 rpm. For 
data collection we used the refractive index detection system (Aviv Biomedical) of the 
analytical ultracentrifuge. Data analysis was performed using Ultraspin software 
package (MRC, Cambridge).  
 
6.8.4. Mass spectrometry 
 
To identify and validate the recombinant proteins we sent samples for analysis to the 
Functional Genomics Center in Zürich. Proteins were initially separated via SDS-
PAGE. Bands corresponding to the molecular weight of the recombinant proteins 
were localized with coomassie-blue staining, cut out and sent to Zürich for analysis. 
Doctoral Thesis   Sandro Manni 
 
51 
The gel bands were cut in small pieces and washed twice with 100 µL of 100 mM 
NH4HCO3/50% acetonitrile and washed once with 50µL acetonitrile. The 
supernatants were discarted. 10 µL of trypsin (10 ng/µL in 10 mM Tris/2 mM CaCl2, 
pH 8.2) and 10 µL of buffer (10 mM Tris/2 mM CaCl2, pH 8.2) were added to the 
samples. The samples were incubated over night at 37°C. After incubation the 
supernatants were removed and the gel pieces were extracted twice with 100 µL 
0.1% TFA/50% acetonitrile. All supernatants were combined and dried. To dissolve 
the dried samples 25 µL of 0.1% formic acid was used. The samples were then 
transferred into auto sampler vials. 0.5 µL of the sample was injected for ESI-MS-MS 
(Waters Synapt G2). Database searches (of detected peptides) were performed by 
using the Mascot search programs (NCBI: all species). 
 
7. Results 
 
7.1. Functional analysis of VEGFR-2 mutants carrying an artificial 
dimerization interface in the transmembrane domain 
 
It has previously been shown that many receptor tyrosine kinases can be artificially 
dimerized and activated by interactions mediated by their TMD. Previous 
experiments in our lab focused on the role of dimerization and activation of VEGFR-2 
by using artificial dimerization-promoting TMDs. Dimerization and activation was 
achieved by introducing glutamic acid residues at specific positions to an all valine 
TMD. Only receptor kinase dimers with specific spatial orientation were activated. 
Dimerization is therefore required but not sufficient for activation of VEGFR-2 
carrying artificial Vx/x + 7E TMD. To further confirm these findings in the human 
VEGFR-2, we designed constructs that contained the wild-type TMD with glutamic 
acid residues in distinct positions. 
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7.1.1. Activity of extracellular domain-deleted VEGFR-2 mutants carrying 
a single glutamic acid dimerization promoting interface in the 
transmembrane domain 
 
Initially we used VEGFR-2 constructs that were ECD-deleted (765-1356). It was 
therefore possible to study the activation mechanism independently from VEGF and 
compare mutants carrying TMDs containing glutamic acid point mutations with the 
previously screened Vx/x + 7E TMD-helices, where only distinct dimerization-
promoting variants were able to activate the receptor kinase. In the first constructs 
we mutated one single amino acid to glutamic acid. The receptor constructs were 
cloned into the mammalian expression vector pcDNA3 and contained a N-terminal 
HA-tag for immunodetection. Glutamic acid point mutations were introduced into the 
TMD by site-directed mutagenesis. Mutations of the wt-TMD are shown in table 7. 
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ΔECD-VEGFR-2 wt HA IIILVGTAVIAMFFWLLLVIILRTV VEGFR-2 KD 
ΔECD-VEGFR-2 
I767E HA IIELVGTAVIAMFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
L768E HA IIIEVGTAVIAMFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
V769E HA IIILEGTAVIAMFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
G770E HA IIILVETAVIAMFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
T771E HA IIILVGEAVIAMFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
A772E HA IIILVGTEVIAMFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
V773E HA IIILVGTAEIAMFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
I774E HA IIILVGTAVEAMFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
A775E HA IIILVGTAVIEMFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
M776E HA IIILVGTAVIAEFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
F777E HA IIILVGTAVIAMEFWLLLVIILRTV 
VEGFR-2 
KD 
 
Table 7: Schematic representation of ΔECD-VEGFR-2 mutants carrying a single 
glutamic acid dimerization interface in the TMD 
The wt-TMD sequence of VEGFR-2 is shown on top. HA: Haemaglutinin tag, point mutations 
are highlighted in red, VEGFR-2 KD: Kinase domain of VEGFR-2.  
 
Doctoral Thesis   Sandro Manni 
 
54 
The TMD-mutants were transiently expressed in HEK293 cells. After lysis we 
assessed receptor activity by immunoblotting with an antibody specific for pY1175 
the major phosphorylation site of VEGFR-2. For the detection of the total amount of 
receptor protein the same membrane was decorated with an anti-HA antibody. Three 
constructs carrying glutamic acid point mutations at positions I767, L768 and V769 
showed significantly higher activity than the construct with the wt-TMD. Mutant 
V769E reproducibly showed the highest activity, all the other point mutations showed 
less dramatic increase compared to the activity of the wt-construct (figure 11) 
indicating that a distinct orientation of the kinase domain is required to fully activate 
the receptor kinase reminiscent of earlier mutagenesis using Vx/x + 7E TMD 
receptors. 
 
A 
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Figure 11: Activity of ΔECD-VEGFR-2 mutants with glutamic acid point mutations in 
the TMD 
(A) Lysates from HEK293 cells were separated by SDS-PAGE and transferred to a PVDF 
membrane. The membrane was decorated with an antibody specific for pY1175 then 
stripped and incubated with an antibody recognising the HA-tag of the receptor. Equal 
loading was confirmed by incubating the membrane with an anti-β-actin antibody. A 
representative experiment is shown in (A). (B) Quantification using three independent 
experiments. Receptor phosphorylation is indicated as mean ± S.E. with wt set to 100%. 
 
We observed significant basal receptor activation in the construct carrying the native 
TMD probably due to the lack of the ECD (figure 11). Moreover, this finding agrees 
with previous experiments from our lab where the ΔECD-VEGFR-2 mutant carrying 
the wt-TMD showed constitutive dimer formation in co-immunoprecipitation assays 
(Dell'Era Dosch and Ballmer-Hofer, 2009b). In order to prevent spontaneous trans-
activation of the receptor kinase as a result of overexpression within the cell 
membrane we used carrier DNA in the transfection assays to dilute the expression 
plasmid and to attenuate protein expression.  
In the next experiments we compared ECD-deleted wt-TMD VEGFR-2 with full-length 
wt-TMD VEGFR-2 in VEGF-stimulated and unstimulated cells. The ΔECD construct 
was cloned into the mammalian expression vector pcDNA3 and contained a HA-tag 
for immunodetection at the N-terminus. The full-length VEGFR-2 construct was 
cloned into the mammalian eGFP expression vector pBE and contained a HA-tag for 
immunodetection at the N-terminus. Both constructs were transiently transfected in 
HEK293 cells. After lysis we assessed receptor activity by immunoblotting with an 
antibody specific for pY1175 and anti-HA for total amount of receptor, respectively. 
The data shows that the ΔECD construct has 50% of the activity of full-length 
VEGFR-2 (figure 12). 
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Figure 12: Activity of ΔECD-mutant compared to full length VEGFR-2  
Activity of the full-length wt-TMD construct is shown in comparison to the ΔECD wt-TMD 
mutant. (A) Lysates from HEK293 cells were separated by SDS-PAGE and transferred to a 
PVDF membrane. The membrane was decorated with an antibody specific for pY1175 then 
stripped and incubated with an antibody recognising the HA-tag of the receptor. (B) 
Quantification of Blot shown in (A).  
 
7.1.2. Activity of full-length VEGFR-2 mutants carrying a single glutamic 
acid dimerization interface in the transmembrane domain 
 
To see whether the constitutively activating mutations L768E and V769E identified in 
the ECD-truncated VEGFR-2 constructs were able to activate the receptor by 
compensating for the apparent ECD-mediated inhibition of dimerization in the 
absence of ligand we introduced these mutations into the TMD of the full-length 
receptor. Mutant G770E, that showed pY1175 phosphorylation similar to the wt, was 
introduced as a negative control (table 8). 
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ΔECD-VEGFR-2 
L768E HA IIIEVGTAVIAMFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
V769E HA IIILEGTAVIAMFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
G770E HA IIILVETAVIAMFFWLLLVIILRTV 
VEGFR-2 
KD 
 
Table 8: Schematic representation of full-length VEGFR-2 mutants with single 
glutamic acid mutations in the TMD 
The wt-TMD sequence of VEGFR-2 is shown on top. HA: Haemaglutinin tag, point mutations 
are highlighted in red, VEGFR-2 KD: Kinase domain of VEGFR-2.  
 
The full-length VEGFR-2 mutants with a single glutamic acid point mutation were 
transiently transfected in HEK293 cells and Y1175 phosphorylation was determined. 
Mutation L768E and V769E, active in the ΔECD-VEGFR-2 constructs, did not show 
significantly higher activity than wt-VEGFR-2 neither in VEGF-stimulated nor in 
unstimulated cells (figure 13). This data indicates that the dimerization promoting 
energy of a single glutamic acid residue introduced into the wt-TMD does not 
compensate for the repulsive force induced by the extracellular domain of VEGFR-2.  
 
A 
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Figure 13: Activity of full-length VEGFR-2 mutants with single glutamic acid mutations 
in the TMD 
(A) Activity of the L768E, V769E and G770E mutants is shown in comparison to wt VEGF 
stimulated and VEGF unstimulated cells. (B) Quantification using three independent 
experiments, receptor phosphorylation is given as mean ± S.E. with wt set to 100%. 
 
7.1.3. Activity of extracellular domain-deleted VEGFR-2 mutants carrying 
a double glutamic acid dimerization interface in the TMD 
 
The TMD of receptor tyrosine kinases consists of a single alpha helix. A full helix turn 
contains ~ 3.5 amino acids. For the next set of experiments we designed mutants 
with dimerization motifs consisting of two glutamic acid mutations in the wt-TMD. Our 
constructs localize the two glutamic acid residues on the same face of the helix, 
giving rise to a more rigid dimerization interface. The glutamic acids were spaced 
seven residues apart and thus two helix rotations apart in the TMD-helix. This motif 
was sequentially shifted along the TMD-helix in order to generate dimers with distinct 
spatial orientations. We introduced the glutamic acid mutations at position V769E 
(that was previously found to activate the receptor)/M776E; G770E/F777E and 
T771E/F778E (table 9). 
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ΔECD VEGFR-2 
wt HA IIILVGTAVIAMFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
V769E; M776E HA IIILEGTAVIAEFFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
G770E; F777E HA IIILVETAVIAMEFWLLLVIILRTV 
VEGFR-2 
KD 
ΔECD-VEGFR-2 
T771E; F778E HA IIILVGEAVIAMFEWLLLVIILRTV 
VEGFR-2 
KD 
 
Table 9: Schematic representation of ΔECD-VEGFR-2 mutants with double glutamic 
acid mutations in the TMD 
The wt-sequence of the TMD is shown on top. HA: Haemaglutinin tag, point mutations are 
highlighted in red, VEGFR-2 KD: Kinase domain of VEGFR-2.  
 
In the absence of ligand the mutants were transiently transfected into HEK293 cells 
and Y1175 phosphorylation was determined. Mutant V769E/M776E, G770E/F777E 
and T771E/F778E were all inactive as compared to wt (figure 14). The data therefore 
reveal the tight regulation of the kinase since this rigidified interface maintains the 
kinase dimers in an inactive conformation. 
 
A 
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Figure 14: Activity of ΔECD-VEGFR-2 mutants with double glutamic acid dimerization 
interface in the TMD 
(A) Activity of V769E/M776E, G770E/F777E and T771E/F778E mutants is shown in 
comparison to wt. (B) Quantification using three independent experiments, receptor 
phosphorylation is indicated as mean ± S.E. with wt set to 100%. 
 
7.1.4. Activity of full-length VEGFR-2 mutants carrying a double glutamic 
acid dimerization interface in the transmembrane domain 
 
We next evaluated whether it was possible to generate a dimerization interface that 
was strong enough to compensate for the repulsive force exerted by the extracellular 
domain in the absence of ligand that might thus be able to activate the receptor. We 
were also interested whether in the context of the full-length receptor distinct 
activating and inactivating dimeric conformations similar to those in the ΔECD-
VEGFR-2 constructs could be identified. Mutated positions within the wt-TMD are 
shown in table 10. 
 
ECD-VEGFR-2 
wt 
HA IIILVGTAVIAMFFWLLLVIILRTV VEGFR-2 KD 
ECD-VEGFR-2 
V769E; M776E 
HA IIILEGTAVIAEFFWLLLVIILRTV VEGFR-2 KD 
ECD-VEGFR-2 
G770E; F777E 
HA IIILVETAVIAMEFWLLLVIILRTV VEGFR-2 KD 
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ECD-VEGFR-2 
T771E; F778E 
HA IIILVGEAVIAMFEWLLLVIILRTV VEGFR-2 
KD 
ECD-VEGFR-2 
A772E; W779E 
HA IIILVGTEVIAMFFELLLVIILRTV VEGFR-2 KD 
ECD-VEGFR-2 
V773E; L780E 
HA IIILVGTAEIAMFFWELLVIILRTV VEGFR-2 KD 
ECD-VEGFR-2 
I774E; L781E 
HA IIILVGTAVEAMFFWLELVIILRTV VEGFR-2 KD 
 
Table 10: Schematic representation of full-length VEGFR-2 mutants with double 
glutamic acid point mutations in the TMD 
The wt-sequence of the TMD is shown on top. HA: Haemaglutinin tag, point mutations are 
highlighted in red, VEGFR-2 KD: Kinase domain of VEGFR-2.  
 
Full-length VEGFR-2 TMD mutants carrying two glutamic acid mutations were 
transiently transfected into HEK293 cells and Y1175 phosphorylation was 
determined. Mutant G770E/F777E and T771E/F778E showed constitutive activity in 
VEGF-stimulated and in unstimulated cells (figure 15). All the other mutants were 
constitutively inactive. The data again indicates that only distinct orientations of the 
kinase domain are able to fully activate the receptor kinase. This clearly shows that 
the TMD of VEGFR-2 carrying a double glutamic acid dimerization interface is able to 
compensate for the repulsive force exerted by the receptor ECD. The constitutively 
active G770E/F777E and the inactive mutant I774E/L781E were previously found to 
have the same effect in the all valine TMD. This demonstrates a common spatial 
arrangement of the two TMD-helices in the cell membrane, which is independent of 
the amino acid composition of the TMD. 
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Figure 15: Activity of full-length VEGFR-2 mutants with double glutamic acid 
dimerization interface in the TMD 
(A) Activity of the double mutants is shown in comparison to wt in VEGF stimulated and 
VEGF unstimulated cells. (B) Quantification using three independent experiments. Receptor 
phosphorylation is indicated by mean ± S.E. with wt set to 100%. 
 
7.2. 3D-structure of the transmembrane domain of VEGFR-2 
determined by NMR spectroscopy 
 
It was shown earlier that several TMD-helices present in membrane proteins interact 
with each other via distinct dimerization motifs like the heptad- (XxxxxxxX, where X is 
G, A or S) or the GG4-like-repeat (XxxxX, where X is G, A, S or T). Helices 
containing such dimerization motifs have thus a strong propensity to interact with 
each other. The small amino acid residues in these motifs are important to bring the 
TMD-helices in close proximity. As a consequence helix-helix interactions are 
mediated and stabilized by van der Waals interactions and/or hydrogen bonding. The 
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VEGFR-2 TMD helix does not contain such a dimerization motif. Nevertheless, it was 
shown that the VEGFR-2 TMD helix has a low propensity to dimerize relative to the 
strong interaction of the wt-TMD of for instance human glycophorin A (GpA) (Finger 
et al., 2009b). Our goal was to determine the structural basis of helix-helix interaction 
in the wt and in the TMDs containing our previously introduced artificial glutamic acid 
residue dimerization motif. In collaboration with an NMR research group we 
determined the interaction of two wt and mutant TMD-helices of VEGFR-2 (residues 
759-795) in membrane mimicking DPC micelles using conventional 13C, 15N-
heteronuclear NMR spectroscopy. At the conclusion of this thesis we obtained 
preliminary unrefined data.  
 
7.2.1. 3D-structure of the wild type transmembrane domain of VEGFR-2 
 
The NMR chemical shifts, connectivities and NMR relaxation data show that the 
peptides form long α-helical structures between amino acid 761-794 (figure 16).  
 
 
 
 
 
 
 
 
Figure 16: NMR data of wt-TMD peptides of VEGFR-2 
Sequential and medium range characteristic NOE-based distances (dxx(i1,i2) are shown by 
horizontal lines. Line thickness is proportional to the intensity of the corresponding peak in 
the NOESY spectrum. Contacts not imposing restraints on the spatial structure were 
removed by the built-in algorithm of the CYANA software (Guentert, 2003). P_helix indicates 
the α-helical propensity predicted by the TALOS+ software on the basis of NMR chemical 
shifts (Shen et al., 2009). Figure by Alexander S. Arseniev. 
 
In order to monitor the dimerization process we recorded NMR spectra at various 
protein/DPC concentrations. In the experimental conditions used (figure 17) we found 
two different forms with population states that were dependent on detergent/protein 
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ratio. The dilution of the sample with detergent revealed that these two states 
corresponded to the monomeric wt-TMD helix and the wt-TMD dimer (figure 17A). At 
protein/DPC ratio of 1:150 the population of the monomeric state was ~70%. 
Additionally, the dilution of the sample with detergent showed a very slow transition. 
The free energy of dimerization (ΔG0) was found to be -2.1±0.2 kcal/mol  
(figure 17B).  
 
A B 
 
 
 
 
 
 
 
Figure 17: Spectra of cross-peaks of different oligomeric states and corresponding 
oligomerization constant of wt-TMD  
(A) Signals of amide group residue G770 in 1H, 15N-TROSY-HSQC spectrum of VEGFR-2 wt 
TMD (see Appendix for full spectra). Cross peaks originating from monomeric (M) and 
dimeric (D) species are assigned Spectra was acquired with the following conditions: 
Lipid/protein ratio = 300 : 1, 318K and pH 4.5. (B) Oligomerization constants of VEGFR-2 wt-
TMD. Apparent free energies of dimerization are plotted against the logarithm of 
concentration of empty micelles. Red points indicate a two-fold dilution of the sample with 
water. Significant points have a linear dependence of the form y = ax+b where a equals γRT 
and b represents the standard free energy (ΔG0). Standard conditions are 1M of empty DPC 
micells and 318K. Figure by Alexander S. Arseniev. 
 
The VEGFR-2 wt-TMD helices appeared as symmetrical dimer with a left-handed 
orientation. The angle between the axes of helices was 25±1°C. Heteronuclei-filtered 
NOESY experiments revealed nine intermolecular contacts which were used for the 
calculation of the 3D-structure. The dimerization surface is long and apolar and 
spans across the entire helix. The dimer interface consists of a hydrophobic “heptad-
repeat”-like cluster stabilized by intermonomeric van der Waals interactions of side 
chains: T761xxE764xxI767L768xxT771A772xxA775xxF778W779xL781L782xxI785xxxV789. The 
polar and flexible N- and C-termini are solvent exposed. The interface is further 
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stabilized by a symmetric edge to face stacking interaction of F778 and W779  
(figure 18). 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure 18: 3D-structure of the wt-TMD of VEGFR-2 
(A) Overall structure of the TMD of VEGFR-2 side and top-view. Axis and orientation is 
indicated on top. (B) Intermonomeric contact surface area of VEGFR-2 TMD residues shown 
as percentage of the total solvent accessible area. N- and C-termini are colored in green. 
Helix backbone exposed to hydrophobic environment is depicted in grey. Dimerization 
interface is colored in blue. Models were made with PyMOL. Figures by Sandro Manni and 
Alexander S. Arseniev. 
90° 
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7.3. 3D-structure of the V769E transmembrane domain of  
VEGFR-2 
 
The NMR chemical shifts, connectivities and NMR relaxation data show that the 
V769E-TMD-peptides synthesized and inserted into DPC micelles at pH 4.5 form 
long α-helical structures between amino acids 761-794 similar to the wt-TMD helices 
(figure 18A).  Contacts of I, V and L- methyl groups of the TMD-section to residual 
protons of DPC methyl groups could be found in C13-filtered NOESY experiments 
indicating a “true” TMD-helix but not a surface-bound helix.  
 
 
 
 
 
 
 
Figure 18: NMR data of V769E-TMD peptides of VEGFR-2 
Sequential and medium range characteristic NOE-based distances (dxx(i1,i2) are shown by 
horizontal lines. Line thickness is proportional to the intensity of the corresponding peak in 
the NOESY spectrum. Contacts not imposing restraints on the spatial structure were 
removed by the built-in algorithm of the CYANA software (Guentert, 2003). P_helix indicates 
the α-helical propensity predicted by the TALOS+ software on the basis of NMR chemical 
shifts (Shen et al., 2009). Figure by Alexander S. Arseniev. 
 
For the V769E-TMD we found three oligomeric states as characterized by correlation 
times for rotational diffusion (figure 19A and Appendix). In order to find the exact 
model for the oligomerization process we tested three equilibrium models by diluting 
the sample with water and concentrated DPC solution: “monomer-dimer1-dimer2”, 
“monomer-dimer-trimer” and “monomer-dimer-tetramer”. When calculating the free 
energies of oligomerization from the signals derived from 1H, 15N-TROSY-HSQC 
spectra we found that only the “monomer-dimer-trimer” model fitted the obtained data 
with the following ΔG0 values: ΔGdimer = -2.4 ± 0.2 kcal/mol, ΔGtrimer = -2.9 ± 0.2 
kcal/mol (figure 19B). The energetic contribution to dimerization caused by the 
V769E mutation is -0.3 kcal/mol. The contribution is therefore not significant and lies 
in the range of experimental error.  
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Figure 19: Cross-peaks of different oligomeric states and calculated oligomerization 
energies of tested models 
(A) Signals of amide group residue G770 in 1H, 15N-TROSY-HSQC spectrum of VEGFR-2 
V769E-TMD (see Appendix for full spectra). Cross peaks originating from monomeric (M), 
dimeric (D) and trimeric (T) species are indicated. Spectra was acquired with the following 
conditions: Lipid/protein ratio = 300 : 1, 318K and pH 4.5. (B) Oligomerization constants of 
VEGFR-2 V769E-TMD. Free energies of oligomerization are calculated out of intensities of 
signals derived from 1H, 15N-TROSY-HSQC spectra according to different equilibrium 
models: “trimerization: MD/T; two dimers: M2/T; tetramerization: D2/T; dimerization: M2/D. 
Free energies are plotted against the logarithm of concentration of empty micelles. Red 
points indicate a two-fold dilution of the sample with water. Significant points have a linear 
dependence of the form y = ax+b where a equals γRT and b represents the standard free 
energy (ΔG0). Standard conditions are 1M of empty DPC micelles and 318K. Figure by 
Alexander S. Arseniev. 
 
The determination of the dimeric spatial structure of V769E TMD of VEFR-2 was 
significantly affected by the presence of the highly stable trimeric state (stable up to 
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200:1 DPC/protein ratio). In order to investigate the 3D-structure we applied the 
analysis of covariance of N-H chemical shifts upon dimerization of wt and mutant 
V769E-TMD. To perform the analysis the chemical shift of the backbone N-H group 
derived from the 15N-TROSY spectrum (cosine of angles between vectors) that arises 
from dimerization of the helices was plotted against the ratio of their modules (figure 
20). Chemical shifts were measured in Hz to balance contributions of shift-changes 
for protons and nitrogen. 
 
 
 
 
 
 
 
 
 
Figure 20: Analysis of covariance in amide chemical shift changes during dimerization 
of wt- and V769E-TMD 
The cosine of angle between the vectors of each residue in the 2D 1H, 15N-TROSY-HSQC 
NMR signal (cos(θ)) was plotted against the ratio of their modules (ΙA1Ι / ΙA0Ι). Good 
correlations are shown in blue. Points having “some” correlation are shown in cyan and 
points with no correlation are shown in red. The spatial structure of a TMD monomer of 
VEGFR-2 colored according to the correlation in the graph is depicted on the right. Figures 
by Alexander S. Arseniev. 
 
During the dimerization process most of the residues showed a good correlation for 
chemical shift-changes of the nitrogen and the amide-proton. This means that with 
high probability the spatial structure of the wt-TMD and the one of the mutant V769E-
TMD adopt the same dimeric conformation. Introdution of the mutation V769E in the 
TMD of VEGFR-2 does therefore not induce a conformation different from the wt-
dimer. 
To analyse the trimeric form we prepared a concentrated sample (90% trimer) with a 
detergent / protein ratio of 60 to perform a X-filtered NOESY experiment. The quality 
of the spectrum was poor due to line broadening and allowed only the detection of 
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seven interhelical contacts. These seven contacts were used to generate a 
symmetrical trimer with 21 distance restraints. The resulting spatial structure is 
shown in figure 21. The trimerization interface consists of the following residues: 
T761, E764, I765, L768, E769, A772, V773, M776, F777, W779, and L780. Due to 
the quality of the structure it is not possible to derive binding determinants such as H-
bonding interactions. The interaction between the helices may be supported by H-
bonds formed by the side chain of E769. Furthermore, stacking of aromatic rings may 
further stabilize the structure. 
 
 
 
 
 
At pH 4.5 both sidechains of E764 and E769 were protonated  
 
 
 
 
Figure 21: Model of trimeric V769E-TMD of VEGFR-2 represented by the 10 best spatial 
structures 
Backbone atoms are shown in ribbon representation. Residues in the interface are shown in 
yellow. The intermonomeric contact surface area of V769E-TMD residues is indicated on the 
right in percentage of the total solvent accessible area. Figures by Alexander S. Arseniev. 
 
Based on the overall structure of the trimer it is feasible that side chain E769 
interacts with the carbonyl group of L768 and the amide group of A772. Interestingly, 
the asymmetric dimeric unit shares similar geometrical parameters previously found 
in TMD structures corresponding to the active state of other RTKs such as the TMD 
of ErbB2 (angle between the axes of helices of -50 ± 5° and C-termini pointing away     
from each other). Taken together the introduction of a glutamic acid residue at 
position 769 in the TMD of VEGFR-2 does not thermodynamically promote 
dimerization but allows for additional surface area and therefore novel helix-helix 
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interaction sites that may be used by the ECD-deleted VEGFR-2 construct to form 
the active state. 
 
7.3.1. Functional analysis of kinase domain mutants of VEGFR-2 
 
The only structural information describing the kinase domain of VEGFR-2 is available 
in a crystal structure representing the monomeric catalytic core of the cytoplasmic 
domain of VEGFR-2. In this structure one finds the highest sequence homology 
among all receptor tyrosine kinases. In order to achieve crystallization of the protein, 
dramatic truncations were necessary and it is therefore not possible to derive any 
information on the regulation of the monomeric kinase by the domains missing in this 
structure such as the kinase insert domain (KID) or the C-terminal domain of the 
receptor. It could be shown earlier that these domains have an impact on the 
regulation of receptor tyrosine kinases. The C-terminus of the Tie-2 receptor for 
example auto-inhibits the activity of the kinase domain in the absence of the ligand. 
This inhibitory mechanism is clearly dependent on the KID. In chimeric receptor 
constructs consisting of the extracellular domain of the CSF receptor and the kinase 
domain of VEGFR-2 carrying a truncated C-terminus it was shown that the catalytic 
domain of VEGFR-2 could not be activated by ligand (CSF) binding. Here we studied 
the role of the KID and the C-terminal tail in the regulation of VEGFR-2. We studied 
the native VEGFR-2 and not chimeric constructs since we assumed that the ECD of 
VEGFR-2 plays an essential role in receptor dimerization and is required to exactly 
position the intracellular domains relative to each other in active dimers.  
 
7.3.2. Activity of extracellular domain deleted-kinase domain mutants 
 
We performed our initial experiments with constructs that were all ECD-deleted. We 
investigated whether the domain truncations had an effect on kinase activity 
independently from VEGF. Besides the wild type construct (aa 765-1356), we 
designed a VEGFR-2 mutant according to the construct used for crystallization that 
lacked the 50 central residues of the 68 residues of the KID (aa 765-939 and aa 990-
1356). Another construct was truncated at the C-terminus (aa 765-1180). To monitor 
phosphorylation we maintained the phosphorylation site Y1175 including its 
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consensus recognition motif. Finally we created the double deleted constructs that 
lacked the KID and the C-terminus. The catalytic domain mutants were transiently 
transfected into HEK293 cells and Y1054/59 and Y1175 phosphorylation was 
determined (figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Activity of ΔECD-VEGFR-2 kinase domain mutants 
Y1054/59 and Y1175 phosphorylation of kinase domain mutants is shown in comparison to 
the wt. pY1054/59 and pY1175 quantification using three independent experiments, receptor 
phosphorylation is indicated as mean ± S.E. with wt set to 100%. 
 
VEGFR-2 constructs with KID-deletion showed drastically reduced phosphorylation 
at Y1175 while the activation loop sites Y1054/59 were still phosphorylated. The 
VEGFR-2 construct with C-terminal deletion showed a significantly higher activity  
(3 fold increase) than wt when determined by phosphorylation of Y1175 or Y1054/59.  
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7.3.3. Activity of full-length VEGFR-2 kinase domain mutants 
 
In a next set of experiments we introduced the kinase domain mutations of the ECD-
deleted VEGFR-2 constructs into the full-length receptor and studied receptor 
phosphorylation in transfected HEK293 cells. Y1054/59 and Y1175 phosphorylation 
was determined (figure 23). 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
Figure 23: Activity of full-length-VEGFR-2 kinase domain mutants 
(A) Y1054/59 and Y1175 phosphorylation of kinase domain mutants is shown in comparison 
to wt in VEGF stimulated control. (B) pY1054/59 and pY1175 quantification using three 
independent experiments, receptor phosphorylation is indicated as mean ± S.E. with wt set 
to 100%. 
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The results show that our previous data obtained with the ΔECD-VEGFR-2 kinase 
domain mutant constructs were reproducible in the context of the full-length receptors 
(figure 23). The VEGFR-2 construct with the KID deletion showed reduced 
phosphorylation at Y1175 while the activation loop sites Y1054/Y1059 were 
phosphorylated. The full-length VEGFR-2 constructs carrying the C-terminal deletion 
showed receptor activation independent of VEGF stimulation at levels of the 
stimulated wt construct. As a negative control we used a mutant construct (K868M) 
that is deficient for binding ATP and therefore unable to catalyse autophosphorylation 
reactions.  
 
7.3.4. Downstream signaling by kinase domain mutants 
 
Phosphorylation of Y1175 at the C-terminus of the intracellular kinase domain of 
VEGFR-2 leads to recruitment of PLC-γ. The activation of PLC-γ promotes 1, 2-
diacylglycerol (DAG) release resulting from phosphatidylinositol 4,5-bisphosphate 
(PIP2) hydrolysis. DAG activates protein kinase C (PKC) that further activates 
members of the MAP kinase family, which results in upregulation of immediate early 
genes. We determined phospholipase C-γ activation using the above analysed cell 
lysates (figure 24). PLC-γ activity was monitored by immunoblotting using an 
antibody specific for pPLC-γ. For the detection of total PLC-γ the same membrane 
was decorated with an anti PLC-γ antibody.  
 
A 
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Figure 24: PLC-γ  activity of ΔECD-VEGFR-2 kinase domain mutants 
(A) PLC-γ activity of kinase domain mutants is shown in comparison to wt. (B) Quantification 
using three independent experiments. Relative activity is indicated as mean ± S.E. with wt 
set to 100%. 
 
Activation of PLC-γ was consistent with the phosphorylation pattern of the ΔECD-
VEGFR-2 constructs and was not dependent on VEGF. The VEGFR-2 construct with 
the KID deletion showed no PLC-γ activation while a construct with C-terminal 
deletion showed significantly higher PLC-γ activity (7 fold increase) compared to wild 
type. 
We next determined PLC-γ activity in full-length VEGFR-2 kinase domain mutant 
constructs (figure 25). 
 
A 
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Figure 25: PLC-γ  activity of full-length VEGFR-2 kinase domain mutants 
(A) PLC-γ activity is shown in comparison to VEGF stimulated wt-control (B) Quantification 
using three independent experiments, Relative activity is indicated by mean ± S.E. with wt 
set to 100%. 
 
PLC-γ activation in these constructs was comparable to the ΔECD-VEGFR-2 
constructs. The VEGFR-2 construct with the KID deletion showed no signaling 
through PLC-γ while the construct with the C-terminal deletion showed constitutive 
activation (8 fold increase) as compared to VEGF stimulated wt receptor. The 
activation was independent of VEGF. As a negative control we used a mutant 
construct (K868M) that was deficient in ATP binding and therefore not able to 
autophosphorylate to activate downstream effectors.  
 
7.3.5. Activity of full-length VEGFR-2 Y951F mutant 
 
The results of the VEGFR-2 constructs with the KID deletion showed reduced 
phosphorylation at Y1175 and therefore no downstream signaling through PLC-γ. 
These findings let us speculate about a more complex mechanism for VEGFR-2 
activation that involved also the KID. Our working hypothesis was that prior to Y1175 
phosphorylation Y951, situated in the KID, has to be phosphorylated first. We 
mutated Y951 to F and determined the phosphorylation pattern of VEGFR-2 in VEGF 
stimulated and unstimulated cells (figure 26).  
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Figure 26: Phosphorylation pattern of VEGFR-2 Y951F mutant compared to wt  
Phosporylation of Y1054/59, Y1175 and Y1214 of the mutants is shown in comparison to wt 
in VEGF stimulated and control cells. 
 
The VEGFR-2 mutant Y951F showed no phosphorylation at Y1175 neither in VEGF 
stimulated nor in VEGF unstimulated cells whereas Y1054/59 in the activation loop 
and Y1214 in the C-terminal tail were phosphorylated. The data shows that 
phosphorylation at Y951 is mandatory for downstream signaling to Y1175.  
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7.4. Expression, purification and biophysical characterization of 
VEGFR-2 kinase domain proteins 
 
At the beginning of this project there was only limited structural and functional 
information on the kinase domain of VEGFR-2 available. The only structural 
information available to date is based on crystal structures of the catalytic core of 
VEGFR-2 (1VR2) and VEGFR-1 (3HNG). To achieve crystallization all the regulatory 
domains such as the JMD, KID or the C-terminal tail had been removed in the used 
constructs. Biophysical and biochemical information is required to understand the 
role of these domains and therefore we engineered several mutant constructs for 
high level expression in insect cells (table 11).  
 
Construct JMD 
 
KID 
(Y951VGAIP) 
 
Murine KID 
(Y951VGELS) 
C-terminus K868M 
VEGFR-2 KD + + - + - 
K868M VEGFR-2 KD + + - + + 
ΔJMD VEGFR-2 KD - + - + - 
ΔKID VEGFR-2 KD + - - + - 
mKID VEGFR-2 KD + - + + - 
ΔC VEGFR-2 KD 
(+Y1175) 
+ + - 
 
- 
(+Y1175) 
- 
ΔJMDΔC VEGFR-2 
KD (+Y1214) 
- + - 
 
+ 
(+Y1214) 
- 
ΔJMDΔKIDΔC 
VEGFR-2 KD 
(+Y1175) 
- - - 
- 
(+Y1175) 
- 
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Table 11: Schematic representation of VEGFR-2 kinase domain constructs used for 
high level expression 
VEGFR-2 KD: Full-length kinase domain (786-1356). K868M VEGFR-2 KD: Full-length 
kinase domain with K868M mutation in the ATP binding site of the kinase. ΔJMD VEGFR-2 
KD: Kinase domain with JMD deletion (807-1356). ΔKID VEGFR-2 KD: Kinase domain with 
KID deletion (786-939 / 991-1356). mKID VEGFR-2 KD: Human kinase domain carrying 
murine KID. ΔC VEGFR-2 KD (+Y1175): Kinase domain with C-terminal deletion (786-1179, 
including Y1175 and consensus recognition motif). ΔJMDΔC VEGFR-2 KD (+Y1214): 
Kinase domain with JMD deletion and C-terminal truncation (807-1228, including Y1214 and 
consensus recognition motif). ΔJMDΔKIDΔC VEGFR-2 KD: Kinase domain with JMD 
deletion, KID deletion and C-terminal deletion (807-939, 991-1179) including Y1175 and 
consensus recognition motif). 
 
Besides kinase constructs with domain mutations we also created a kinase mutant 
that was deficient in ATP binding (K868M) and a mutant carrying the murine KID for 
further binding studies with TSAd (see next chapters). All the constructs were cloned 
into one of the two multiple cloning sites of the Multibac baculovirus expression 
vector pFL (Berger et al., 2004). The pFL plasmid contains two bidirectionally 
oriented expression cassettes for the production of multiprotein complexes. Our 
intention was to use this vector for future expression of complexes between the 
kinase domain and TSAd which binds to Y951 of VEGFR-2. All the constructs carried 
a C-terminal 10xHis-tag with a preceding TEV protease cleavage site allowing tag 
removal. The pfL vectors were then used to generate baculovirus for insect cell 
infection. Recombinant protein expression was performed in baculovirus infected 
Sf21 insect cells. Sf21 cells are ovarian cells originating from Spodoptera frugiperdia. 
The infected cells were harvested 72-96 h post infection. Expression of the 
recombinant protein was verified by immunoblotting using an 5xHis-tag specific 
antibody. Expression of proteins with a Mr ranging from 37.5-65.9 kDa (theoretical) 
could be verified (figure 27). 
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Figure 27: Expression of VEGFR-2 kinase domain proteins in Sf21 insect cells 
Baculovirus infected cell lysates were analyzed for their recombinant proteins on 
immunoblots using an antibody recognising the His-tag.  
 
In a first step the proteins were purified by immobilized metal ion affinity 
chromatography (IMAC) to remove most of the impurities. Proteins were eluted using 
an imidazole gradient. SDS-PAGE was used to monitor the quality of the eluate. In a 
second step we purified the proteins via size exclusion chromatography (SEC). After 
this step the proteins showed a purity of 95% as judged from SDS-PAGE. The 
protein yields ranged from 1-4 mg per litre of cultured cells. In order to achieve 
homogenous phosphorylation of the kinase domains we phosphorylated the proteins 
in vitro after the first IMAC purification step by addition of ATP and MgCl2. The 
phosphorylation state of the purified protein was then determined using specific anti 
phospho-tyrosine antibodies (figure 28). 
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Figure 28: Purification of VEGFR-2 kinase domain constructs 
(A) VEGFR-2 KD and its inactive counterpart (B) K868M VEGFR-2 KD. To monitor 
phosphorylation state of K868M VEGFR-2 KD we used inhibitor treated VEGFR-2 KD that 
mimicks the K868M mutation. (C) ΔKID VEGFR-2 KD (D) ΔC VEGFR-2 KD (E) ΔJMDΔKID 
ΔC VEGFR-2 KD. Purified proteins were analyzed on immunoblots using an antibody against 
the His-tag. Phosphorylation state of the proteins was analysed using phosphosite-specific 
antibodies described in section 6.2. 
 
All VEGFR-2 kinase domain proteins were expressed in an upscaled format. 
Purification of VEGFR-2 KD, K868M VEGFR-2 KD, ΔKID VEGFR-2 and mKID 
VEGFR-2 (analogous to VEGFR-2 KD, not shown) appeared as one single 
homogeneous band on SDS-gels and were fully phosphorylated at their critical 
phospho-sites (shown for the full-length VEGFR-2 KD) after treatment with ATP and 
MgCl2. ΔC VEGFR-2 KD showed an additional weaker band of slightly higher 
IMAC purification     SEC purification 
eluate    eluate 
kDa  kDa  
75 
50 
37 
75 
50 
37 
elution volume: 92.84 mL 
ΔJMD ΔKID 
ΔC  
VEGFR-2 KD  
 
ΔJMD ΔKID ΔC VEGFR-2 KD
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molecular weight (close to 50 kDa). The His-tag antibody recognized both bands 
therefore it was probably the result of an exposed cleavage site in this C-terminally 
deleted construct. The retention time and the resulting elution volume was consistent 
with the Mr of each kinase domain construct: VEGFR-2 KD: 73.86 mL < ΔKID 
VEGFR-2 KD: 76.45 mL < ΔC VEGFR-2 KD: 88.18 mL < ΔJMDΔKIDΔC VEGFR-2 
KD. VEGFR-2 KD and K868M VEGFR-2 KD with the same Mr of 65.9 kDa differed 
slightly in their retention time: VEGFR-2 KD: 73.86 mL and K868M VEGFR-2 KD: 
78.21 mL. The shift can be explained with the different phosphorylation pattern of 
each protein and the resulting alteration in the shape (hydrodynamic radius) of these 
proteins. K868M VEGFR-2 KD adopts a more compact inactive conformation that 
results in a retention time different from VEGFR-2 KD (78.21mL vs 73.86 mL). While 
VEGFR-2 KD shows phosphorylation at all the critical Y-residues, K868M VEGFR-2 
KD shows only partial phosphorylation at Y1175. Y1054/59 and Y951 were not 
phosphorylated when the cells were treated with a VEGFR-2 specific inhibitor during 
protein production. Inhibitor binding mimicks K868M mutation that prevents ATP from 
binding to VEGFR-2 KD. 
 
7.4.1. Multi Angle Light Scattering (MALS) analysis of purified VEGFR-2 
kinase domain proteins 
 
Besides visualizing purity and homogeneity of the recombinant proteins by SDS-
PAGE we analysed proteins by MALS to determine protein quality and Mr. MALS 
allows to determine the Mr of a protein independent of its shape. Shape information 
of the analysed proteins can be extracted from the elution volume of the coupled 
SEC column in the same way as in normal SEC and is standardised with an 
appropriate standard protein. All the purified kinase domain proteins were analysed 
separately (figure 29). 
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Figure 29: MALS analysis of VEGFR-2 kinase domain constructs 
 
The theoretical Mw of the kinase domain proteins could be verified with a small 
percentage error (table 12). The proteins were injected at concentrations of 2 mg/mL. 
Taken into account a 1:10 dilution on the coupled SEC column the final concentration 
of the kinase domains in the system resulted in concentrations in the low µM range 
(3-5 µM). All proteins were monomeric and showed a homogeneous mass 
distribution at this concentration.  
 
 
 
K868M KD 
ΔC KD 
 ΔJMDΔKIDΔC KD 
ΔKID KD 
mKID KD 
KD 
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VEGFR-2 kinase domain 
construct 
Theoretical Mr [kDa] Experimental Mr [kDa] 
(MALS) 
KD 65.9 61.62 (0.2%) 
K868M KD 65.9 64.94 (0.5%) 
ΔC KD (+Y1175) 45.9 44.87 (0.4%) 
ΔKID KD 60.6 59.52 (0.4%) 
ΔJMDΔKIDΔC KD 
(+Y1175) 
37.5 39.37 (0.7%) 
mKID KD 65.9 65.91 (0.4%) 
 
Table 12: Comparison of theoretical and experimentally determined Mr of VEGFR-2 
kinase domain proteins by MALS 
 
7.4.2. Analytical Ultracentrifugation (AUC) analysis of VEGFR-2 kinase 
domain proteins 
 
We found that VEGFR-2 constructs carrying specific domain deletions showed 
different activation profiles. KID deletion and mutation of the KID residue Y951 to F 
resulted in a defect in phosphorylation at Y1175 whereas deletion of the C-terminus 
rendered the kinase constitutively active.  
With the various kinase domain mutants we performed sedimentation equilibrium 
AUC, which is able to separate proteins based on their Mr and not on their shape or 
hydrodynamic properties. We were especially interested in the concentration 
dependence of the kinase domain. In this way we might detect an intrinsic 
dimerization propensity of the KD in the absence of the ECD and the TMD. Another 
focus was to determine the dimerization propensity of the activating and inactivating 
kinase mutants (ΔC and ΔKID mutants). Three different concentrations of each 
kinase domain protein were analysed at two different rotor speeds (10, 30 and 80 µM 
at 14’000 and 20’000 rpm). The concentrations were chosen based on earlier MALS 
experiments of the kinase domain at high concentrations (>20 mg/mL) where small 
dimer peaks were observed (data not shown). For data collection we used the 
refractive index detection (Aviv Biomedical) together with a Beckman ProteomLab 
XL-I analytical ultracentrifuge. The data was fitted with a double-exponential 
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monomer-dimer equilibrium model with fixed monomer and dimer Mr. The data 
yielded a good fit. All the constructs showed dimer formation at increasing 
concentration (dimer : monomer ratio). Kd values were subsequently determined 
using the monomer-dimer amplitudes (see table in figure 30) of the 14’000 rpm run 
for at least two concentrations. Kd values calculated with amplitudes of the 20’000 
rpm were not significant due to early sedimentation of the dimer (amplitudes of the 
dimer around 0, see tables). All the figures show representative graphs from the 
global analysis of each kinase construct for the highest concentration at 14’000 rpm 
and 20’000 rpm with the experimental and calculated values given in the table below. 
A good alignment of the residuals for the two speeds at 14’000 and 20’000 rpm was 
only achieved for VEGFR-2 ΔJMDΔKIDΔC KD that has the smallest Mr of 37.5 kDa. 
The good fit results from the incomplete sedimentation of the protein at 20’000 rpm 
due to its lower Mr compared to the other constructs.  
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AUC of VEGFR-2 KD in fully phosphorylated state 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conc 
[µM] 
M 
14’000rpm 
D 
14’000rpm 
D/M M 
20'000rpm 
D 
20'000rpm 
Kd [M] 
(14’000rpm) 
10 2.296 0.432 0.18 1.782 0.110 - 
30 7.879 2.798 0.35 6.011 0.171 0.12E-3 
80 15.415 5.630 0.36 10.330 0.050 0.2E-3 
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AUC of VEGFR-2 KD lacking the KID in fully phosphorylated state 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conc 
[µM] 
M 
14'000rpm 
D 
14’000rpm 
D/M M 
20’000rpm 
D 
20’000rpm 
Kd [M] 
(14'000rpm) 
10 3.752 0.373 0.09 3.594 0.178 0.22E-3 
30 9.104 2.488 0.27 8.690 0.529 0.19E-3 
80 20.858 9.657 0.46 16.871 1.415 0.26E-3 
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AUC of VEGFR-2 KD lacking the C-terminus in fully phosphorylated state 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conc 
[µM] 
M 
14’000rpm 
D 
14’000rpm 
D/M M 
20’000rpm 
D 
20’000rpm 
Kd [M] 
(14’000rpm) 
10 2.09 0.02 0 2.073 0.024 - 
30 5.04 0.59 0.11 4.991 0.335 0.3E-3 
80 11.84 3.92 0.33 10.640 1.753 0.28E-3 
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AUC of VEGFR-2 KD lacking the JMD, KID and C-terminus in fully phosphorylated 
state 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conc 
[µM] 
M 
14’000rpm 
D 
14’000rpm 
D/M M 
20’000rpm 
D 
20’000rpm 
Kd [M] 
(14'000rpm) 
10 1.865 0.052 0.02 1.873 0.029 0.6E-3 
30 5.531 0.455 0.08 5.451 0.340 0.6E-3 
80 12.113 3.005 0.24 11.661 1.688 0.46E-3 
 
Figure 30: Sedimentation equilibrium AUC of VEGFR-2 KD constructs 
The global analysis of the highest concentration at 14’000 and 20’000 rpm and the 
corresponding fit of each kinase construct are shown in the upper graph. The lower graph 
shows the overlay of the two residuals of each speed at 14’000 and 20’000 rpm. All the 
experimental and calculated values are indicated in the tables below: M: monomer 
amplitude; D: dimer amplitude; D/M: dimer / monomer ratio; Kd: dissociation constant. 
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The fully phosphorylated full-length kinase domain of VEGFR-2 (VEGFR-2 KD) 
showed the highest concentration dependent propensity to dimerize with an apparent 
Kd of 160 ± 56 µM whereas the truncated construct ΔJMDΔKIDΔC VEGFR-2 KD 
showed the lowest tendency to dimerize at higher concentrations with a Kd of 553 ± 
80 µM. The Kd of kinase constructs carrying KID and C-terminal truncations were 
225 ± 35 and 290 ± 14 µM respectively (table 12). The phosphorylated kinase 
domain itself has therefore a low propensity to dimerize at high concentration. 
Deletion of the C-terminus does not favour dimerization as one might expect from the 
fact that this construct showed constitutive activity in the above shown in vivo 
experiments. 
 
Construct Kd ± S.E. [µM] 
VEGFR-2 KD 160 ± 56 
ΔKID VEGFR-2 KD 225 ± 35 
ΔC VEGFR-2 KD 290 ± 14 
ΔJMDΔKIDΔC VEGFR-2 KD 553 ± 80 
 
Table 12: Kd values of VEGFR-2 kinase domain mutant constructs 
Kd values were determined as mean ± S.E. from at least two concentrations. 
 
7.4.3. In vitro phosphorylation kinetics of purified VEGFR-2 kinase 
domain  
 
VEGFR-2 kinase tyrosine sites are phosphorylated upon ligand stimulation of the 
receptor. It has been shown that Y801 in the JMD is phosphorylated as a first event 
followed by Y1054 and Y1059 in the activation loop. Activation loop phosphorylation 
leads to a further increase in kinase activity. To date the order of autophosphorylation 
of the downstream signaling tyrosine residues has not been determined. We 
previously found that Y951 has to be phosphorylated in order to activate receptor 
signaling trough phosphorylated Y1175. Our concept was to enzymatically 
characterize the kinase domain of VEGFR-2 and to determine the order of the 
phosphorylation events. We performed an in vitro phosphorylation assay with the 
completely dephosphorylated kinase domain of VEGFR-2 (VEGFR-2 KD). The 
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reaction took place at high ATP and low protein concentration. Aliquots of several 
time points (sampled over 30min) of the reaction were stopped and monitored by 
immunoblotting (figure 31A). Phosphorylation intensities over time showed that after 
5 min the pY1054/59 signal shows the strongest intensity and reaches saturation at 
the fastest rate. This finding confirms previously published data where Y1054 and 
Y1059 phosphorylation immediately followed Y801. The second highest extent of 
phosphorylation at 5 min was detected for pY1212 and then followed by pY951. The 
slowest phosphorylation rate was observed for Y1175. All pY-intensity signals 
reached saturation after 30 min. These findings support our previous results where 
Y951 was shown to be phosphorylated first in order to allow phosphorylation of 
Y1175 and promote downstream signaling to PLC-γ (section 7.3.5). 
 
A 
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Figure 31: Phosphorylation kinetics of VEGFR-2 KD 
(A) The phosphorylation-reaction was stopped at several time points. Samples were 
analysed by immunoblotting using phospho-specific antibodies described in section 6.2. (B) 
Quantification of relative phosphorylation intensities over time with highest intensity of each 
site set to 100% (saturation).  
 
7.4.4. Solution structural analysis of VEGFR-2 kinase domain proteins 
by Small Angle X-ray Scattering (SAXS) and Multi Angle Light 
Scattering (MALS) 
 
SAXS is used to retrieve shape and size information from macromolecules in 
solution. Ab initio modelling allows to model low-resolution structures of proteins. 
From a SAXS experiment it is possible to determine the maximum intramolecular 
distance of a particle (Dmax), the radius of gyration (Rg) that is defined as the root-
mean-squared distance of all elemental scattering volumes from their centre of mass 
weighted by their scattering densities, the hydrated particle volume or the Mr of a 
protein. The p(r) function (distance-distribution function) can be calculated by Fourier-
transformation from the scattering intensities of the SAXS experiments. It is known 
from other receptor tyrosine kinases that subdomains like the JMD or the C-terminus 
tightly regulate the catalytic kinase domain. Our goal was to visualize the various 
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active and inactive conformations of the VEGFR-2 kinase domain induced by 
phosphorylation / dephosphorylation or deletion of subdomains. We performed SAXS 
analysis of the previously biophysically characterized constructs mKID VEGFR-2 KD, 
K868M VEGFR-2 KD, ΔKID VEGFR-2 and ΔJMDΔKIDΔC KD VEGFR-2 as a control 
for the published crystal structure. All proteins were measured at various 
concentrations. mKID VEGFR-2 KD, K868M VEGFR-2 KD and ΔKID VEGFR-2 KD 
showed a flat intensity curve whereas ΔJMDΔKIDΔC VEGFR-2 KD showed more 
features. The Guinier-approximation yielded comparable Rg values for the various 
concentrations measured. Aggregation was visible for ΔKID VEGFR-2 KD at 
concentration 5 and 1 mg/mL ΔJMDΔKIDΔC VEGFR-2 KD showed signs of 
aggregation at concentration 1.01 and 5.01 mg/mL. These Rg values were not used 
for calculation of final Rgs (table 13). The Kratky plots confirmed a general globular 
fold. The p(r) functions of mKID VEGFR-2 KD, K868M VEGFR-2 KD and ΔKID 
VEGFR-2 KD had a defined maximum and a tail indicating that the proteins were of 
elongated shape. ΔJMDΔKIDΔC VEGFR-2 KD showed a p(r) function with defined 
maximum but no elongated tail, just a small bulge at Dmax that is probably an 
artefact of the collected data (figure 32A). Nevertheless the p(r) function indicates a 
globular protein as expected from the corresponding crystal structure of the protein. 
All Dmax values are summarized in (table 13). The result of the Ab initio modelling of 
mKID VEGFR-2 KD in the fully phosphorylated state was an elongated shape with a 
Dmax of 167 Å. At one end the SAXS envelope shows a bigger volume that is 
narrowing down to the other end. Ab initio modelling of K868M VEGFR-2 KD yielded 
a very similar model with a more compact “head”-part and the same elongated “tail”-
domain seen in the mKID VEGFR-2 KD model. The bigger volume of the “head”-part 
in the K868M VEGFR-2 KD model presumably results from partial phosphorylation of 
the protein. The activation loop adopts an inactive conformation inside the cleft 
between the N- and the C-lobe of the kinase domain (no phosphorylation at 
Y1054/59) and the JMD is probably folded back onto the kinase domain as shown 
before for inactive kinases of the same family (Griffith et al., 2004;Mol et al., 
2004;Mol et al., 2003;Schubert et al., 2006). The model of ΔKID VEGFR-2 KD in the 
fully phosphorylated state showed a similar picture with a smaller Dmax of 124 Å and 
less volume in the “head”-domain presumably due to the lack of the KID (figure 32B). 
Superimposition of the crystal structure of VEGFR-2 catalytic domain (1VR2) with the 
SAXS envelopes resulted in a good fit with the bigger “head”-part of the particles 
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mKID VEGFR-2 KD, K868M VEGFR-2 KD and ΔKID VEGFR-2. However, the crystal 
structure represents only a part of the catalytic core of the kinase domain where the 
JMD, the KID and the C-terminus are missing. Furthermore flexible loops like parts of 
the activation loop or the JMD are not visible and SAXS models show therefore a 
bigger volume. In addition, proteins in solution contain a hydration shell that expands 
the volume of the SAXS envelopes. The overlay of the crystal structures with the 
SAXS models (ΔJMDΔKIDΔC VEGFR-2 KD) by SITUS yielded several plausible 
conformations (one representative superimposition is shown in figure 32C). In order 
to fit the experimental SAXS data of ΔJMDΔKIDΔC VEGFR-2 KD with the calculated 
solution scattering profile of the crystal structure of VEGFR-2 (1VR2) we used 
CRYSOL. The fit was good with a Chi value of 0.483 (figure 32D). 
 
Structure of VEGFR-2 KD in fully phosphorylated state 
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B 
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Structure of K868M VEGFR-2 KD in partially phosphorylated state 
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Structure of the phosphorylated VEGFR-2 KD lacking the KID 
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Structure of VEGFR-2 KD lacking the JMD, KID and the CD in fully phosphorylated 
state 
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Figure 32: SAXS results of VEGFR-2 kinase domain constructs 
(A) Shown for all measured concentrations are: The intensity plotted as a function of s, linear 
Guinier region with calculated Rg-values, The Kratky-plot and the p(r)-function as calculated 
from AUTOGNOM for the experiment used for ab initio modelling. (B) The averaged ab initio 
model (grey). The most typical particle (blue, small box). (C) SITUS superimposition of the ab 
initio model with the crystal structure of the truncated VEGFR-2 catalytic domain (PDB: 
1VR2). For VEGFR-2 ΔJMDΔKIDΔC KD: (D) CRYSOL evaluation of the solution scattering 
from the crystal structure of the VEGFR-2 catalytic domain (PDB: 1VR2) and the fitting with 
the experimental SAXS data. 1) Experimental scattering vector. 2) Theoretical intensity in 
solution 3) theoretical intensity in-vacuo 4) Solvent scattering. Figures by Sandro Manni and 
Kaisa Kisko using PyMOL. 
 
The overlay of the ab initio models, the scattering profiles and the p(r) functions of 
VEGFR-2 KD, K868M VEGFR-2 KD and ΔKID VEGFR-2 are visualized in figure 33. 
Differences in intensities and the p(r) functions clearly indicate differences in shape.  
 
A 
Construct Concentrations [mg/mL] 
Rg [Å] (Guinier-
region) ± S.E. Dmax ± S.E. [Å] 
mKID VEGFR-2 
KD 1, 1.5, 2 47.9 ± 0.4 167.5 ± 1.5 
K868M VEGFR-
2 KD 1.5, 2.5 44  ± 0.6 153.9 ± 2.2 
ΔKID VEGFR-2 
KD 1.5, 2.5 48.1 ± 2.4 123.8 ± 8.1 
ΔJMDΔKID ΔC 
VEGFR-2 KD 3, 5 25.2 ± 0.6 88.3 ± 2.2 
 
Table 13: Summary of SAXS experimental parameters determined by SAXS 
Rg and Dmax values were determined as mean ± S.E. for at least two concentrations.  
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Figure 33: Overlay of scattering-intensity plots, p(r)-functions and ab initio models of 
mKID VEGFR-2 KD, K868M VEGFR-2 KD and ΔKID VEGFR-2 KD 
Blue: mKID VEGR-2 KD. Green: K868M VEGFR-2 KD. Red: ΔKID VEGFR-2 KD. Figures by 
Sandro Manni and Kaisa Kisko. 
 
At the conclusion of this thesis we had not yet collected a high quality SAXS-dataset 
of the dephosphorylated (inactive) KD of VEGFR-2. We were therefore not able to 
generate an ab initio structural model. Nevertheless, we monitored conformational 
changes between the active (phosphorylated) and the inactive (dephosphorylated) 
KD of VEGFR-2 by MALS. As mentioned above it is possible to derive shape 
information from MALS data. The information can be derived from the elution volume 
of the coupled SEC column. The elution volumes of the measured proteins may 
slightly vary from those of previous runs (section 7.5) since we performed these 
experiments with a new SEC column and different analytical SEC columns from the 
same type show slightly different features. Comparison of experimental MALS data 
was always performed with data of samples obtained from the same column. To 
directly compare the active with the inactive KD we overlaid the elution profiles of the 
separately analysed samples (figure 34A). The theoretical Mr of the sample proteins 
could be verified with a small percentage error (table 14). All proteins were 
monomeric and showed a homogeneous mass distribution (concentrations of 2 
mg/mL). The previously observed shift of the SEC elution peak in SEC purification 
and MALS experiments of VEGFR-2 KD and K868M VEGFR-2 KD was indeed 
confirmed in these experiments. Furthermore, the elution peak of the 
dephosphorylated VEGFR-2 KD was shifted towards a higher volume: VEGFR-2 KD: 
13.3 mL < K868M VEGFR-2 KD: 13.41 mL < dephos VEGFR-2 KD: 13.57 mL. The 
shift clearly arises from the changes in the hydrodynamic properties of the protein 
90°  
Doctoral Thesis   Sandro Manni 
 
104 
indicating an altered molecular shape. Taken together the dephosphorylated inactive 
VEGFR-2 KD adopts a more compact conformation than VEGFR-2 KD and K868M 
VEGFR-2 KD which are partially phosphorylated after purification from cell lysates. 
 
A B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: MALS analysis of VEGFR-2 kinase domain constructs 
(A) MALS analysis of VEGFR-2 KD (top), K868M VEGFR-2 KD (middle) and 
dephosphorylated VEGFR-2 KD. Molecular envelope derived from SAXS data is indicated in 
the corresponding graph. (B) Overlay of MALS data for VEGFR-2 KD with K868M VEGFR-2 
KD (top) and VEGFR-2 KD, K868M VEGFR-2 KD and dephosphorylated VEGFR-2 KD 
(bottom). Molecular envelope is indicated in the graph. Dephosphorylated VEGFR-2 KD 
envelope is shown as a representative illustration with the crystal structure of VEGFR-2 
(1VR2) as the catalytic core of the KD. The CD is depicted as a schematic loop colored in 
khaki. The JMD is depicted as a schematic black loop. 
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VEGFR-2 KD 
constructs 
 
Theoretical Mr 
[kDa] 
 
Experimental Mr 
[kDa] 
 
VEGFR-2 KD 
 
65.9 
 
66.4 (0.1%) 
 
VEGFR-2 KD + I 
 
65.9 
 
65.5 
 
VEGFR-2 KD 
dephos 
65.9 63.9 (0.1%) 
 
Table 14: Comparison of theoretical and experimentally determined Mr of VEGFR-2 
kinase domain proteins in different phosphorylation states. VEGFR-2 KD: fully 
phosphorylated, VEGFR-2 KD + I: phosphorylated CD, VEGFR-2 dephos: fully 
dephosphorylated protein. 
 
7.5. Expression, purification and biophysical characterization of 
TSAd and of a TSAd-VEGFR-2 KD complex 
 
The adapter protein TSAd initially identified in immune cells was found to interact 
with VEGFR-2 Y951 via its central SH2-domain. In order to perform biophysical 
studies with TSAd and with a complex between TSAd and the kinase domain of 
VEGFR-2 we cloned the murine version of TSAd (366 AA) into one of the two 
multiple cloning sites of the Multibac vector pFL. The constructs carried a C-terminal 
10xHis-tag with a preceding TEV protease cleavage site for tag-removal. 
Recombinant protein was expressed in baculovirus infected Sf21 insect cells. The 
infected cells were harvested 72-96 h post infection. Expression of the recombinant 
protein was verified by immunoblotting using a 5xHis-tag specific antibody. A protein 
with a Mr of 42 kDa was detected (figure 35). Varying the virus inoculum did not 
change the expression level. TSAd was also detected in the culture supernatant due 
to baculovirus induced leakage of insect cells.  
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Figure 35: Expression of TSAd in Sf21 insect cells 
Sf21 insect cells were infected with various amounts of TSAd baculovirus. (1x-6x). The 
recombinant protein was detected by immunoblotting using an antibody against the His-tag. 
SN: Supernatant.  
 
To optimize the solubility of TSAd for further purification we performed a solubility 
screening by lysing the cells with lysis buffers in the pH range of 6-9. Earlier attempts 
to purify TSAd with a theoretical Pi of 7.34 at pH of 6 did not succeed. Best solubility 
of TSAd was achieved in Tris buffer of pH 8-8.5 (figure 36). Hence, all following 
purification steps were conducted at pH 8.3. 
 
 
 
 
 
 
 
 
 
Figure 36: Solubility of TSAd in the pH range of 6-8.5 
TSAd could be solubilised with Tris buffer at pH 8-8.5. 
 
Doctoral Thesis   Sandro Manni 
 
107 
The complex of TSAd with the KD of VEGFR-2 was evaluated by co-infecting Sf21 
insect cells with baculoviruses of both constructs. TSAd and the TSAd-VEGFR-2 KD 
complex were purified by IMAC with increasing imidazole concentration to remove 
most of the impurities. After IMAC the purified complex was in vitro phosphorylated to 
achieve a homogenously phosphorylated protein population and to increase binding 
of TSAd to pY951 of the VEGFR-2 KD. In a second step we purified the proteins via 
SEC (figure 37). SEC purification yielded a protein purity of 95% as judged from 
SDS-PAGE. The protein yield ranged from 0.5-1.5 mg per litre of cultured cells for 
TSAd and the complex. The SEC fractions of the purified complex contained equal 
amounts of TSAd and VEGFR-2 KD along the entire elution peak indicating efficient 
complex formation. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
elution volume: 85.4 mL 
IMAC purification    SEC purification 
eluate     eluate 
kDa  kDa  
TSAd TSAd 
75 
37 37 
75 
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Figure 37: Purification of TSAd and TSAd-VEGFR-2 KD complex 
(A) IMAC and SEC purification of TSAd and (B) TSAd-VEGFR-2 KD complex. 
 
7.5.1. SEC analysis of TSAd-VEGFR-2 KD complex 
 
SEC separates proteins on the basis of mass and shape. A gel filtration column that 
was calibrated with globular proteins was used to determine the mass of a standard 
globular protein based on the elution volume. A nonglobular protein with identical Mr 
will elute differently since it has different hydrodynamic radius. We used a calibrated 
Superdex S-200 16/60 column to monitor TSAd binding to the VEGFR-2 kinase 
domain. TSAd and TSAd-VEGFR-2 KD complex were purified by IMAC as shown 
above (figure 38A). IMAC fractions of TSAd and TSAd-VEGFR-2 KD complex were 
pooled at a ratio of 1:1 and loaded on the gel filtration column (figure 38B). As a 
result we detected an excess of TSAd on the column. The following elution peaks 
IMAC purification    SEC purification 
eluate 
kDa  
kDa  
TSAd-VEGFR-2 KD 
complex 
TSAd-VEGFR-2 KD complex 
100  
100  
55 
55 
35 
35 
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were identified: TSAd-VEGFR-2 KD complex at 71.72 mL and TSAd eluted at 83.54 
mL. VEGFR-2 KD eluted at 73.86 mL as shown in section 7.4. All protein species 
eluted with a well-defined retention time. The complex peak was obviously shifted to 
the left (elution of heavier protein species) compared to the elution peak of VEGFR-2 
KD. It was not possible to determine the appropriate Mr of VEGFR-2 KD and 
therefore the Mr of TSAd-VEGFR-2 complex since VEGFR-2 KD is elongated in the 
fully phosphorylated state (see ab initio models of previous SAXS experiments). 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMAC purification    IMAC purification 
TSAd TSAd-VEGFR-2 KD  
complex 
eluate eluate 
kDa  
75 
37 
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Figure 38: Analysis of TSAd-VEGFR-2 KD complexes 
(A) IMAC purification of TSAd and TSAd-VEGFR-2 KD complex. (B) SEC purification of 
pooled IMAC factions. (C) Overlay of SEC purifications of TSAd, TSAd-VEGFR-2 KD 
complex (blue) and VEGFR-2 KD (red). 
 
 
 
 
elution volume TSAd: 83.5 mL   
elution volume TSAd-VEGFR-2 KD: 71.72 mL   
kDa  
75 
37 
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TSAd TSAd-VEGFR-2  
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7.5.2. Mass spectrometry of TSAd 
 
In order to confirm protein identity and to verify the expression of the full-length 
protein we sent a protein sample to the Functional Genomics Center Zürich. The 
sample was proteolytically digested and the peptides were analysed via 
LC/ESI/MS/MS. The peptide sequences were used for a database search with the 
Mascot search program. The most significant hits are marked in yellow (figure 39A). 
TSAd was identified with good sequence coverage. In the course of TSAd purification 
we always co-purified an unknown protein with the Mr of 70kDa. We were able to 
identify the unknown protein as heat shock protein 70 (figure 32B). Hsc70 proteins (in 
eukaryotes) are ubiquitously expressed proteins that are important for proper protein 
folding and are upregulated upon cellular stress. Hsc70 recognizes hydrophobic 
residues on the surface of partially denatured proteins or during release from 
ribosomes. Interaction with the nascent not yet folded peptide chain prevents 
aggregation of newly synthesized proteins. Although we obtained reasonable 
amounts of TSAd protein, production seems to be a challenge for the expressing 
organism. We further noticed a remarkable loss of protein between IMAC and SEC 
purification steps that may result from instability of the protein.  
 
A 
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Figure 39: Mass spectrometry of TSAd and a co-purified Hsc70 protein 
A) Mascot search results for TSAd B) Coomassie gel showing TSAd (lower band) together 
with a co-purified 70 kDa protein (upper band). Lower panel: Mascot search results of 70 kDa 
protein. 
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7.5.3. Multi Angle Light Scattering (MALS) analysis of TSAd and a TSAd-
VEGFR-2 KD complex 
 
To confirm binding of TSAd to VEGFR-2 KD we performed a MALS analysis. TSAd, 
VEGFR-2 KD and VEGFR-2 K868M (as a negative control) KD were first analysed 
without their binding partner. The analysis of VEGFR-2 KD and VEGFR-2 K868M KD 
is shown in section 7.5 and 7.8. TSAd was injected at a concentration of 2 mg/mL. 
The TSAd peak was monodisperse and showed a homogeneous mass distribution 
corresponding to a monomer (figure 40A). The theoretical Mr of TSAd was verified 
with a small error (table 14). VEGFR-2 KD, VEGFR-2 K868M KD and TSAd eluted at 
distinct volumes. TSAd-VEGFR-2 KD and TSAd-K868M VEGFR-2 were purified from 
a co-infected culture as shown in section 7.9 The purified protein fractions were 
loaded on the SEC column coupled to the MALS instrument. TSAd-VEGFR-2 
fractions gave rise to two peaks with Mr of 119 and 46.64 kDa corresponding to the 
theoretical Mr of the 1:1 TSAd-VEGFR-2 KD complex (108 kDa) and the theoretical 
Mr of excess monomeric TSAd (42.1 kDa). TSAd-K868M VEGFR-2 KD fractions 
resulted in two peaks with Mr of 72.65 and 49.9 kDa corresponding to the theoretical 
values of monomeric VEGFR-2 K868M KD and monomeric TSAd.  
We conclude that VEGFR-2 KD (human KID) forms a complex with murine TSAD 
when Y951 is phosphorylated. The inactive VEGFR-2 K868M does not bind to 
murine TSAd due to the lack of phosphorylation at Y951 (figure 40B).  
 
A 
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Figure 40: MALS analysis of TSAd and TSAd-VEGFR-2 KD complex 
A) Analysis of TSAd. B) Analysis of TSAd-VEGFR-2 KD and TSAd-K868M VEGFR-2 KD (left 
panels). Overlay of TSAd-VEGFR-2 KD, VEGFR-2 KD and TSAd is shown in the top right 
panel. Y951 phosphorylation of VEGFR-2 KD and VEGFR-2 KD shown in a kinase-Inhibitor 
treated culture of VEGFR-2 KD, KD+I) is shown in the lower right panel. 
 
Construct Theoretical Mr [kDa] Experimental Mr [kDa] 
VEGFR-2 KD 65.9 61.62 (0.2%) 
K868M VEGFR-2 KD 65.9 64.94 (0.5%) 
TSAd 42.1 43.41 (0.3%) 
TSAd-VEGFR-2 KD 
complex 108 119 (5%); 46.64 (14%) 
TSAd-K868M VEGFR-2 
KD 65.9; 42.1 72,65 (1%); 49.9 (4%) 
 
Table 14: MALS analysis of TSAd and TSAd-VEGFR-2 KD complex 
Comparison of theoretical and experimentally determined Mr of VEGFR-2 KD, K868M 
VEGFR-2 KD, TSAd and the complex of TSAd with VEGFR-2 KD via MALS.  
KD   KD+I  
M 
kDa  
10
0 
5
5 
pY951 
TSAd-VEGFR-2 complex 
TSAd-K868M VEGFR-2 KD 
TSAd-VEGFR-2 KD, VEGFR-2 KD, TSAd 
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In addition, we propose that the SH2-domain of murine TSAd also binds to VEGFR-2 
KD in vitro when Y951 is phosphorylated while K868M VEGFR-2 KD does not bind to 
murine TSAd due to the lack of phosphorylation at Y951. The binding is mediated by 
the consensus recognition sequence of the SH2-domain of TSAd, which is different 
for murine and human Y951. The murine sequence differs in two amino acids: 
Y951VGAI (human) vs. Y951VGEL (murine). Yet both sequences are recognized by the 
TSAd SH2-domain. 
 
7.5.4. Solution Structure of TSAd and TSAd-VEGFR-2KD complex 
determined by Small Angle X-ray Scattering (SAXS) 
 
We performed a SAXS analysis of the biophysically characterized constructs TSAd 
and TSAd-VEGFR-2 KD complex (figure 41). Our goal was to characterize the 
interaction of the two binding partners and to obtain an overall structure. All proteins 
were measured at several concentrations. TSAd and TSAd-VEGFR-2 KD complex 
showed a flat intensity curve. The Guinier-approximation of TSAd showed 
comparable Rg values for the two concentrations measured. Two of the three 
measured concentrations (1 and 4.7 mg/mL) of TSAd-VEGFR-2 KD complex showed 
significant signs of aggregation. Further processing was therefore exclusively 
conducted with the 2 mg/mL protein sample. Kratky plots of TSAd and TSAd-
VEGFR-2 KD complex confirmed a general globular fold. P(r) functions of TSAd and 
TSAd-VEGFR-2 KD had a defined maximum and a tail indicating that the proteins 
were elongated. All Rg and Dmax values are summarized in table 15. The Ab initio 
model of TSAd showed an elongated shape with a broad globular central domain and 
a Dmax of 137 Å. We superimposed the crystal structure of the SH2 domain of src 
(PDB: 1O4C) with the SAXS envelope of TSAd using SITUS software. The SH2-
domain of src is homologous to the SH2-domain of TSAd (figure 41C). The crystal 
structure of the SH2-domain fitted well into the globular domain of the ab initio model 
of TSAd. The data is also in agreement with the predicted secondary structure of 
TSAd. Ab initio modelling of TSAD-VEGFR-2 KD complex resulted in an elongated 
protein with a Dmax of 202 Å. The quality of this sample was not satisfying and 
needs to be verified by additional measurements. Nevertheless it was possible to 
retrieve a model from the data measured at the concentration of 2 mg/mL. Alignment 
of TSAd and VEGFR-2 KD with the ab initio model of TSAd-VEGFR-2 KD complex 
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(figure 42) suggests a linear interaction of TSAd with the ”head” part of the kinase 
domain. The sum of the calculated volumina belonging to VEGFR-2 KD and TSAd 
corresponds to the total volume of the complex (table 15). 
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Structure of TSAd-VEGFR-2 KD complex 
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Figure 41: SAXS results of TSAd and TSAd-VEGFR-2 complex 
A) Shown for all measured concentrations: The intensity plotted as a function of s, the linear 
Guinier region with calculated Rg-values, the Kratky-plot and the p(r)-function as calculated 
from AUTOGNOM for the experiment used for ab initio modelling. B) The averaged ab initio 
model (in grey), the most typical particle (blue particle, small left box) and the most typical 
paricle superimposed with the averaged envelope (small box on the right) C) SITUS 
superimposition of the ab initio model of TSAd with the crystal structure of the SH2-domain of 
src (PDB: 1O4C). Alignment of TSAd-SH2 domain with those of other cytoplasmic signaling 
proteins. Boxed, unshaded: identical amino acids. Boxed, shaded: Conserved amino acids 
(Li-Wha Wu et al., 1999). Figures by Sandro Manni and Kaisa Kisko. 
 
SAXS experimental parameters are summarized in table 15. Overlay of the scattering 
intensities, p(r) functions and the Ab initio models, of VEGFR-2 KD, TSAd and TSAd-
VEGFR-2 KD, are visualized in figure 42.  
 
A 
Construct Concentrations [mg/mL] 
Rg [Å] (Guinier-
region) ± S.E. Dmax ± S.E. [Å] 
TSAd 1, 1.8 42.6 ± 3.4 136.9 ± 4.4 
TSAd-VEGFR-2 KD 
complex 1, 2, 4.7 59.16 202.63 
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Construct 
 
Volume (x103) [Å] 
(ab initio model) 
mKID VEGFR-2 KD 134.9 
TSAd 104.1 
TSAd-VEGFR-2 KD complex 234.2 
 
Table 15: SAXS experimental parameters  
A) Rg and Dmax values for TSAd were determined as mean ± S.E. for at least two 
concentrations. Rg and Dmax values for TSAd-VEGFR-2 KD complex were determined from 
one single concentration. (B) Volumes of VEGFR-2 KD, TSAd and TSAd-VEGFR-2 KD 
complex determined by SAXS and used for ab initio modelling. 
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Figure 42: Overlay of intensities, p(r)-functions and ab initio models of mKID VEGFR-2 
KD, K868M VEGFR-2 KD and ΔKID VEGFR-2 KD 
Figures by Sandro Manni and Kaisa Kisko. 
 
8. Discussion and Outlook 
 
8.1. The Role of the transmembrane domain in VEGFR-2 
activation 
 
VEGFR-2 is a key regulator of vasculogenesis and angiogenesis. Ligand binding to 
the ECD of VEGFR-2 induces distinct conformational changes within the receptor 
resulting in receptor dimerization. It was shown that, besides ligand-receptor 
contacts, receptor dimers are engaged in homotypic interactions in domains 4 and 7 
(Ruch et al., 2007). To activate the receptor, the intracellular kinase domains must be 
reoriented in a distinct orientation. In the case of the EGFR (Zhang et al., 2006) and 
the FGFR (Bae et al., 2010) the activated kinase domains form an asymmetric dimer. 
One of the goals of this project was to shed light on the role of the TMD during 
VEGFR-2 activation. Earlier studies on Neu (Bell et al., 2000; Lofts et al., 1993) or 
EGF receptors (Smith et al., 1996) made clear that receptor tyrosine kinases can 
also be artificially dimerized and activated by interactions mediated by their TMDs. 
Previous experiments in our lab examined the role of dimerization and activation of 
VEGFR-2 by using artificial TMDs consisting of sequentially arranged glutamic acid 
residues in an all valine transmembrane helix (Dell'Era Dosch and Ballmer-Hofer, 
90°  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2009a). Introduction of glutamic acid residues at specific positions of the TMD gave 
rise to either active or inactive dimers. Dimerization is therefore required but not 
sufficient for activation of VEGFR-2. We were able to confirm these findings in the 
context of the wt-TMD of VEGFR-2. Our ECD-deleted VEGFR-2 constructs carrying 
glutamic acid point mutations in the TMD gave rise to either active or inactive 
receptors. I767E, L768E and V796E showed significantly higher receptor activity 
compared to wt. V769E was the most active (3.5x increase compared to wt) whereas 
several other point mutations along the TMD showed activities in the range of wt. An 
interesting finding was that these activating single glutamic acid mutations did not 
affect the baseline activity of full-length VEGFR-2 and could still be activated by 
ligand. These data suggest that the ECD of VEGFR-2 plays an important role in the 
autoinhibition of the kinase domain in the absence of the ligand as discussed earlier 
(Tao et al., 2001). Furthermore, our lab recently published data demonstrating that 
binding of VEGF to recombinantly produced ECD protein encompassing Ig-domains 
1-7 of VEGFR-2 is 1.0-1.7 kcal/mol less favourable than binding of VEGF to Ig-
homology domains 2-3 (Brozzo et al., 2012b). Based on these findings we propose 
that Ig-domains 4-7 attenuate receptor activity in the absence of ligand. The 
observed energetic penalty might arise from the reported homotypic interactions in 
Ig-domains 4 and 7. In agreement with this it was shown for the FGFR3 that the ECD 
prevents dimerization in the absence of ligand with a ΔG of 1 kcal/mol (Chen et al., 
2010). A392E, a mutation in the TMD helix of FGFR3, has been associated with a 
human disease called Crouzon syndrome. It has been reported that the change in 
free energy of dimerization of the isolated TMD of FGFR3 in lipid bilayers induced by 
this mutation is -1.3 kcal/mol (Li et al., 2006). Based on these thermodynamic data it 
is thus possible that the A392E mutation activates FGFR3 by stabilizing receptor 
dimers in the absence of ligand giving rise to the observed receptor-mediated 
pathology. The ΔG change by a single glutamic acid residue in the TMD in a 
particular position in ECD-deleted receptor constructs therefore reflects the 
reorientation of the kinase domains and thus activates the receptor. As shown by our 
data, change in ΔG is not sufficient to compensate for the repulsive force of the ECD 
in full-length receptor constructs. The ECD might thus reduce the structural flexibility 
of the TMD in the lipid bilayer and allow only distinct conformations of the TMD-helix. 
To override steric hindrance induced by the VEGFR-2 ECD and to maintain the 
receptor in an active conformation sustained by glutamic acid-induced hydrogen 
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bonding in the lipid bilayer a single glutamic acid residue is thus not sufficient. When 
comparing ECD-deleted VEGFR-2 with VEGF stimulated full-length VEGFR-2 and 
unstimulated receptor it becomes apparent that the ECD of VEGFR-2 tightly 
regulates receptor kinase activity. ECD-deleted VEGFR-2 shows a 50% increase in 
activity compared to unstimulated full-length VEGFR-2 constructs in agreement with 
previous experiments from our lab using ECD-deleted VEGFR-2 constructs (Dell'Era 
Dosch and Ballmer-Hofer, 2009a). 
 
We also studied the mechanism of VEGFR-2 activation by comparing ECD-deleted 
with full-length constructs carrying two glutamic acid mutations in the TMD. In these 
artificial TMDs glutamic acids were spaced 7 residues apart thereby positioning them 
on the same face of the helix. The idea was to rigidify the dimerization interface and 
to generate dimers with specific spatial orientations of the two monomers that might 
either activate or inactivate the receptor similar to the all valine TMD constructs 
studied previously in our lab. The introduction of two glutamic acid mutations is 
expected to compensate for the repulsive force of the ECD and to facilitate the 
formation of distinct dimeric TMD conformations. Surprisingly, the introduction of 
glutamic acid pairs in the TMD of the ECD-deleted VEGFR-2 constructs at positions 
V769E/M776E, G770E/F777E and T771E/F778E gave rise to inactive receptor 
variants whereas mutations G770E/F777E and T771E/F778E were able to activate 
the full-length receptor independent from VEGF stimulation (figure 43B and C). The 
positions of the activating pair of mutations G770E/F777E and the inactivating 
I774E/L781E mutations is in agreement with our earlier data obtained with all valine 
TMDs where V770/777E gave rise to active and V774/781E to inactive receptor 
constructs. The fact that the V769E mutation activated the ECD-deleted receptor 
while V769E/M776E gave rise to inactive ECD-deleted receptors documents the tight 
control of the activation of VEGFR-2. As a matter of fact no disease-related 
constitutively active or inactive VEGFR-2 variants are known, demonstrating that 
activation of VEGFR-2 must be tightly regulated presumably to prevent embryonic 
lethality resulting from vascular defects (Shalaby et al., 1995).  
Our data also show that the orientation of the interacting side chains in the dimerized 
TMDs vary in the presence or absence of the ECD. On the other hand the 
V770/777E mutations in the all valine TMD gave rise to active receptors both in the 
ECD-deleted and in full-length receptors presumably as a result of reduced sterical 
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hindrance in the all valine dimeric helices, which allows for increased side chain 
flexibility. The introduction of a single glutamic acid residue into the TMD of VEGFR-2 
may allow for flexibility so that the kinase domains are able to orient relative to each 
other in an active conformation. Introduction of a pair of glutamic acid residues 
further restricts this flexibility by maintaining the TMD helices in either an activating or 
an inactivating receptor conformation. Based on our findings we speculate that there 
are possibly two alternative arrangements of the TMD helices in the dimeric and 
active full-length VEGFR-2 (G770E/F777E and T771E/F778E, see figure 43B). Both 
conformations are rotated by 100° relative to each other along the helix axis since 
two adjacent side chain residues span an angle of 100° in a helix while a full turn of 
360° involves 3.6 amino acids (figure 43A). 
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Figure 43: Schematic representation of putative TMD helix orientation by double 
glutamic acid dimerization TMDs  
(A) Schematic top view of helices and rotation angles relative to V769 (B) Introduction of 
glutamic acid pairs G770E/F777E and T771E/F778E into the TMD of the full-length receptor 
leads to constitutive activation. Each glutamic acid pair may induces a distinct activated 
dimeric KD conformation (each TMD corresponds to one asymmetric activated dimer). (C) 
The same mutations as in (B) render ECD-deleted receptors inactive (KDs are shown as 
inactive, symmetric dimers). A) B) C) Active and inactive kinase dimers arrangements are 
shown as possible asymmetric and symmetric dimers, respectively (interaction via KID or C-
terminus,). Ig-domains 1-7 of the ECD are indicated. VEGF is depicted in green. Homotypic 
interactions in domains 4 and 7 in the ECD are indicated as blue parallel lines. JMD: black 
loop. The αC-helix is shown for each KD in either a blue or a yellow colored cylinder. The 
activation-loop is shown for each KD as either a green or magenta loop. KID: dark blue 
colored domain. The C-terminus is shown for each KD as either a brown or orange loop. 
Phosphorylation sites are depicted as red dots. TMDs are indicated by a schematic dimeric 
helix arrangement with monomers in orange and grey. Helices were generated with PyMOL. 
 
To further elucidate the exact molecular mechanism of receptor activation it is 
indispensable to generate high-resolution structural information. Based on our 
previous cell biological data we therefore solved the structure of TMD helix-dimers in 
the native and the V769E containing TMD helices in collaboration with Alexander S. 
Arseniev using NMR spectroscopy. It has previously been shown that the TMD of 
VEGFR-2 has an intrinsic propensity to dimerize although none of the known 
dimerization motifs like a distinct heptat (XxxxxxxX, X=G, A or S) or the GG4-like 
repeat (XxxxX, X=G, A, S or T) motifs is present (Finger et al., 2009a). Bell et al. (Bell 
et al., 2000) proposed a model in which the rotational angle perpendicular to the 
inactive inactive 
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plane of the plasma membrane at which the kinase subunits interact with each other 
is important for receptor activation (in their case the neu receptor). However, several 
other results show that the TMDs of RTK are more likely to interact in an X-shaped 
conformation (Bocharov et al., 2008; Gullick et al., 1992; Mineev et al., 2010; Smith 
et al., 1996). Our NMR data indeed show that the wt-TMD of VEGFR-2 adopts such 
an X-shaped, symmetrical dimer with a left-handed helix orientation. 
The dimerization interface spans across the entire helix and consists mainly of 
apolar, hydrophobic contacts formed by a “heptad-repeat”-like cluster: 
T761xxE764xxI767L768xxT771A772xxA775xxF778W779xL781L782xxI785xxxV789. The interface is 
further stabilized by a symmetric edge to face stacking interaction of F778 with 
W779. NMR analysis of the dimerization process at the lower protein / DPC ratio of 
1:150 gave rise to ~70% monomeric TMD-helices. This is in agreement with earlier 
dimerization studies using Toxcat assays which showed that the wt-TMD of VEGFR-
2 is a weak dimerizer (Finger et al., 2009a). The dimeric conformation coexists with 
the monomeric state and represents the thermodynamically most stable form of the 
wt-TMD helix in a lipid environment. The dimer may indeed represent a stable 
conformation activating ECD-deleted VEGFR-2 which would agree with our data 
showing a 50% increase in activity compared to the unstimulated full-length VEGFR-
2 construct (figure 44). Our data also shows that introduction of a glutamic acid 
residue at position 769 of the TMD of VEGFR-2 did not induce a conformational 
change of the TMD helix. Furthermore, the energetic contribution to dimer formation 
by the V769E mutation was insignificant (-0.3 kcal/mol) and the calculated dimer 
structure was with high probability identical to the previously found wt-TMD dimer 
(good correlation for chemical shift-changes of the nitrogen and the amide-proton). 
Mutation of V769 to E769 creates a third trimeric and highly stable oligomeric state 
generating additional surface area that promotes helix-helix interactions leading to 
active ECD-deleted VEGFR-2 constructs. The asymmetric dimeric unit in the trimer 
shares similar geometrical parameters previously found in TMD structures 
corresponding to the active state of RTKs such as the EGFR (Bocharov et al., 2008). 
The angle between the axes of helices are -50 ± 5° and C-termini point away from 
each other. To determine the conformations of the activating TMD in the context of 
the full-length VEGFR-2 we performed NMR studies on TMD-helices carrying our 
previously identified activating glutamic acid pairs G770E/F777E and T771E/F778E. 
Doctoral Thesis   Sandro Manni 
 
126 
Unfortunately we were not able to finish these experiments at the conclusion of this 
thesis.  
Taken together, our structural data demonstrates that the introduction of a single 
glutamic acid residue at position 769 in the TMD of VEGFR-2 does not 
thermodynamically favour dimerization but allows for additional surface area that 
generates multiple oligomeric states. This might suggest that the activation of the 
V769E mutant of ECD deleted VEGFR-2 constructs is kinetically rather than 
thermodynamically driven. E769 might “trap” the dimer in an energetically 
unfavourable conformation thereby exposing binding sites for additional helix-helix 
interactions that, depending on the concentration of receptors in the cell membrane, 
give rise to a stable trimeric form. The wt-TMD dimer may therefore represent an 
intermediate state that is entropically favoured. Further structural and kinetic studies 
are now required to shed light on these processes. 
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Figure 44: Role of the ECD and the TMD in VEGFR-2 activation 
(A) ECD-deleted VEGFR-2 shows spontaneous activation compared to unstimulated full-
length VEGFR-2 (50% increase, B). A) B) Active dimeric kinase conformations are shown as 
asymmetric dimers (interaction via KID or C-terminus). Inactive kinases in the full-length 
receptor are shown as monomers. JMD: black loop. The αC-helix is shown for each KD in 
either a blue or a yellow colored cylinder. The activation loop is shown for each KD in either a 
green or magenta loop. KID: dark blue colored domain. The C-terminus is shown for each 
KD in either a brown or orange loop. Phosphorylation sites are depicted as red dots. 
Experimentally determined 3D-structure of the wt-TMD is colored in grey. 
 
8.2. The role of the kinase insert and the C-terminal domain in 
VEGFR-2 activation 
 
The goal of this project was to identify the function of distinct VEGFR-2 kinase 
subdomains such as the KID and the CD. Previous data from several research 
groups suggest that these domains fulfil regulatory functions of receptor tyrosine 
kinases in general. Deletion of the KID of αPDGFR, for instance, impaired PDGF 
induced autophosphorylation of tyrosine residues, phosphatidylinositol turnover and 
receptor-associated PI-3 kinase activity (Heidaran et al., 1991) and deletion of 164 
amino acids in the C-terminus of EGFR rendered the receptor inactive. Hence, the C-
terminus of EGFR is required for the receptor to adopt a fully active conformation 
(Wedegaertner et al, 1992). Another regulatory contribution of the CD was described 
active active 
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for the Met-receptor. Peptides derived form the CD inhibited the kinase domain in 
vitro and the intracellular delivery of such peptides impaired HGF-dependent Met 
phosphorylation and downstream signaling (Bardelli et al., 1999). To date the only 
structural information that is able to explain the role of the KID and the CD in RTK 
activation derives from the Tie-2 receptor (Shewchuk et al., 2000b). This structure 
represents an inactivated monomeric kinase domain that is inhibited by its CD. The 
phenyl ring of Y1112 that represents a major C-terminal phosphorylation site is 
packed between the hydrophobic side chains of L696, L579, F1114 and R577 in the 
KID of Tie-2. The KID is therefore an essential structural element enabling 
inactivation of Tie-2 via the CD. The negative regulatory role of the CD was further 
verified in later studies where it was shown that mutation of Y1112F or deletion of the 
CD of Tie-2 leads to receptor activation (Niu et al., 2002; Sturk et al., 2009). Since 
the mentioned subdomains are missing in the crystal structure of VEGFR-2 (McTigue 
et al., 1999a) their role in kinase regulation remains unclear. In addition to further 
structural analysis it was therefore essential to perform functional studies to gain 
more insight into the regulation of the kinase domain of VEGFR-2. We found that 
KID-deleted constructs showed reduced phosphorylation at Y1175 in HEK293 cells, 
but, most remarkably, the activation-loop residues Y1054/59 of VEGFR-2 was still 
phosphorylated. McTigue et al. (McTigue et al., 1999a) demonstrated earlier that the 
truncated kinase domain of VEGFR-2 used for crystallization did not show a 
significant decrease in the catalysis of the phosphotransfer reaction in vitro. The KID 
is therefore not necessary for phosphorylation of the activation loop and the 
subsequent activation of the kinase domain. But, as our data show, the absence of 
the KID prevents phosphorylation at downstream phosphorylation sites such as 
Y1175 (figure 44A). To see whether this effect is induced by the complete deletion of 
the KID or whether it is the dependence of Y1175 phosphorylation on 
phosphorylation at Y951 we mutated this residue. Our data show that 
phosphorylation of Y1175 requires prior phosphorylation at Y951. Phosphorylation of 
Y1212 further downstream of Y1175, on the other hand seems not to be affected by 
the Y951F mutation. Based on these findings we propose that VEGFR-2 activation 
depends on the coordinated phosphorylation of specific sites.  
The CD-deleted VEGFR-2 constructs were constitutively active with strong 
phosphorylation signals at Y1175 and Y1054/59 (figure 45B). We verified the data in 
the full-length and in ECD-deleted receptor constructs with and without VEGF-
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stimulation. Downstream signaling via PLC-γ was consistent with the phosphorylation 
pattern of the constructs. 
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Figure 45: Schematic representation of VEGFR-2 KD mutants 
(A) KID-deletion prevents phosphorylation at Y1175 of the KD whereas the activation loop 
sites Y1054 and Y1059 are phosphorylated. (B) Deletion of the CD renders VEGFR-2 
constitutively active independent of VEGF stimulation (shown as two alternative active 
asymmetric dimers). 
 
 
 
inactive 
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This data is not in agreement with earlier reports where chimeric receptor variants 
carrying the ECD of the CSF receptor fused to the CD-deleted kinase domain of 
VEGFR-2 were not activated upon CSF stimulation (Meyer et al., 2003). The authors 
proposed the existence of an inactive dimer of the kinase domain in the absence of 
the CD. On the basis of previously discussed results concerning our TMD-mutant 
constructs we think that the ECD of VEGFR-2 plays a crucial role in autoinhibition 
and activation of the KD of VEGFR-2. To perform these tasks the ECD must be able 
to orient the kinase domains inside cells based on bioavailability of ligand. 
Replacement of the native ECD with the ECD from a different RTK impairs the 
authentic regulatory mechanism. Based on our results, such data acquired with 
chimeric VEGFR-2 constructs should therefore be considered with caution. 
Our data for the KID and the CD of VEGFR-2 let us propose a highly ordered and 
complex activation mechanism that is initiated upon ligand binding to the ECD.  
 
In order to perform further biophysical experiments and to gain a deeper insight into 
the regulatory mechanism of the kinase of VEGFR-2 we expressed several mutant 
constructs in Sf21 insect cells yielding protein of high purity and amounts in the 
milligram range. MALS analysis of recombinant proteins confirmed their 
monodispersity. All kinase domain proteins produced in this way were monomeric at 
the measured protein concentration of 2 mg/mL.  
We were further interested whether the kinase shows intrinsic potential to dimerize at 
increasing concentration and whether activating and inactivating kinase domain 
modifications were able to alter the intrinsic dimerization propensity. From previous 
crystal structures we knew that kinase-subdomains could have an impact on dimer 
formation. It was shown e.g. that the intracellular JMD of EGFR is involved in 
formation of the activated asymmetric dimer. The C-terminal half of the JMD-segment 
links the activated kinase domain to the activator kinase while the N-terminal half is 
thought to potentiate dimerization by adopting an antiparallel helical dimeric 
conformation (Jura et al., 2009). In the crystal structure of the FGFR1 dimer 
phosphotyrosine Y583 in the KID of one monomer is bound to the catalytic cleft of 
the other monomer resulting in asymmetric dimer formation (Bae et al., 2010). Chen 
et al. (Chen et al., 2008) solved the crystal structure of FGFR-2 in the act of trans-
phosphorylation of Y769 which represents the most important phosphorylation site in 
the CD. The asymmetric dimer was formed by residues close to the C-terminus upon 
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interacting with the active site of the participating kinase monomer.  
Our sedimentation equilibrium AUC-data demonstrates that the activated, fully 
phosphorylated kinase domain of VEGFR-2 has a low, but significant propensity to 
form dimers when increasing protein concentration (Kd=160 ± 56 µM). Specific 
subdomains of VEGFR-2 enhance dimerization while deletion of the JMD, KID and 
the CD results in a reduction of the affinity (Kd=553 ± 80 µM). This data is in 
agreement with the literature. Notably the deletion of the CD reduces dimer formation 
(Kd=290 ± 14 µM) in vitro although this construct showed constitutive activation of 
the receptor in HEK293 cells. The same effect was observed with the KID-deletion 
mutant (Kd=225 ± 35 µM). We assume that in the plasma membrane of cells deletion 
of the CD leads to receptor dimerization. To prove receptor dimerization also in live 
cells additional co-immunoprecipitation or crosslinking experiments are required.  
McTigue et al. (McTigue et al., 1999a) were not able to see a significant difference in 
catalytic activity by comparing the truncated kinase domain of VEGFR-2 (ΔJMD, 
ΔKID and ΔC) used for crystallization with the full-length kinase in vitro. To further 
clarify the role of the CD and the KID in the isolated, monomeric VEGFR-2 kinase 
protein, kinase assays of the specific deletion mutants would be helpful.  
 
Besides looking at active and inactive mutants it is crucial to acquire also information 
on the activation process itself. It has previously been demonstrated that 
autophosphorylation in the kinase domain of RTKs occurs in an ordered and 
sequential way (Furdui et al., 2006). Upon activation of the isolated kinase domain of 
VEGFR-2 by ATP, Y801 in the JMD is phosphorylated as a first event, followed by 
Y1054 and Y1059 phosphorylation in the activation loop that further potentiates 
kinase activity (Dougher Vermazen et al., 1994; Kendall et al., 1999; Solowiej et al., 
2009). From crystal structures of type III receptor tyrosine kinases we know that the 
JMD binds at an interface between the N- and the C-terminal subunits of the kinase 
domain and sterically blocks the activation loop and the αC-helix from adopting a 
catalytically active conformation (Griffith et al., 2004; Mol et al., 2004; Mol et al., 
2003; Schubert et al., 2006). Similarly, phosphorylation of Y801 in the JMD domain of 
VEGFR-2 might initiate the release of the autoinhibitory JMD from the catalytic cleft 
as the initial step in the activation process. In agreement with this idea 
phosphorylation of the JMD of the c-Kit receptor was shown to be required for 
activation (Ma et al., 1999). Another study found that only Y1175 was important for 
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the activation process, while the mutant Y801F in the JMD and Y1214F in the CD did 
not affect phosphorylation of Y1175 (Takahashi et al., 2001b). In addition, studies 
with chimeric VEGFR-2 receptors proposed a role for Y1214 during receptor 
autophosphorylation and kinase activation (Dayanir et al., 2001;Meyer et al., 2002). 
However such data obtained with chimeric RTKs must be considered with care 
because such constructs may not adequately reflect the situation in wt-receptors. 
Later knock-in studies in mice proved the dispensability of Y1214 in physiological 
function (Sakurai et al., 2005). 
Based on our finding that Y1175 is phosphorylated after phosphorylation of Y951, we 
performed in vitro phosphorylation assays with the completely dephosphorylated and 
thus inactivated KD of VEGFR-2. After 5 min the pY1054/59 signal showed the 
strongest intensity reaching saturation at the fastest rate. In agreement with Solowiej 
et al. (Solowiej et al., 2009) who showed hat Y1054/59 immediately follows 
phosphorylation of the JMD residue Y801 of VEGFR-2. Autophosphorylation of Y801 
occurs via an intramolecular mechanism as determined by Solowiejet al. who found 
that autophosphorylation was independent of the enzyme concentration. In our 
experiments the degree of phosphorylation of Y801 could not be monitored due to 
the lack of a suitable phospho-specific antibody for analysis. Phosphorylation of 
Y1214 closely follows activation of Y1054/59. The latest phosphorylation event with 
the slowest phosphorylation rate takes place at Y1175 immediately following 
phosphorylation of Y951. Further experiments would be necessary to determine 
whether autophosphorylation of downstream tyrosines is mediated via an inter- or 
intramolecular mechanism. 
These results support our previous activation data for the Y951F mutant and also 
show that Y1214 does not act as a bottleneck of receptor activation since it is 
immediately phosphorylated after activation (figure 46).  
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Figure 46: Autophosphorylation of soluble VEGFR-2 kinase domain 
Initial phosphorylation of activation loop residues Y1054/59 leads to activation of VEGFR-2 
KD and phosphorylation of the C-terminal Y1214 closely follows. The latest phosphorylation 
event with the slowest phosphorylation rate takes place at Y1175 immediately following 
phosphorylation of Y951. 
 
VEGFR-2 is activated according to the generally accepted mechanism for activation 
in RTKs. VEGF binding to the monomeric ECD of VEGFR-2 induces dimerization 
and subsequent activation of the KD, which leads to downstream signaling. However, 
less well understood is how these pathways are modulated, amplified and timed in 
response to environmental changes. It is essential for the cell to maintain receptor 
signaling within a narrow time window. Suppression and limitation of signal duration 
is crucial to prevent over-stimulation and deregulation of the cell. Major downstream 
phosphorylation sites of VEGFR-2 are Y951 in the KID of VEGFR-2 that serves as a 
Doctoral Thesis   Sandro Manni 
 
134 
docking site for TSAd (Matsumoto et al., 2005;Wu et al., 2000) and regulates actin 
reorganization and migration but not mitogenicity upon VEGF-stimulation in 
endothelial cells. pY1175 is a binding sites for downstream mediators such as PLC-
γ1 and is responsible for activation of mitogenic and survival pathways. NCK binds to 
pY1214 and activates Cdc42 and p38MAPK (Lamalice et al., 2004). It was discussed 
earlier that phosphorylation of Y951 may be specifically regulated since this site was 
found to be phosphorylated in some but not all tested endothelial cell lines 
expressing VEGFR-2 (Matsumoto et al., 2005). Activation of the Y951-mediated 
signaling pathway might be affected by VEGF splice variants specific for co-receptors 
such as neuropilin. Furthermore, phosphorylation of Y951 was more pronounced in 
vessel structures lacking associated pericytes, which are displaced from vessels 
during angiogenesis. It is therefore possible that Y951 phosphorylation is required for 
active angiogenesis and might play only a minor role in differentiated vessels. 
 
To visualize the conformational changes arising from activation within the kinase 
domain of VEGFR-2 we applied structural biological techniques. A prerequisite to 
solve a high-resolution structure is the generation of high quality diffracting protein 
crystals. Crystallization trials with activated (phosphorylated) kinase domain mutant 
constructs did not yield protein crystals so far (Appendix). Hence, we used SAXS to 
determine structures at low resolution. SAXS studies depend on monodispersity of 
the measured protein. Since our purification protocol yielded homogeneous protein of 
high purity we met the requirements for the analysis. Our previous MALS and AUC 
analysis showed that VEGFR-2 kinase domain proteins in the concentration range of 
2 mg/mL are monomeric in solution. SAXS requires protein concentration in this 
range. Examination of dimeric symmetry of VEGFR-2 kinase domain protein 
interaction in solution was not possible since we would have required much higher 
protein concentrations which would prevent proper measurement due to 
intermolecular van der Waals interactions and perhaps aggregation. Thus, our 
characterization refers to monomeric VEGFR-2 kinase domains in solution. Several 
structural studies on monomeric kinase domains have been performed in the past. 
As mentioned before most studies were conducted with truncated proteins analyzing 
only the conserved catalytic domain. The role of specific kinase subdomains like the 
KID and the CD could not be addressed for most of the studies. Shewchuk et al. 
(Shewchuk et al., 2000b) solved the crystal structure of the inactive and monomeric 
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form of the full-length Tie-2 kinase domain. In the crystal structure the CD adopts an 
inhibitory conformation by folding back on the catalytic cleft of the KD. The 
conformation of the CD is stabilized by hydrophobic interactions of Y1112 with the 
KID of the kinase domain. The negative regulatory role of the CD was then further 
examined (Niu et al., 2002; Sturk et al., 2009). Our activation data of VEGFR-2 are in 
perfect agreement with these data. Deletion of the CD of VEGFR-2 leads to 
constitutive activation similar to Tie-2 suggesting an analogue autoinhibitory 
mechanism for these RTKs. We anticipate that a completely inactive VEGFR-2 
kinase would adopt a compact and globular conformation as compared with the fully 
activated kinase. To address this we performed a SAXS analysis of the 
phosphorylated VEGFR-2 kinase mutants. Ab initio modelling of the full-length 
VEGFR-2 kinase in the phosphorylated state gave rise to particles with an overall 
elongated shape. One end of the protein was globular while the other end was much 
thinner with a total length of ~167Å. The crystal structure of the catalytic domain of 
VEGFR-2, which lack the CD (McTigue et al., 1999a) fitted nicely to the globular 
domain of the particle. The solution structure of the partially phosphorylated kinase 
domain (K868M VEGFR-2 KD) showed a very similar overall shape with the globular 
part having a larger diameter. This compact structure may result from the activation 
loop folded back on the core KD in the inactive kinase conformation and the JMD in 
the inactive conformation as shown in previous crystal structures of VEGFR-2 related 
RTKs such as Flt3 (Griffith et al., 2004). The particle in solution was smaller with a 
total length of ~154 Å reflecting an overall more compact shape. The deletion of the 
KID in the fully phosphorylated protein did not affect the overall particle shape. 
However, significant differences were found in the total length of 124 Å and the 
smaller globular catalytic domain of the kinase. 
The KID of VEGFR-2 with a length of 68 amino acids is one of the largest among 
RTKs. We further investigated the truncated kinase domain protein of VEGFR-2 
using the published crystal structure (McTigue et al., 1999a). As expected ab initio 
modelling of the data showed a globular shape and CRYSOL fitting of the solution 
scattering data retrieved from the published crystal structure with our experimental 
data gave a good fit. The particle clearly showed a smaller Dmax value of 88 Å and a 
smaller Rg value of 25 Å due to the missing kinase subdomains including the large 
~200 amino acid CD. In order to retrieve an ab initio model of the inactive kinase of 
VEGFR-2 we completely dephosphorylated the protein and subjected the sample to 
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SAXS analysis. Unfortunately the sample quality was poor and we were not able so 
far to collect a satisfying dataset for further processing. Data collection is currently 
repeated with higher quality samples.  
To gain structural information we performed also a MALS analysis of the active, 
partially active and inactive KD proteins (VEGFR-2 KD, K868M VEGFR-2 KD and 
dephosphorylated VEGFR-2 KD). MALS analysis allows to besides determine the Mr 
of a protein and to retrieve its Rg with radii >10 nm. Rg is defined as the mass 
weighted average distance from the centre to each mass element in the molecule. 
For proteins with radii <10 nm, which accounts for most of the proteins, light 
scattering is not depending on the incident angle. Therefore light is scattered equally 
at all angles (such particles are known as Raleigh scatterers). Experimentally 
determined radii of such proteins are not very accurate. However, as shown before it 
will be possible to obtain accurate Rg values using SAXS or SANS (small angle 
neutron scattering). An indication referring to the globularity of a protein could be 
provided by calculating the ratio of Rg/Rh where Rh represents the hydrodynamic 
radius. Rh is defined as the equivalent radius of a hard sphere diffusing with the 
same rate as the protein and can be determined using dynamic light scattering 
(DLS). The characteristic Rg/Rh ratio for a globular protein is ~0.775 meaning that 
Rg is smaller than Rh. The Rg/Rh ratio of an elongated protein, like the active KD of 
VEGFR-2, would deviate upwards from 0.775, i.e. Rg will be larger than Rh. The 
SEC on the MALS instrument will supply additional important shape information of 
the analyzed proteins. The partially and completely dephosphorylated kinase 
domains clearly adopt a more compact conformation compared to the fully 
phosphorylated and active kinase as shown by their shift in the elution volume on the 
SEC which is in the order VEGFR-2 KD: 13.3 mL < K868M VEGFR-2 KD: 13.4 mL < 
dephosphorylated VEGFR-2 KD: 13.6 mL. The progressively more tight packing of 
the KD can only arise from a conformational change in the CD induced by 
dephosphorylation of C-terminal tyrosine residues (figure 47). 
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Figure 47: Progressively tight packing of VEGFR-2 KD upon dephosphorylation 
(A) Crystal structure of catalytic domain (in red, 1vr2) fitted into the experimentally 
determined SAXS envelopes of VEGFR-2 KD, K868M VEGFR-2 KD and a schematically 
drawn envelope of dephosphorylated VEGFR-2 KD where the JMD and the CD are folded 
back on the catalytic core of the KD. (B) Overlay of coupled SEC-MALS experiments of 
VEGFR-2 KD, K868M VEGFR-2 KD and dephosphorylated VEGFR-2 KD. JMD: black loop. 
CD: brown loop. 
 
Taken together, we think that the CD of VEGFR-2 folds back onto the kinase domain 
to prevent spontaneous activation. Deletion of the CD renders the KD constitutively 
active as demonstrated by our cell biological data in HEK293 cells. In the fully active 
state the kinase domain adopts an elongated, open conformation as supported by 
our preliminary SAXS analysis. We assume that the KD of VEGFR-2 follows a similar 
autoinhibitory mechanism as previously demonstrated for the Tie-2 kinase domain. In 
order to determine the precise shape and structure of the different kinase constructs 
additional SAXS analysis with high quality samples is required and crystallization 
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trials with dephosphorylated kinase domain mutant constructs should be considered 
as well. A high-resolution structure of the autoinhibited KD would shed light on the 
exact activation mechanism. 
 
8.3. Structural analysis of TSAd and TSAd-VEGFR-2 complex 
 
The adapter protein TSAd, initially identified in immune cells, was previously found to 
interact with VEGFR-2 by binding to Y951 via its central SH2-domain in a yeast-two 
hybrid screen (Wu et al., 2000). Y951 mediated complex formation of TSAd with 
VEGFR-2 was found to be essential for VEGF-induced actin reorganization and 
migration but did not affect VEGF mitogenicity (Matsumoto et al., 2005). In this 
project we were interested in characterizing the interaction between TSAd and 
VEGFR-2 in vitro to gain insight into the binding mode and the structural 
requirements using low and high-resolution methods. The human KID sequence 
differs from the murine sequence in three amino acids and we therefore expected no 
problems using murine TSAd with the human receptor. Initial expression trials of 
recombinant murine TSAd performed in E.Coli were not successful and resulted in 
inclusion bodies with aggregated protein. Eukaryotic protein expression in Sf21 
insect cells finally yielded amounts in the range of milligrams of murine full-length 
TSAd. However, expression of TSAd is challenging also in insect cells. The tedious 
purification procedure of TSAd and co-purified HSC70 heat shock protein hinted at 
the presence of potentially unfolded protein. Nevertheless, it was possible to purify 
temporarily stable TSAd protein to perform biophysical measurements. We verified 
that murine TSAd is able to bind to human VEGFR-2 KD in vitro through its central 
SH2-domain. We further demonstrated that binding is dependent on phosphorylation 
at Y951 as shown in earlier in vivo studies (Matsumoto et al., 2005). As mentioned 
above the human KID differs from the murine sequence in three amino acids C-
terminal to Y951 (human): KDY951VGAIP (human) vs.KDY949VGELS (mouse). 
Sequence specificity of phosphopeptides was analyzed in a previous study using a 
library of phosphopeptides that were degenerate at the three positions adjacent to 
the phosphotyrosine (Songyang et al., 1993). They found that SH2-domains of Src, 
Fyn, Lck, Fgr, Abl, Crk, and Nck prefered sequences with the general recognition 
motif pY-hydrophilic-hydrophilic-I/P whereas SH2-domains of p85, PLC-γ, and 
SHPTP2 prefered pY-hydrophobic-X-hydrophobic. Only very few SH2-domains 
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recognized unique sequences in this assay. The exceptions are the SH2-domains of 
Src, Fyn, Lck, and Fgr that belong to the Src subfamily. They all recognized the 
sequence pY-E-E-I. The KID of VEGFR-2 contains a hydrophobic V at position +1, G 
at position +2 and A in the +3 position (human) therefore matching the binding mode 
of the p85 subgroup. It has previously been discussed that the SH2-domain of TSAd 
may have a unique structure since the amino acid sequence of the domain is quite 
different from SH2-domains of other proteins and only shares limited homology with 
SH2-domains of PLC-γ, corkscrew (protein tyrosine phosphatase), LNK (cytosolic 
protein tyrosine kinase) and c-Src. Using a yeast-two hybrid system Wu et al. 
demonstrated that the isolated SH2-domain of TSAd by itself was not able to bind 
VEGFR-2 (Wu et al., 2000). The same applies for the isolated N- and C-terminal 
domains of TSAd. SH2-domain-mediated binding of TSAd to VEGFR-2 KD may 
therefore be influenced by N- and C-terminal domains of TSAd. We found that the 
isolated SH2-domain of TSAd was highly unstable as shown in our expression trials 
of the isolated SH2-domain constructs, which gave rise to insoluble protein. 
Purification of SH2-domain proteins was solely possible in the presence of 
detergents (Appendix). High-resolution structures of TSAd bound to its 
phosphopeptide substrate or one of its interaction partners may be required to define 
the exact binding determinants. 
To understand how TSAd binds to VEGFR-2 KD from a structural point of view we 
performed SAXS analysis of the purified complex. The p(r) function of the complex 
clearly deviated from the p(r) functions of the binding partners suggesting a much 
longer particle with multiple domains. Ab initio modelling of TSAD-VEGFR-2 KD 
complex resulted in an elongated protein with a Dmax of ~202 Å. Superposition of 
TSAd and VEGFR-2 KD on to the SAXS derived envelope of TSAd-VEGFR-2 KD 
complex with PyMOL software matched well when orienting the two binding partners 
in parallel although binding of TSAd to VEGFR-2 KD seems to distort the CD of 
VEGFR-2 via a conformational change. The calculated volume of the complex 
corresponds well to the sum of the individual volumes of TSAd and VEGFR-2 KD. 
We therefore conclude that pY951 mediated binding of TSAd to VEGFR-2 KD leads 
to an elongated shape of this signaling complex in which the binding partners orient 
in a parallel orientation. Up to now, sample quality was not satisfying enough to 
further study the complex structure. Hence, measurements must be repeated in order 
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to verify these results. High resolution structural data of the complex will remain the 
final goal to decipher the binding mode and orientation of the binding partners. 
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9. Conclusion 
 
VEGFRs and their ligands are key players in both physiological and pathological 
angiogenesis and vasculogenesis. VEGFR-2 represents the prevailing receptor 
engaging angiogenic and vasculogenic signaling pathways induced by VEGFs. 
Hence, VEGFR-2 is a clinically very attractive and validated target for drug 
development. Mechanistic studies giving new insights into the receptor activation 
mechanism are therefore important to find new targeting sites for the development of 
novel pharmaceutical compounds. We were able to verify and expand previous 
studies made by our own lab (Dell'Era Dosch and Ballmer-Hofer, 2009a). The 
introduction of glutamic acid residue into the wt-TMD of VEGFR-2 gave rise to either 
activate or inactive receptor variants. These findings proved that receptor 
dimerization is necessary but not sufficient for receptor kinase activation. Moreover, 
we were able to visualize the conformational changes in the TMD of VEGFR-2 
induced by activating glutamic acid residues using high-resolution structural biology 
methods. We identified TMD conformations presumably important for receptor 
activation. In the course of this project we also showed that the ECD of VEGFR-2 
plays an essential role maintaining the receptor in the inactive state in the absence of 
ligand. Furthermore, the ECD promotes the correct TMD conformation during the 
activation process, which culminates in the proper orientation of the intracellular 
kinase domains leading to receptor activation. 
In a second project, we aimed at elucidating the role of specific individual kinase 
subdomains such as the KID and the CD in VEGFR-2 activation based on previously 
reported data for related RTKs (Niu et al., 2002; Shewchuk et al., 2000b; Sturk et al., 
2009). We also studied the role of distinct tyrosine residues as targets of 
autophosphorylation. In this study we discovered that the KID and a particular 
tyrosine residue located within the KID at position 951 regulate phosphorylation of 
another canonical downstream tyrosine residue at position 1175, which regulates the 
activation of downstream signaling pathways. In addition, we were able to verify 
these results with biochemical data of the soluble kinase domain. From these 
findings we conclude that VEGFR-2 follows a well-ordered activation sequence 
orchestrated by stepwise phosphorylation of a series of tyrosine residues located in 
the various subdomains of the kinase. Furthermore, we found that the CD of VEGFR-
2 is able to autoinhibit the receptor in the absence of ligand since its deletion leads to 
Doctoral Thesis   Sandro Manni 
 
142 
constitutive, ligand-independent activation of VEGFR-2. Our structural studies 
support this finding. Low-resolution structural analysis of the activated compared to 
the inactivated KD reveals significant conformational rearrangement. We showed that 
the active kinase adopts an elongated open conformation whereas the inactive state 
adopts a compact globular conformation with the CD blocking the catalytic site of the 
KD as previously found for the Tie-2 receptor (Shewchuk et al., 2000b). 
In a third project we looked at the in vitro interaction between TSAd and active 
VEGFR-2. We demonstrated that TSAd binds to pY951 of VEGFR-2 in vitro via its 
central SH2-domain as previously proposed by cell biological studies (Matsumoto et 
al., 2005). Furthermore, we were able to structurally characterize the TSAd-VEGFR-2 
KD complex as well as the individual proteins using low-resolution structural analysis. 
Isolated TSAd adopts a symmetrical conformation with a large central globular 
domain, presumably corresponding to its SH2-domain as predicted from secondary 
structure analysis. Structural analysis of the TSAd-VEGFR-2 complex showed an 
elongated signaling complex in which the binding partners orient in a mostly parallel 
orientation. 
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10. Appendix 
 
 
 
 
 
 
 
 
 
Figure 48: Expression of murine TSAd (42 kDa) in E. Coli via autoinduction 
Murine TSAd was cloned into pET 15b-vector and expressed in different E.Coli strains 
(indicated) via autoinduction. Expression of TSAd was monitored on immunoblots using an  
antibody against the His-tag.  
 
 
A 
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Figure 49: Expression and purification of SH2-domain of murine TSAd in Sf21 insect 
cells 
(A) The soluble and insoluble fraction of baculovirus infected cells were analyzed for their 
recombinant proteins on immunoblots using an antibody against the His-tag (construct 
boundaries are indicated). (B) IMAC purification of SH2-domain construct A94-T211 in 
presence of either 0.5% Chaps or 0.1% Triton. 
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Construct Tag Cleavage Site 
Expression 
(Sf21) Pattern 
In 
vitro 
phos 
In vitro 
dephos 
Tag 
Removal 
VEGFR-2 KD + TEV + 1 band + - - 
VEGFR-2 K868M 
KD 
+ TEV + 1 band + - - 
VEGFR-2 ΔKID 
KD 
+ TEV + 1 band + - - 
VEGFR-2 ΔC KD 
(Y1175) 
+ TEV + 2 bands + - - 
VEGFR-2 ΔJMD 
KD 
+ TEV + 1 band + - - 
VEGFR-2 
ΔJMDΔC (1214) 
KD 
+ TEV + 2 bands + - - 
VEGFR-2 +JMD 
(GELK) ΔKIDΔC 
KD (Y1175) 
+ TEV + 
 
1 band 
+ - - 
VEGFR-2 +JMD 
(TGYL) ΔKIDΔC 
KD (Y1175) 
+ TEV + 1 band + - - 
 
Table 15: VEGFR-2 KD constructs used for crystallization trials 
All VEGFR-2 constructs were screened at several concentrations ranging from 5 mg/mL-15 
mg/mL. All proteins (except of VEGFR-2 K868M KD) were initially in vitro phosphorylated to 
fully activate the kinase. The His-tag was not removed for crystallization. Screens used for 
the assessment of crystal growth: pHClear I and II (determination of optimal concentration), 
JCSG core suite, Classics, PEG suite and AmSO4 suite. 
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Figure 50:  1H, 15N-TROESY-HSQC spectrum of V769E-TMD  
Conditions: Lipid / protein ratio was 800:1, pH 4.5, 318K. The Assignment of signals to amino 
acid residues and the oligomeric state is indicated. 
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NMR Distance & Dihedral Restraints 
TMD domain wt mutant 
Total unambiguous NOE restraints 418 606 
intra-residue 98 150 
inter-residue 302 435 
sequential (|i-j|=1) 138 150 
medium-range (1<|i-j|<4) 164 285 
long-range (|i-j|>4) 0 0 
inter-monomeric 18 21 
Hydrogen bond restraints (upper / lower) 162/162 243/243 
Total torsion angle restraints  136 204 
backbone φ 62 93 
backbone ψ 62 93 
side chain χ1 12 18 
side chain χ2 0 0 
Structure calculation statistics  
CYANA target function (Å2) 1.2 ± 0.2 0.5 ± 0.1 
Restraint violations   
distance (>0.2 Å) 2 3 
distance (>0.3 Å) 0 0 
dihedral (>5)o) 0 0 
Average pairwise r.m.s.d. (Å)   
α-helical region (761-794)2/(761-794)3   
backbone atoms 0.24 ± 0.08 1.5 ± 0.5 
all heavy atoms 0.74 ± 0.12 2.0 ± 0.4 
Ramachandran analysis a   
% residues in most favored regions 100.0 87.9 
% residues in additional allowed regions 0 12.1 
% residues in generously allowed regions 0 0 
% residues in disallowed regions 0 0 
Helix-helix packing   
Contact surface area per monomer  
in pair of interacting helices (Å2) 
613 ± 20 340 ± 10 
Angle θ between the helix axes (deg.) 25 ± 1 -50 ± 5 
Distance d between the helix axes (Å) 9.2 ± 0.2 9.5 ± 0.5 
 
Table 16: Statistics of ensemble of 10 best NMR structures of wt-TMD and V769E-TMD 
of VEGFR-2 
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11. Publications 
 
11.1. Manuscripts in preparation 
 
I. An analysis of specific VEGFR-2 kinase subdomains required for 
activation and downstream signaling of the receptor. 
 
II. Receptor kinase activation by dimerization-promoting transmembrane 
domains of VEGF receptor 2; a functional and structural study. 
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